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Abstract 
Breast cancer is the second-leading cause of cancer related death in women and 
future therapies may involve the strategic use of previously developed drugs, 
which have established toxicity profiles and are often ex-patent. The alcohol-
deterrent disulfiram has been proposed as an anti-cancer agent, based on its 
capacity to interact with copper-dependent processes. However, little has been 
done to determine the relationship between this drug and zinc, despite 
knowledge that disulfiram binds this metal and zinc levels are dysregulated in 
breast cancer. This thesis investigated whether zinc is an important factor when 
considering disulfiram efficacy as an anti-breast cancer agent. 
 
Disulfiram was toxic to MCF-7 and BT474 breast cancer cell lines and 
produced a striking time-dependent biphasic toxicity response between 5-
20 µM. Co-incubation of the drug with low-level zinc removed this effect, 
suggesting that the availability of extracellular zinc significantly influenced 
disulfiram efficacy. Structure-activity relationship studies with disulfiram 
analogues revealed the biphasic effect could be influenced by altering the size 
of chemical groups bound to the drug’s nitrogen atom. 
 
Live-cell confocal microscopy using fluorescent endocytic probes and the zinc 
dye Fluozin-3, coupled with the development of a complimentary Fluozin-3 
flow cytometry assay found that disulfiram rapidly increased zinc levels in 
breast cancer cells specifically in endo-lysosomes. This indicates that the 
ii 
 
cytotoxic effects of this drug may be due to acute zinc overload. Further 
investigation into disulfiram effects on lysosomes suggested that the drug 
disrupts lysosomal membranes and releases hydrolytic enzymes into the 
cytosol. Lysosomal membrane permeabilisation has been demonstrated to 
promote apoptosis and may be a mechanism to explain disulfiram cytotoxicity 
in breast cancer. This could have important clinical implications in situations of 
high intracellular zinc as seen in breast tumours, indicating that breast cancer 
cells may be more susceptible to the zinc ionophore action of disulfiram than 
non-cancer cells.  
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1. Introduction 
1.1. Clinical breast cancer 
1.1.1. Breast cancer incidence and mortality worldwide  
According to the most recent worldwide statistics, in 2012 there were 
1.7 million cases of breast cancer diagnosed, accounting for 25% of all cancers 
in women (Cancer Research UK 2014a). This makes breast cancer the second 
most frequently diagnosed form of the disease, narrowly behind lung, and the 
most prevalent in the female population. Despite the high incidence, mortality 
due to breast cancer ranks fifth worldwide (Cancer Research UK 2014b). 
However it is still the second leading cause of cancer death in women, resulting 
in 522,000 fatalities in 2012.  
 
According to the best available data, incidence of breast cancer is higher in less 
developed regions and mortality is 1.6 fold greater (Ferlay et al., 2015). These 
figures are likely to reflect differences in early detection, treatment availability, 
lifestyle and life expectancy between socio-economic climates. Reducing the 
mortality gap between world regions remains an ongoing challenge. 
 
1.1.2. Tumour formation and progression to metastatic disease 
Breast tumours originate from cells which have acquired genetic abrogation 
that prime the cell for cancer growth (Figure 1.1). This process, known as 
initiation, can occur as a result of inherited mutations in genes such as breast
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Figure 1.1. Progression of tumours from initiation to metastatic disease. 
 
cancer genes 1 and 2 (BRCA 1 and 2), discussed in Section 1.1.4, or through 
exposure to environmental carcinogens such benzene (Collins et al., 2015). 
Initiation results in loss of tumour suppressor genes which further contributes 
to genomic instability and activation of oncogenes which increase cell 
replication. Tumour growth then occurs due to increased replication rate and 
inhibition of cell death processes which may require growth promoting 
compounds, such as oestrogen which is particularly relevant to the study of 
breast cancer (Section 1.1.4). Here, oestrogen binds to its cytoplasmic receptor 
which then translocates to the nucleus and promotes expression of genes 
associated with replication and restricts those associated with cell death (Frasor 
et al., 2003; Sadler et al., 2009). At this stage tumour growth is limited by the 
diffusion barrier which prevents acquisition of nutrients and excretion of waste 
products. For the developing tumour to grow beyond 1-2 mm
2
 in size requires 
the recruitment of new blood vessels (Muthukkaruppan et al., 1982; Hanahan 
and Weinberg 2011). This processes known as angiogenesis, involves the 
secretion of angiogenic factors which stimulate growth and migration of 
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Figure 1.2. Sites of breast 
cancer metastases. Figure 
from Weigelt et al., 2005. 
 
 
 
 
endothelial cells lining blood vessels towards the tumour, ultimately resulting 
in tumour vascularisation (Hillen and Griffioen 2007). In order to become 
metastatic, a condition associated with significantly worse clinical outcomes as 
highlighted in Section 1.1.3, the tumour cells must penetrate the basement 
membrane and invade into either neighbouring tissues or the vasculature where 
they can form distal tumours. In breast cancer, common sites of local 
metastases are in surrounding tissues such as lymph nodes and the collar bone 
(Figure 1.2). However, in advanced disease, distal tumours preferentially occur 
in organs such as lung, liver and bone (Weigelt et al., 2005).  
 
The tumour initiating cells share many of the properties of stem cells, and are 
therefore frequently referred to as cancer stem cells (CSC). CSC can be 
characterised based on expression levels of marker proteins such as aldehyde 
dehydrogenase (ALDH), low expression of CD24 and high expression of 
CD44 (Al-Hajj et al., 2003; de Beca et al., 2013). They have the capacity to 
self renew and may differentiate to form the heterogeneous population of 
cancer cells observed within a tumour (Hope et al., 2004; Anderson et al., 
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2011). As all cells within the tumour originate from these CSC, it is their 
properties which govern the clinical nature of the tumour. For example in 
acquired chemoresistance it is hypothesised that CSC which survive 
chemotherapy are able to reform tumours with resistant properties (Yu et al., 
2007a; Vidal et al., 2014). 
 
1.1.3. Role of the oestrogen receptor and its signalling in breast cancer 
An important consideration in the study of breast cancer is the role of 
oestrogen receptors (ERs) in tumour growth, this is the primary feature for 
stratifying the disease (Section 1.1.5) and optimising treatment (Section 1.2). 
Oestrogens are a class of steroid hormones capable of passive diffusion 
through the cell membrane and binding to cytoplasmic ERs, of which there are 
two structurally related forms: ERα and ERβ. Of these, ERα is the best 
characterised, predominately associated with the transcription of growth 
promoting genes and frequently over-expressed in breast tumours. It is ERα 
which is responsible for classification of ER
+
 disease. In comparison the role of 
ERβ is less well defined, although it is noted for its tumour suppressor 
properties and has been associated with favourable properties such as low 
grade tumours and decreased lymph node involvement (Marotti et al., 2010). 
 
The classical model of ER activity involves its activation by ligand, 
dissociation of cytoplasmic chaperone proteins and translocation of the ligand-
receptor complex to the nucleus. Here it binds to distinct regions of DNA in 
gene promoter regions, known as oestrogen responsive elements (ERE) and 
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can alter the expression of oestrogen responsive genes (O’Lone et al., 2004). 
The activity of ER at ERE is dependent on the binding of nuclear co-regulators 
which may activate or repress the action of ER primarily through their ability 
to alter chromatin structure such that gene transcription is promoted or 
repressed (Green and Carroll, 2007). The distribution of these co-regulators 
may partially explain why ER antagonists behave differently in certain tissues 
(Martinkovich et al., 2014). 
 
Extensive study of ER activity, motivated by its importance in the pathology of 
breast cancer, has identified other mechanisms of action to modulate cell 
activity outside this classical framework. For example ER activation and 
nuclear translocation may alter the activity of other transcription factors such 
as nuclear factor κB (NFκB; Biswas et al., 2005). In addition, ER may be 
phosphorylated and activated in the absence of ligand by membrane bound 
receptor tyrosine kinases such as epidermal growth factor receptor (EGFR; 
Marquez et al., 2001). This observation is particularly relevant to breast cancer 
due to the over-expression of EGFR in this disease (Section 1.1.5). 
 
1.1.4. Diagnosis and pathology of breast cancer 
Breast cancer diagnosis relies upon biopsy of the suspected tumour and 
pathology reporting to confirm invasive disease. As well as this, pathology 
reports also include information which may be used to determine prognosis and 
therapeutic strategies. These factors include apparent differentiation of cancer
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Table 1.1. Summary of breast cancer stages and 5 year relative disease free survival. 
Relative disease free survival (RDFS) is a normalised value which considers death from causes 
other than cancer. *indicate values for which individual sub-categories were not available. 
RDFS are obtained from the National Cancer Institute: Surveillance Epidemiology and End 
Results program (NCI: SEER) database, 2012 statistics (Howlader et al., 1975-2012). 
 
cells, tumour size, extent of lymph node involvement, and presence of 
therapeutic or diagnostic markers. Tumour size, number and location of 
positive lymph nodes combine to determine disease stage and the aggression 
required for treatment. Staging is prognostically ranked 0-IV with stage IV 
considered incurable. The features and 5 year survival rate of each stage, as 
determined at initial diagnosis, is shown in Table 1.1.  
 
1.1.5. Molecular sub-types of breast cancer 
Pathology reports also include information regarding the presence of 
therapeutic and diagnostic markers, such as ER, progesterone receptor (PR), 
human epidermal growth factor receptor 2 (HER2) and EGFR. These are used 
Stage Description RDFS 
0 Carcinoma in situ 100% 
I Evidence of invasion, tumour size <2 cm and no lymph node 
involvement 
100% 
IIA No tumour in the breast but lymph node positive OR tumour 
<2 cm and lymph node involvement OR tumour 2-5cm and no 
lymph node involvement 
93%* 
IIB Tumour 2-5 cm and lymph node involvement OR tumour >5cm 
and no lymph node involvement 
93%* 
IIIA No tumour found but gross lymph node involvement or in 
lymph nodes close to breastbone OR tumour (any size) and 
lymph node positive with evidence of structure formation 
72%* 
IIIB Tumour (any size) and spread to chest wall and/ or skin AND 
lymph node positive with evidence of structure formation 
72%* 
IIIC No tumour found or tumour any size and spread to chest wall 
and/or skin AND cancer spread to lymph nodes surrounding 
collarbone AND lymph nodes near breastbone 
72%* 
IV Cancer has spread beyond breast and surrounding lymph nodes 
to other organs 
22% 
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Table 1.2. Molecular sub-classification of breast cancer. Table adapted from Holliday and 
Speirs 2011, frequency and 5 year survival data from O'Brien et al., 2010 where 12% of cases 
were unclassified. 
 
 
to subcategorise the disease in order to optimise response to certain therapies; 
for this purpose the most relevant markers are ER, PR and HER2. Sub-
categories include: luminal A, luminal B, HER2 over-expressing and basal-like 
(triple negative). The molecular features, frequency and prognosis of each sub-
type are summarised in Table 1.2. Additionally “normal-like” disease is also 
commonly described, in which many genes associated with non-cancerous 
epithelial cells are expressed (Sorlie et al., 2001; Liu et al., 2014). This 
sub-category shares many of the molecular features of basal-like disease. 
Despite the prevalence of ER, PR and HER2 in distinguishing between sub-
types, other molecular features also aid in disease categorisation. For example, 
relative expression of Ki67, a protein found exclusively in the nucleus of 
proliferating cells, is an indication of disease aggression which indicates the 
need for more aggressive treatment (Inwald et al., 2013). This feature partially 
distinguishes between luminal A and B type tumours. 
 
Although not required for identifying sub-types, there are numerous molecular 
features which are common to certain sub-categories of breast cancer. Of these 
EGFR is the best characterised due to the potential for targeted therapies and 
Sub-type ER/ 
PR 
HER2 Other molecular 
features 
Frequency 5 year 
survival 
Luminal A 
+
 - Ki67 low 54% 91% 
Luminal B 
+
 - Ki67 high 10% 88% 
HER 2
+
 - 
+
 Ki67 high 6% 74% 
Basal-like - - Ki67 high, EGFR
+
 18% 76% 
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its frequent over-expression in difficult to treat and aggressive tumours, such as 
ER/ PR negative, HER2
+
 and basal-like (Rimawi et al., 2010). These sub-types 
generally lack druggable targets and therefore anti-EGFR therapies may 
improve prognosis. Genetic counselling is also available in order to determine 
whether an individual carries a mutation which increases their risk of 
developing cancer. A common genetic test for breast cancer is mutation of 
tumour suppressor genes BRCA1 and BRCA2, which together provide the 
most common cause of hereditary breast cancer (Petrucelli et al., 2010). These 
proteins are involved in preventing chromosomal abnormalities primarily due 
to their function in DNA double strand break repair (Venkitaraman 2002; Yao 
et al., 2015). Loss of function mutations in these proteins increases the risk of 
developing breast cancer before the age of 70 from 12% to 57% with BRCA1 
mutation, and 49% with BRCA2 mutation (Howlader et al., 1975-2012; Chen 
and Parmigiani 2007). 
 
In vitro pre-clinical studies typically use cell lines which model breast cancer 
sub-categories in order to predict patient response to drugs or aid further 
disease characterisation. Some common breast cancer lines, the disease they 
model and information regarding the patient from which they originate are 
shown in Table 1.3.
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Table 1.3. Cellular models of breast cancer sub-types. Patient information and derivation 
site columns contain data from American Type Culture Collection (ATCC). In the cell line 
column, typically only the abbreviation preceding the “/” is used to identify these cell lines. 
*MCF-10A cells derive from a patient with benign masses in the breast tissue. 
 
1.2. Current breast cancer therapeutics 
Breast cancer treatment typically involves a combination of surgery, radiation 
and drug therapy. The molecular characteristics of the tumour and stage at 
diagnosis dictate the nature of drug therapy, which may include chemotherapy 
and targeted therapeutics. Tumours which have a favourable prognosis, for 
example <1 cm diameter and hormone receptor positive, may not require 
chemotherapy and may rely on targeted therapeutics, such as tamoxifen, alone 
(Tryfonidis et al., 2014). Drug administration can be started before (neo-
adjuvant) or after (adjuvant) surgery depending on tumour size, with stage III 
or large stage II tumours receiving neo-adjuvant treatment. Neo-adjuvant 
therapies are also used to decrease size of in-operable tumours and enable 
further treatment options. Wherever possible, targeted therapies against 
Cell line/ ATCC Ref.  Classification Patient info. Derivation site 
MCF-7/ HTB-22 Luminal A 69 year old, 
Caucasian, female, 
adenocarcinoma 
Pleural effusion 
metastatic site 
T47D/ HTB-133 Luminal A 54 year old, female, 
ductal carcinoma 
Pleural effusion 
metastatic site 
BT-474/ HTB-20 Luminal B 60 year old, 
Caucasian, female, 
ductal carcinoma 
Mammary duct 
MDA-MB-231/ CRM-
HTB-26 
Basal-like 51 year old, 
Caucasian female, 
adenocarcinoma 
Pleural effusion 
metastatic site 
SK-BR-3/ HTB-30 HER2
+
 43 year old, 
Caucasian, female, 
adenocarcinoma  
Pleural effusion 
metastatic site 
MCF-10A/ CRL-10317 Fibrocystic 
disease* 
36 year old, 
Caucasian female 
Mammary gland 
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molecular drivers of the disease are administered which have a more 
favourable side effect profile than chemotherapy and frequently used in 
combination (Jackson and Chester 2015).  
 
1.2.1. Tamoxifen 
Tamoxifen binds the ER and in breast tissue acts as an antagonist by 
preventing the binding of co-activators and instead increasing co-repressor 
binding (Shiau et al., 1998; Kanaujiya et al., 2013). Thus, the drug prevents 
transcription of oestrogen regulated pro-growth and anti-apoptotic genes, and is 
frequently used in the treatment of ER
+ 
disease. The most recent follow up 
studies show that 5 year tamoxifen treatment can halve recurrence rates 
(Davies et al., 2011). However there is conflicting evidence suggesting that the 
benefits of tamoxifen may extend beyond the treatment period; recurrence rates 
decrease by 32% in the 4 years following cessation of treatment, but there is no 
benefit in overall survival.  
 
Tamoxifen exhibits partial ER agonist activity in some tissues including bone 
and uterus, which provides both favourable and adverse off target effects. 
Studies using tamoxifen as a preventative medicine have shown that it can 
reduce fracture rate in post-menopausal patients with ER
+
 tumours, but also 
produces a small increase in rates of endometrial cancer and cardiac 
abnormalities (Fisher et al., 2005). Despite this, the adverse effect profile of 
tamoxifen is considered favourable as only 0.6% of patients taking tamoxifen 
die from these combined complications (Davies et al., 2011).  
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These benefits have led to tamoxifen being used as a preventative medicine in 
individuals with high risk of developing breast cancer. Here, it has been shown 
that 5 year treatment can decrease overall breast cancer incidence by 28% and 
ER
+
 incidence by 33% (Cuzick et al., 2015).  
 
1.2.2. Fulvestrant 
Fulvestrant (ICI 182, 780, Faslodex
TM
) is another ER antagonist with a 
different mechanism of action to tamoxifen, which avoids the partial agonistic 
effects and may be favourable to some patients. It inhibits receptor 
dimerisation, up-regulates receptor degradation, and has been shown to inhibit 
nuclear ER content to a similar extent as tamoxifen (Robertson et al., 2001). 
Clinically, fulvestrant is equally as effective as tamoxifen at decreasing 
progression and increasing overall survival in patients with advanced disease 
(Howell et al., 2004). However this study revealed that time to treatment 
failure was 2 months longer with tamoxifen, therefore fulvestrant is inferior as 
a front line treatment. As a second line treatment the drug still has clinical 
benefit, and advanced disease patients with progression on aromatase inhibitors 
(AI; Section 1.2.3) have shown partial response or stable disease for an average 
of 6 months when treated with fulvestrant (Ingle et al., 2006).  
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1.2.3. Aromatase Inhibitors 
Aromatase is responsible for the synthesis of oestrogens in breast cancer tissue 
thereby encouraging the growth of local ER
+
 breast cancer cells (De 
Mukhopadhyay et al., 2015). Due to this AIs decrease the responsiveness of 
the tumour to oestrogen by limiting its availability. This strategy is counter-
indicated in the treatment of pre-menopausal women because a large 
proportion of the hormone is still supplied by the ovaries, although there is 
clinical data indicating benefit of AIs when combined with treatments to 
reduce ovarian oestrogen supply (Pagani et al., 2014). The AI anastrozole has 
been shown to decrease recurrence in ER
+
 patients by 4.6% compared to 
tamoxifen in the neo-adjuvant setting (Cuzick et al., 2010). This success has 
also been noted for letrozole, another example of an AI, which was shown to 
be more effective than tamoxifen at increasing disease free survival (Regan et 
al., 2011).  
 
AIs are also associated with less serious side effects than tamoxifen. For 
example, tamoxifen is associated with a 4 times greater risk of endometrial 
cancer than anastrozole (Baum et al., 2002; Cuzick et al., 2010). However ER 
agonistic properties of tamoxifen provide favourable effects in tissues such as 
bone, where AIs continue to act as an antagonist leading to side effects. For 
example, several AIs have been associated with an increase in fracture 
incidence, although this may only be apparent during the treatment period 
(Baum et al., 2002; Thurlimann et al., 2005; Coombes et al., 2007; Cuzick et 
al., 2010). The superiority of AIs at decreasing recurrence and increasing 
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disease free survival, combined with the favourable side effect profile, has 
supported the advancement of AIs as the first line treatment for post-
menopausal ER
+
 breast cancer. 
 
1.2.4. Trastuzumab 
Trastuzumab (Herceptin
TM
) is a human-mouse chimeric monoclonal antibody 
which prevents HER2 signalling leading to cell cycle arrest and cancer cell 
death. There are several models to explain the exact mode of action of 
trastuzumab including: inhibition of extracellular domain function, increased 
internalisation and degradation of receptor in lysosomes, and recruitment of 
natural killer immune cells to the tumour (Valabrega et al., 2007).  
 
Studies have shown that when given alongside chemotherapy for HER2
+
 
tumours, 1 year adjuvant trastuzumab can increase 10 year disease free survival 
by 9% compared to chemotherapy alone (Perez et al., 2014). Extending the 
treatment period to 2 years has no additional benefit in terms of disease free 
survival and increased incidence of adverse effects, providing evidence that a 
treatment period of 1 year is optimal (Goldhirsch et al., 2013). 
 
The most severe adverse effect associated with trastuzumab therapy is cardiac 
toxicity. It has been shown that 9.8% of patients treated with adjuvant 
trastuzumab experience decreased cardiac output, which represents a 6.9% 
increase compared to no adjuvant therapy (Procter et al., 2010). This study also 
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noted an increase of 0.8% in the incidence of more severe congestive heart 
failure.  
 
1.2.6. Chemotherapies  
Chemotherapeutic agents are often given in combination with targeted 
therapies to treat tumours with less favourable prognosis. These agents have 
multiple mechanisms of action but all serve to target rapidly dividing cells. As 
such cancer cells are particularly sensitive to these drugs, however the same is 
true for cells in tissues such as the lining of the gut, bone marrow and hair 
follicles which also have high replication rates. Therefore chemotherapeutic 
drugs are associated with high toxicity and produce symptoms such as nausea, 
immunosuppression and alopecia. Chemotherapeutic drugs with multiple 
distinct mechanisms of action are often used as part of a multi-drug regime in 
order to maximise the response of the tumour to treatment. Table 1.4 describes 
some examples of the more commonly used chemotherapeutic agents and their 
mechanisms of action. 
Table 1.4. Examples of chemotherapeutic agents and their mechanisms of action.  
Chemotherapeutic  Mechanism of Action 
Doxorubicin Intercalates DNA strands inhibiting DNA transcription 
5-Fluorouracil  Inhibits production of the nucleoside thymidine 
Cyclophosphamide  Forms DNA crosslinks preventing gene transcription 
Docetaxel  Stabilises microtubules by inhibiting cell division 
Gemcitabine Inserted into DNA during cell division and prevents DNA 
synthesis 
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1.2.7. Future therapeutic strategies 
As discussed in Section 1.1.4 breast cancer can be sub-categorised based on the 
molecular features of an individual’s tumour. However, recent genome wide 
studies have suggested that there may be at least 10 sub-categories of the  
disease and only a few genes are commonly mutated with many tumours 
having rare mutations about which little is known (Curtis et al., 2012). 
Therefore the molecular features of an individual’s tumour are unique and the 
most benefit could be achieved through personalised therapies which target 
these molecular drivers. For example, this approach is currently the subject of a 
clinical trial whereby patients undergo whole genome analysis in order to 
identify their unique oncogenic abnormalities and this information is then used 
to determine the most appropriate choice of targeted therapy (NCT02299999). 
Other clinical trials focus on the ability of drugs to target distinct molecular 
drivers of the disease. Examples of drugs which are currently in, or recently 
completed, clinical trials investigating their ability to target a specific 
oncogenic process are described in Table 1.5. 
 
Table 1.5. Examples of future personalised medicine approaches. Some examples of drugs 
currently in clinical trials for the treatment of cancer due to their ability to inhibit specific 
oncogenic processes within an individual’s tumour. 
Drug Target Rationale Clinical 
Trials 
Identifier 
Gefitinib EGFR HER1, or EGFR, as the name implies 
belongs to the same receptor tyrosine 
kinase family as HER2, and is thought 
NCT00024154 
NCT00052169 
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to have a prominent role in the 
pathogenesis of breast cancer and 
acquired resistance. Gefitinib (Iressa
TM
) 
is a small molecule inhibitor which 
results in decreased kinase activity of 
the receptor and reduced signalling. 
When investigated as a front line 
treatment patients did not respond to 
gefitinib, despite receptor inhibition 
(Baselga et al., 2005). However the drug 
produces clinical benefit in ER
+
 patients 
with acquired tamoxifen resistance and 
ER
-
 disease, demonstrating that it has 
potential as a second line treatment and 
may be beneficial to ER
-
 patients 
(Gutteridge et al., 2010). In both cases 
this produces a favourable outcome as 
there are limited options to treat these 
tumours. Additionally, gefitinib may 
have promise as part of a combined 
therapy when used alongside 
anastrozole and current trials focus on 
its use in combination with other 
therapeutics for example trastuzumab, 
docetaxel or tamoxifen (Cristofanilli et 
al., 2010). 
NCT00080743 
AZD5363 
 
Akt 
 
The phosphoinositide 3-kinase (PI3K)/ 
Akt/ mechanistic 
target of rapamycin (mTOR) signalling 
network is commonly up-regulated in 
cancer and meditates cancer cell 
survival (Liu et al., 2009).  
 
Pre-clinical data indicated that breast 
cancer cells with mutations in PIK3CA, 
a downstream activator of Akt, were 
particularly sensitive to the drug (Davies 
et al., 2012). This led to a Phase I/ II 
trial which stratified PIK3CA mutation 
status. 
NCT01625286 
Everolimus mTOR Activation of the PI3K/ Akt/ mTOR 
pathway also contributes to 
chemoresistance and targeting the 
pathway may prolong the sensitivity of 
tumours to other therapies. 
 
The addition of Everolimus to other 
breast cancer treatment regimes is the 
focus of the Breast cancer trials of oral 
Everolimus (BOLERO) group. This 
group have found that the drug has 
clinical benefit in trastuzumab resistant 
NCT00876395 
NCT01698918 
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1.2.8. Drug resistance 
Resistance to anti-breast cancer therapies remains an ongoing problem and a 
further driving force for development of future therapies. The mechanisms of 
tumour resistance are highly diverse and may involve up-regulation of multiple 
cell survival pathways and molecular switching, defined as the ability of a 
tumour to alter its molecular profile and so switch between breast cancer sub-
types. For example, it has been demonstrated that 26% of ER
+
 tumours became 
HER2
+
 upon generating resistance to endocrine therapy (Lipton et al., 2005). 
In order to combat resistance and prevent molecular switching, it may be 
favourable to simultaneously target multiple pathways. In support of this, 
trastuzumab has been shown to double progression free survival in patients 
with metastatic disease treated with anastrozole, compared to anastrozole alone 
(Kaufman et al., 2009). However, to highlight the problem of resistance it 
tumours and on-going trials are 
evaluating the benefit of the drug in the 
treatment of ER
+
 disease (Andre et al., 
2014). 
Olaparib 
 
Poly ADP 
ribose 
polymerase 
(PARP) 
PARP 1 and PARP 2 enzymes are 
involved in DNA repair processes and 
their inhibition by Olaparib results in 
DNA double strand breaks (Rottenberg 
et al., 2008). In tumours which have 
defective DNA repair processes these 
double strand breaks cannot be repaired 
and this leads to cell death. 
 
Due to this Olaparib has been 
investigated as a therapy in patients with 
BRCA mutations where it has shown 
clinical benefit as a monotherapy or in 
combination with chemotherapies (Dent 
et al., 2013; Kaufman et al., 2015).  
NCT00679783 
NCT00494234 
NCT02000622 
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should be noted that disease progression still occurred within 5 months of 
treatment in the trastuzumab group. 
 
1.2.9. Drug repurposing 
One source of future therapies against breast and other types of cancer may be 
drugs used in the treatment of other diseases. As these drugs most often already 
have established toxicity profiles, pharmacophore properties, and identified 
molecular targets, they are likely to progress to clinical trials much quicker 
than new drug entities. Due to this, and the fact that many are ex-patent, drug 
development costs are reduced. Examples of this approach include thalidomide 
for the treatment of acute myeloid leukaemia (Steins et al., 2002), metformin 
re-purposed as a breast cancer therapy (Jiralerspong et al., 2009) and 
rapamycin for leukaemia (Sillaber et al., 2008). Multiple studies have proposed 
that the alcohol deterrent drug, disulfiram may have anti-cancer activity in 
breast, prostate, and other tumour types. As disulfiram is ex-patent, it would be 
cheap to administer for healthcare providers, and may be particularly beneficial 
in countries where cost is a limiting factor in therapeutic options. This thesis 
focuses on this drug in breast cancer and merits much more detailed discussion 
that is provided in Section 1.4. 
 
1.2.10. Clinical history of disulfiram 
Disulfiram (Antabuse
TM
, tetraethylthiuram disulfide, structure shown in Figure 
1.3) was first synthesised in 1881 but received little scientific or commercial 
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interest until the 1920s when it was used as a vulcanising agent in rubber 
production (Kragh 2008). In this context it was noted that workers exposed to 
the compound experienced adverse effects upon ingestion of alcohol. The 
clinical benefit of the compound was first demonstrated as a treatment for
scabies in 1942 and during further investigation researchers also noticed 
adverse effects of taking the drug prior to alcohol ingestion (Gordon and 
Seaton 1942; Jacobsen et al., 1992; Kragh 2008). These observations led to the 
successful introduction of disulfiram into clinical trials as an alcohol deterrent 
in 1948 and it was FDA approved for this application in 1951 (Martensen-
Larsen, 1948; Chick, 1999).  
 
The first studies demonstrating the anti-cancer potential of disulfiram were 
described in 1977 and since then it has been proposed to inhibit or stimulate 
various processes in cancer cells which may provide a mechanism to support 
its use as a future therapy (Lewison 1977; Cvek 2011). These targets may be 
exploited to produce favourable outcomes such as altered metal homeostasis, 
protein turnover, metastasis, angiogenesis, signalling cascades and drug 
resistance (discussed in Section 1.4 and summarised in Figure 1.4). The ability 
of disulfiram to bind metal ions, in particular copper, is attributed to many of 
its anti-cancer properties, however, relatively little has been done to establish 
Figure 1.3. Structure of disulfiram. 
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the relationship of this drug with other metals (Sauna et al., 2005; Chen and 
Dou 2008; Yip et al., 2011; Liu et al., 2013).  
 
Figure 1.4. Summary of the proposed anti-cancer mechanisms of disulfiram.  
 
1.3. Pharmacokinetic, pharmacodynamic and toxicological properties of 
disulfiram 
Disulfiram is a divalent metal ion chelator with particularly high affinity for 
copper and zinc (Chung et al., 2000; Brar et al., 2004). Its chemical properties 
suggest the drug can readily cross biological membranes; small molecular mass 
of 296.5 and favourable water: lipid solubility with a LogP value of 4.16 (Hann 
and Keserue 2012). It is still best known as an alcohol deterrent and has been 
used in this context since the 1950s, during which time it has been established 
as a relatively safe drug, and is well tolerated in high doses e.g. 800 mg/ day, 
for prolonged periods (Chick 1999).  
 
Disulfiram is as an irreversible inhibitor of ALDH, preventing effective ethanol 
metabolism and causing accumulation of acetaldehyde. This substance 
produces symptoms such as nausea, hypotension and flushing, collectively 
termed the disulfiram-ethanol reaction and is responsible for the drugs 
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deterrent properties. The molecular mechanism for this inhibition is through 
binding cysteine thiol groups in the active site of ALDH, causing ejection of a 
catalytically essential zinc ion and the irreversible formation of disulfide bonds 
which permanently deactivate the enzyme, known as the zinc ejection 
hypothesis (Figure 1.5). 
 
Figure 1.5. Zinc ejection hypothesis of disulfiram. Disulfiram and its metabolites transiently 
bind cysteine thiol groups in the active site of an enzyme resulting in ejection of a catalytically 
essential zinc ion and the formation of disulfide bonds.
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Disulfiram is considered a “safe drug”, with rare and generally mild side 
effects. A recent meta-analysis revealed that <1% of patients treated with the 
drug experience adverse events requiring hospitalisation (Skinner et al., 2014).
In most cases, side effects are due to severe disulfiram-ethanol reaction, and 
case studies have documented life threatening cardiac abnormalities due to 
severe hypotension (Becker and Sugarman 1952; Amuchastegui et al., 2014). 
However, the risk of cardiac abnormalities is reduced with dose, and is absent 
upon cessation of ethanol ingestion (Roache et al., 2011). As well as this, there 
are rare cases of neuropathies resulting in lower limb pain and impaired motor 
function (Frisoni and Dimonda 1989; Filosto et al., 2008). This may be due to 
the ability of disulfiram metabolites to accumulate copper into peripheral 
neuronal cells (Tonkin et al., 2004). In addition severe hepatotoxicity has been 
associated with disulfiram treatment, although the cause is incompletely 
understood both the generation of toxic metabolites in this organ and drug-
induced hypersensitivity have been implicated (Berlin 1989; Bjornsson et al., 
2006). There are also reports that disulfiram may induce or worsen psychosis 
(Goldstein et al., 1964; Petrakis et al., 2005).  
 
Disulfiram is rapidly and extensively metabolised and its major metabolite, 
diethyldithiocarbamate (DDC), is generated by reduction of the parent 
compound across the vulnerable disulphide bond (Figure 1.6A). This process 
can occur non-enzymatically, however may be enhanced by conjugation to 
proteins such as albumin or those involved in the glutathione reductase system 
(Agarwal et al., 1983; Nagendra et al., 1991). The rapid reduction of disulfiram 
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suggests that under physiological conditions, and in cell culture where 
disulfiram is added alongside serum, the parent compound has a short half-life. 
To demonstrate this point, studies have shown that reduction of disulfiram to 
DDC is complete 4 min after addition of the drug to human blood samples and 
clinical trials have been unable to detect the parent drug during treatment 
(Cobby et al., 1977; Johansson 1992; Schweizer et al., 2013). However, in vivo 
DDC is also metabolised rapidly and not found in detectable quantities 
within4 hr (Stromme and Eldjarn 1966). Further metabolism occurs via 
glucuronidation, methylation, non-enzymatic digestion, or re-oxidisation into 
 
Figure 1.6. Disulfiram’s metabolic pathway. Disulfiram is reduced across the vulnerable 
disulfide bond to form two molecules of diethyldithiocarbamate (B), further metabolism then 
proceeds via glucuronidation (C), methylation (D) or non-enzymatic degradation (E). 
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disulfiram (Figure 1.6; Eneanya et al., 1981). Of the disulfiram metabolites, the 
methylated derivative is thought to be responsible for many of the in vivo 
properties of the parent compound and one clinical study has suggested that the 
anti-cancer activity of the drug in prostate cancer correlates with S-methyl 
N,N-diethyldithiocarbamate plasma concentration (Schweizer et al., 2013). 
Derivatives of the methylated metabolite are thought to be predominately 
responsible for inhibition of ALDH, and some of the anti-cancer properties of 
disulfiram may also be attributable to other metabolites (Jin et al., 1994; Loo et 
al., 2004; Cvek et al., 2008). The metabolic route of disulfiram breakdown is 
tissue dependent, due to the distribution of the required enzymes, and the 
parent compound and metabolites are excreted via the renal and biliary routes 
(Pike et al., 2001). 
 
1.4. Anti-cancer properties of disulfiram 
Due to its well established safety profile, disulfiram would make an ideal 
candidate for repositioning as an anti-cancer therapeutic agent. Research has 
been conducted to investigate the anti-cancer properties of the drug, which is 
attributed to its ability to bind cysteine thiol groups and divalent cations, 
particularly copper (Sauna et al., 2005; Skrott and Cvek 2012). Hence 
disulfiram is able to interrupt metal dependent processes known to be involved 
in oncogenic development, and there are multiple mechanisms which may 
explain its observed anti-cancer properties.  
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1.4.1. Disulfiram interrupts protein turnover 
One of the most widely reported anti-cancer activities of disulfiram is through 
inhibition of the proteasome. By this mechanism the drug may be able to 
increase levels of cell cycle regulatory proteins such as cyclin dependent kinase 
inhibitors and inhibitor of κB (IκB; Hay et al., 1999; Rousseau et al., 1999; 
Kisselev et al., 2012). Cancer cells have greater sensitivity to proteasome 
inhibition than non-cancer cells and this has been exploited by development of 
the proteasome inhibitor bortezomib, currently used in the treatment of 
multiple myeloma (Drexler et al., 2000; Mateos et al., 2010).  
 
Micromolar concentrations of disulfiram can produce a 75% decrease in 
proteasome activity and as a consequence inhibit nuclear translocation of 
transcription factors such as NFκB family members (Lovborg et al., 2006). The 
NFκB family of transcription factors are responsible for the expression of 
genes associated with a large variety of biological phenomenon, and in cancer 
cells are thought to encourage processes such as proliferation, drug resistance, 
and metastasis (Li et al., 2015). Activation of NFκB is dependent on 
degradation of its endogenous inhibitor, IκB, by the proteasome and it is 
partially through stabilisation of IκB upon proteasome inhibition that 
disulfiram is thought to cause NFκB inhibition; this will be further discussed in 
Section 1.4.3. 
 
The dependence of metal ions on the proteasomal inhibitory effects of 
disulfiram has been investigated. Although one study reported that the addition 
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of copper or zinc had no effect on the drugs proteasome inhibitory activity, 
others have proposed that inhibition is a result of transporting copper to the 
proteasome (Chen et al., 2006; Lovborg et al., 2006). The ability of disulfiram 
to inhibit the proteasome has been reported in myeloma, leukaemic and 
MDA-MB-231 breast cancer cells and xenographs, and in all cases decreased 
cancer cell viability was observed upon disulfiram treatment (Rickardson et al., 
2007; Lovborg et al., 2006; Chen et al., 2006). Hence proteasome inhibition 
appears to be independent of cell type and has in vivo significance. 
Additionally, this proteasome inhibitory effect has been demonstrated with 
DDC and copper co-administration in pancreatic cells and xenographs, 
suggesting that this mechanism may also contribute to the anti-cancer 
properties of the metabolite (Han et al., 2013). The hypothesis that disulfiram 
acts a proteasome inhibitor is the basis of an ongoing clinical trial for the 
treatment of liver metastases whereby the drug is co-administered with copper 
(Clinicaltrials.gov; Identifier NCT00742911). As well as copper, other metals 
have been associated with the ability of disulfiram and its analogues to inhibit 
the proteasome, such as cadmium and gold (Li et al., 2008; Zhang et al., 2010).  
 
As well as disulfiram itself, studies have investigated the role of its analogues 
on proteasome inhibition. Here, the most commonly described analogue is 
pyrollidine dithiocarbamate (PDTC; Figure 1.7A). The structural requirements 
for proteasome inhibition have been investigated in PDTC analogues via 
altering the chemical groups attached to the terminal nitrogen (Yu et al., 
2007b). This study demonstrated that substitution of the pyrrolidine ring with 
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larger and more polar groups decreased the ability of the analogues to bind 
copper and subsequent proteasome inhibition. Some PDTC analogues have 
been found to inhibit the proteasome without causing ALDH inhibition (Wang 
et al., 2011), which may prevent off target and potency limiting effects. 
 
As well as inhibiting the proteasome directly, disulfiram has been reported to 
inhibit an E3 ubiquitin ligase enzyme, termed breast cancer associated gene 2 
(BCA2) via disruption of its zinc finger domain (Burger et al., 1998; Burger et 
al., 2005). Although the exact molecular role of BCA2 in breast cancer has yet 
to be fully elucidated, studies in our laboratory and others have suggested that 
it may have a role on EGFR trafficking (Sakane et al., 2007; Wymant 2015). 
Additional evidence implicating BCA2 in breast cancer is that: (1) its mRNA is 
enriched  in breast  cancer  cell  lines,  (2)  its  transfection into  cells  increases 
proliferation, (3) the gene is found in a region of DNA commonly mutated in 
breast cancer, (4) expression is linked to ER
+
 disease and (5) BCA2 mutation 
 
Figure 1.7. Analogues of disulfiram. (A) Pyrollidine dithiocarbamate (PDTC). (B) Base 
structure of carbamo(diperoxo)thioate analogues. (C) Piperidine analogue of disulfiram. (D) 
Pyrollidine analogue of disulfiram. (E) Base structure of dithiocarbamate analogues. 
 
 28 
 
results in decreased cell metastasis (Burger et al., 2005; Sakane et al., 2007; 
Amemiya et al., 2008). Taken together these results suggest that BCA2 may 
represent a promising therapeutic target in ER
+
 breast cancer.  
 
The observation that the zinc finger domain of BCA2 was required for activity 
led to the hypothesis that disulfiram may be a lead drug candidate for BCA2 
inhibition (Burger et al., 2005; Brahemi et al., 2010). In a collaborative study 
between Cardiff University and Barbara Ann Karmanos Cancer Institute, 
Detroit, several disulfiram analogues were synthesised and their activity 
investigated in BCA2 positive and negative breast cancer cells (Brahemi et al., 
2010). Cell viability studies found that carbamo(dithioperoxo)thioates, 
piperidine and pyrrolidine analogues were only active in BCA2 positive cells 
and in ER (BCA2 positive) transfects (Figure 1.7B-D). Interestingly, 
dithiocarbamate analogues were inactive in all breast cancer cell lines 
demonstrating that the disulphide bridge was required for activity 
(Figure 1.7E). Additionally it was observed that analogues which produced 
growth inhibition also inhibited BCA2 autoubiquitination activity, suggesting a 
causal link between ubiquitination activity and cell death. Zinc 
supplementation with disulfiram analogues was shown to inhibit cell death and 
the authors suggested that these analogues were operating via the zinc ejection 
hypothesis (Figure 1.5). 
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1.4.2. Disulfiram inhibits proteins associated with angiogenesis, metastasis 
and resistance 
Angiogenesis, metastasis and resistance are critical events leading to 
development of more advanced and difficult to treat disease states. Hence 
restricting these processes, and preventing disease progression, may provide a 
favourable outcome in breast cancer. Several studies have been conducted to 
investigate the effects of disulfiram in this regard.  
 
The mechanism of angiogenesis involves hypoxia, followed by release of 
growth factors and formation of new blood vessels. During this process 
reactive oxygen species (ROS) are generated which are toxic in high quantities, 
and require detoxification by enzymes such as superoxide dismutase (SOD; 
Craige et al., 2015). Disulfiram has been shown to inhibit SOD activity and 
thereby decrease new vascular growth in mice injected with basic fibroblast 
growth factor (bFGF) beads (Marikovsky et al., 2002). However, the ability of 
the drug to inhibit angiogenesis in vivo has also been attributed to inhibition of 
matrix metalloproteinases (MMPs; Shiah et al., 2003). MMP enzymes are 
responsible for degradation of extracellular matrix (ECM) allowing for 
migration of endothelial cells towards the tumour, and all MMPs contain a 
catalytically essential zinc ion. This study noted that addition of zinc abrogated 
MMP inhibition, suggesting that the drug was able to eject zinc from the 
enzymes active site. 
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The migration of cells is not only essential for angiogenesis but also for the 
progression to metastatic disease which has a significantly worse prognosis. To 
emphasise the link between angiogenesis and metastasis, disulfiram induced 
inhibition of MMPs has been associated with both processes in endothelial 
cells (Shiah et al., 2003). Inhibition of MMP activity has also been noted in the 
context of breast cancer (Cho et al., 2007). However, it is unclear whether this 
inhibition occurs at the protein or transcriptional level, as this study noted a 
decrease in both MMP expression and activity upon disulfiram treatment. As 
well as this, the drug may alter expression levels of an endogenous MMP 
inhibitor called reversion-inducing cysteine-rich protein with Kazal motifs 
(RECK; Murai et al., 2010). In this context, disulfiram was shown to decrease 
lung metastases following inoculation of fibrosarcoma cells in mice, this may 
also be relevant to breast cancer as the lung is a common site for breast cancer 
metastases. These reports demonstrate three potential mechanisms of inhibition 
of MMP: at the protein level, transcriptional level or up-regulation of 
endogenous MMP inhibitors. 
 
As mentioned in Section 1.2.8, an ongoing problem in cancer therapy is the 
eventual development of drug resistance. Although the issue of resistance is 
complex, one protein family involved are multiple drug resistance (MDR) 
efflux pumps, responsible for ejection of cytotoxins from the cell. Resistant 
cancer cells are able to up-regulate MDR family members, including P-
glycoprotein (P-gp), and prevent drug access to intracellular targets. For 
example, chemoresistance of cancer cells to doxorubicin may be a result of 
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P-gp over-expression and inhibition of this efflux pump has been proposed to 
re-sensitise resistant cells (Umsumarng et al., 2015). Disulfiram and its 
metabolites are able to interact with P-gp and other MDR family members at 
both the ATP and substrate binding sites, and cause irreversible inhibition (Loo 
et al., 2004; Sauna et al., 2004). However as will be discussed in Section 1.4.3, 
the drug is also able to activate Jun N-terminal kinase (JNK) signalling, one 
consequence of which is down-regulation of MDR proteins. This effect has 
been attributed to the re-sensitisation of doxorubicin resistant leukemic cells 
upon disulfiram and copper co-administration (Xu et al., 2011).  
 
One potential therapeutic strategy to limit acquired resistance is through co-
administration of disulfiram with other chemotherapeutic agents, here 
disulfiram may inhibit the causes of resistance and increase sensitivity to the 
chemotherapeutic. To this effect, it has been suggested that encapsulation of 
disulfiram and doxorubicin within micelles may re-sensitise doxorubicin 
resistant MCF-7 cells (Duan et al., 2013). In this study, the micelle was 
manufactured to allow disulfiram release prior to doxorubicin. Encapsulation 
of both agents increased lysosomal doxorubicin accumulation, ultimately 
resulting in reduced tumour size in vivo and cell death in vitro. 
 
It has also been suggested that resistance may be acquired through replication 
of CSC with resistant properties. Disulfiram in combination with copper has 
been shown to target cells which express CSC markers, such as ALDH, Sox2 
and Nanog, and increase sensitivity of chemotherapy drugs in resistant 
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MDA-MB-231 cells (Liu et al., 2013). This effect has also been noted in 
glioblastoma CSC, suggesting that it is a common effect and occurs 
irrespective of tumour type (Hothi et al., 2012). Interestingly ALDH is a 
functional marker of breast CSC suggesting that this effect mirrors the alcohol 
deterrent properties of the drug. To demonstrate this, the ALDH positive 
population of T47D and MDA-MB-231 cell lines have been shown to decrease 
upon disulfiram and copper treatment (Yip et al., 2011). This finding is 
particularly important given the fact that knockdown of ALDH can increase the 
sensitivity of resistant ovarian cancer cells to docetaxel and cisplatin (Landen 
et al., 2010). Taken together these observations provide a potential therapeutic 
strategy for disulfiram in the targeting of CSC, with implications in restoring 
chemo-sensitivity, and directly relates to its well established ALDH inhibitory 
activity. Another potential mechanism of resistance is through up-regulation of 
NFκB signalling, the potential of disulfiram to interfere with this process will 
be further discussed in Section 1.4.3. 
 
1.4.3. Disulfiram can alter gene transcription and signalling cascades 
A common feature of cancer cells is inappropriate induction of signalling 
cascades and activation of transcription factors leading to cancer cell 
proliferation. This process is highly complex and disulfiram has been 
implicated to interfere at various stages and in multiple tumour types. 
 
One of the processes involved in regulating gene transcription is demethylation 
of histones which inhibits tumour suppressor transcription. One histone 
 33 
 
demethylase, JMJD2A, contains a catalytically essential zinc ion and 
disulfiram has been shown to bind this enzyme and release zinc (Sekirnik et 
al., 2009). Although the biological significance of this has yet to be determined 
it is likely that such inhibition will restore expression of tumour suppressors. 
Additionally, methylation of cytosine bases in promoter regions silences gene 
transcription and is viewed as an oncogenic phenomenon, particularly noted in 
prostate cancers (Jones and Baylin 2007). The ability of disulfiram to reduce 
the methylation status of DNA was first identified in 1979 however has only 
recently been attributed to its inhibitory effect on DNA methyltransferase 1 
(DNMT1), due to its interaction with the proteins cysteine thiol groups 
(Swenberg et al., 1979; Lin et al., 2011). Although it is likely that through this 
mechanism disulfiram may restore the expression of multiple tumour 
suppressors, one which has particular relevance in breast cancer is ER-ß 
(Sharma et al., 2015). Here both disulfiram and a novel analogue were capable 
of restoring expression of ERß in prostate cancer cells to levels comparable 
with non-cancerous cell lines. This affect was able to decrease the viability of 
prostate cancer cells in vitro and in mouse xenographs. The hypothesis that 
disulfiram can restore expression of tumour suppressors has led to progression 
of the drug into a Phase II clinical trial, which investigated the ability of 
disulfiram to inhibit DNMT1 activity in patients with non-metastatic, recurrent 
prostate cancer (Schweizer et al., 2013). However, only 20-33% of patients 
showed decreased demethylation activity with daily 250-500 mg oral doses and 
there was unacceptable toxicity in the high dose cohort. The relevance of DNA 
methylation in breast cancer is not as well characterised as in prostate, however 
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increased DNA methylation has been demonstrated in HER2
+
 breast cancers 
and decreased expression of ERß is also a feature of breast cancer cells (Fiegl 
et al., 2006; Omoto and Iwase, 2015). There is also in vivo and in vitro 
evidence to suggest that DNMT inhibitors may increase apoptosis in HER2
+
 
(MCF-7) and HER2
-
 (MDA-MB-231) breast cancer cells (Billam et al., 2010; 
Chen et al., 2012). Therefore there may be value in further investigation of 
disulfiram induced DNMT inhibition in certain types of breast cancer.  
 
As previously discussed in Section 1.4.1, the transcription factor NFB is 
constitutively over-expressed in many types of cancer including breast and 
induces the transcription of pro-cancerous genes, including those associated 
with resistance (Gershtein et al., 2010). As previously discussed, stabilisation 
of Iby disulfiram induced proteasome inhibition has been proposed as a 
mechanism by which the drug inhibits NFB. As NFB is associated with 
chemoresistance, its inhibition would restore sensitivity to drug resistant cancer 
cells. To this effect studies have demonstrated that the drug alone, and in 
combination with copper, is able to decrease NFB DNA binding activity in 
response to chemotherapeutic agents such as 5-Fluorouracil and gemcitabine in 
drug resistant colon cancer cell lines (Wang et al., 2003; Guo et al., 2010). 
Similarly, the inhibitory action of disulfiram and copper on NFκB DNA 
binding activity has been noted in MCF-7, MDA-MB-231 and T47D breast 
cancer cells (Yip et al., 2011). The NFB pathway has also been implicated in 
survival of breast CSC, and disulfiram induced inhibition may be a 
contributing factor in breast CSC death (Liu et al., 2010). Taken together this 
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supports the view that disulfiram targeting of NFκB could provide an effective 
anti-resistance mechanism with favourable clinical implications. 
 
Cross talk between the NFB and JNK- and p38-mitogen activated protein 
kinase (MAPK) pathway is a major obstacle in anti-cancer therapy. Both are 
activated in response to ROS with competing effects; whilst the MAPK 
pathway induces cell death, the NFB pathway mediates survival (McCubrey 
et al., 2006; Nakano et al., 2006). Therefore, inhibition of NFB alone may not 
be sufficient to induce cancer cell death, and a more favourable outcome may 
be achieved through also inducing the MAPK pathway. The ability of 
disulfiram to also stimulate MAPK signalling has been demonstrated in breast 
CSC and doxorubicin resistant leukaemic cells, where it was attributed to CSC 
death and re-sensitisation effects (Xu et al., 2011; Yip et al., 2011). Both 
induction of JNK signalling and inhibition of NFκB activity are properties that 
disulfiram shares with its PDTC analogue (Chung et al., 2000). This dual hit 
approach of disulfiram provides a powerful potential anti-cancer mechanism, 
and may restrict cross talk between these two pathways.  
 
1.4.4. Intracellular metal ion homeostasis and redox affects of disulfiram 
The widely reported synergistic effect of divalent metal ions on disulfiram 
toxicity may be a result of altered intracellular metal homeostasis and 
associated oxidative damage. Oxidative damage may be described as the 
detrimental effect of highly reactive oxygen species on the chemical 
composition of proteins, lipids and DNA resulting in their loss of function. 
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This effect is thought to contribute to the neurotoxicity of disulfiram at high 
concentrations, whereby DDC is able to increase copper levels and induce 
oxidative toxicity in neurones (Tonkin et al., 2004). It has also been 
demonstrated that anti-oxidants, as well as zinc and copper chelators, can 
abrogate the cytotoxic effects of PDTC in neuronal cells (Chung et al., 2000). 
This may also contribute to cancer cell death, as copper and zinc are 
dysregulated in many malignancies and it has been observed that cancer cells 
are under increased oxidative stress than non-cancer cells (Gupta et al., 1991; 
Trachootham et al., 2006). Taken together this could provide a therapeutic 
strategy whereby disulfiram increases oxidative damage though further 
dysregulation of metal ions. This theory has been applied to copper where it 
has been shown that co-administration with disulfiram increases ROS 
production and decreases viability in MCF-7, T47D and MDA-MB-231 cells 
(Yip et al., 2011). Additionally it has been shown that disulfiram is able to 
increase copper ions in melanoma cells (Cen et al., 2004). However there is 
conflicting evidence in the context of this cancer, as it has also been noted that 
disulfiram and copper were unable to increase fluorescence of a redox sensitive 
probe and addition of anti-oxidants did not affect toxicity (Brar et al., 2004). 
Taken together, these studies suggest that the ability of disulfiram to increase 
oxidative damage is cancer type specific and melanoma cells may be able to 
tolerate a higher level of copper compared to other tumour types. Not only 
would oxidative damage contribute to disulfiram cytotoxicity though events 
such as lipid peroxidation, but also may explain some of the drug’s previously 
reported anti-cancer effects. To demonstrate this, the ability of disulfiram 
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analogues to inhibit the proteasome has been attributed to ROS production 
(Zhang et al., 2010).  
 
Many studies investigating the cytotoxic properties of disulfiram and copper 
focus on the ability of the drug to form a copper complex, capable of inhibiting 
the proteasome and inducing oxidative damage (Chen et al., 2006; Tardito et 
al., 2011; Han et al., 2013; Allensworth et al., 2015; Figure 1.8). However, 
Figure 1.8. Disulfiram-copper complex. 
 
more recently the mechanism explaining disulfiram induced generation of ROS 
has been suggested to be a result of the reaction between the drug and copper, 
opposing the idea of this complex being the active form of disulfiram (Lewis et 
al., 2014). This has led to a new proposal regarding the kinetics of the 
disulfiram-copper anti-cancer properties which has been hypothesised as a two 
phase response: rapid cell death caused by a reaction between disulfiram and 
copper leading to generation of ROS followed by the formation of the 
disulfiram-copper complex which has intrinsic cytotoxicity (Tawari et al., 
2015). 
 
Despite knowledge that disulfiram is also able to bind zinc, relatively little has 
been done to investigate its role in this paradigm beyond the zinc ejection 
hypothesis. However, PDTC is able increase intracellular zinc levels and 
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disulfiram and zinc co-incubation increases oxidative damage (Kim et al., 
1999; Pozza et al., 2011). These observations suggest that the relationship 
between disulfiram and zinc is similar to copper with respect to the ability of 
these complexes to increase metal dependent toxicity. This may be particularly 
relevant to the study of disulfiram in the context of breast cancer as zinc is 
known to be dysregulated in this disease (discussed in Section 1.5). However 
beyond its synergistic effect, the influence of zinc on the toxicity of disulfiram 
in breast cancer has yet to be fully elucidated. Interestingly, there is some 
evidence to suggest that disulfiram-zinc complexes do not inhibit the 
proteasome but can still induce apoptosis, suggesting that zinc must enhance 
disulfiram toxicity through separate mechanisms to copper (Li et al., 2008). To 
support the zinc synergistic effects on disulfiram, a case study has 
demonstrated remission in a patient with stage IV liver metastasis treated with 
disulfiram and zinc (Brar et al., 2004).  
 
1.4.5. Disulfiram clinical trials 
The extensive literature surrounding the anti-cancer properties of disulfiram in 
in vivo and in vitro models have led to its progression into clinical trials. For 
example it is currently being investigated as a standalone agent for the 
treatment of prostate cancer (ClinicalTrials.gov identifier: NCT01118741), 
melanoma (NCT00256230) and with copper co-administration for hepatic 
metastases (NCT00742911). Clinical trials are also being conducted where the 
drug is given alongside chemotherapy in non-small cell lung cancer 
(NCT00312819) and glioblastoma (NCT01907165). Data from two of these 
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trials have been published, one of which reported that the drug was able to 
increase survival in patients with advanced lung cancer when used in 
combination with chemotherapy (Nechushtan et al., 2015). However the other 
trial noted safety concerns and a lack of efficacy as discussed in Section 1.4.3 
(Schweizer et al., 2013). This is consistent with a historical clinical trial in 
which the addition of disulfiram increased the toxicity of cisplatin 
chemotherapy in cisplatin sensitive malignancies, but produced no benefit in 
terms of survival or response rate (Verma et al., 1990). These concerning 
results may imply that the favourable side effect profile of the drug when used 
as an alcohol deterrent is not reproduced in its anti-cancer setting. Despite this, 
a clinical trial investigating the effect of adjuvant DDC in breast cancer noted 
its good tolerability with mild nausea being the biggest complaint (Dufour et 
al., 1993). The results of this trial demonstrated that the addition of DDC 
increased the survival of patients by 26% compared to chemotherapy alone and 
indicate the potential of the drug as an anti-breast cancer therapeutic.  
 
1.5. Zinc in breast cancer biology 
With the sole exception of iron, zinc is the most abundant metal in eukaryotic 
systems. The approximate concentration of intracellular zinc is estimated to be 
between 0.1-0.5 mM, although less than 0.001% of this is available in its 
unbound form (Eide 2006). Dysregulation of zinc is implicated in conditions 
such as alopecia, immunodeficiency, and impaired childhood development as 
well as various malignancies including breast (Maret and Sandstead 2006).  
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Zinc has been implicated in oncogenic processes such as caspase and 
phosphatase inhibition, which may result in pro-survival events (Kim et al., 
2006; Velazquez-Delgado and Hardy 2012). In support of the pro-oncogenic 
properties of this metal, over-expression of zinc influx transporters (ZIPs) 
increase breast cancer cell invasiveness and is associated with tamoxifen 
resistance (Kagara et al., 2007; Taylor et al., 2008). Taken together this would 
indicate that zinc promotes survival, however at higher concentrations it is also 
toxic to cancer cells (Bozym et al., 2010). This property may be exploited as 
the basis for a novel cancer therapy whereby drugs which increase intracellular 
zinc will target cancer cells, and induce zinc dependent toxicity. The selectivity 
for this effect is based on the fact that breast cancer cells have higher zinc 
levels than non-cancer cells and therefore will be less able to tolerate changes 
in zinc levels (Rizk and Skypeck 1984; Gupta et al., 1991). 
 
Due the complex relationship between intracellular zinc levels and cell 
viability, intracellular levels of this metal are maintained within tight 
homeostatic control. Regulation may be achieved through expression of metal 
binding proteins, such as metallothionein, or sequestration of the ion into 
intracellular pools including lysosomes (Colvin et al., 2008; Kukic et al., 
2014). As an interesting note, the release of zinc from intracellular stores, 
including the endoplasmic reticulum, in response to extracellular stimuli has 
been implicated as a signalling event (Yamasaki et al., 2007). Therefore the 
subcellular location of zinc is a critical cellular feature which determines not 
only zinc buffering capacity but also signalling processes.
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1.6. Hypothesis and aims 
The current literature surrounding the anti-cancer properties of disulfiram 
predominantly focus on its interaction with copper, however little has been 
done to investigate the role of zinc in this regard. Despite this, there is evidence 
that breast cancer cells may be predisposed to the toxic effects of this metal due 
to zinc accumulation in breast cancer cells compared to non-cancerous cells. 
Therefore this study will investigate the hypothesis that zinc is an important 
factor when considering the ability of disulfiram to induce breast cancer cell 
death.  
 
In order to enhance knowledge of the role of zinc in the sensitivity of breast 
cancer cells to disulfiram, this thesis will address the following aims: 
 Characterisation of the cytotoxic effect of disulfiram in cancerous and 
non-cancerous breast cells. 
 Fully investigate the effect of disulfiram on intracellular zinc in breast 
cancer cells. 
 Define mechanisms to describe the potential link between intracellular 
zinc levels and the anti-breast cancer effect of disulfiram. 
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2. Materials and Methods 
2.1. Chemicals and reagents 
2.1.1. Chemicals, reagents and kits 
Table 2.1. List of chemicals, reagents and kits used in this study. Where appropriate, 
information is also included regarding the stock concentration and diluent.  
Reagent Source Cat. No. [Stock] Diluent 
3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium 
bromide (MTT) 
Sigma-
Aldrich 
M5655 5.5 mg/ml PBS 
4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid 
(HEPES) 
Sigma-
Aldrich 
H3375 - - 
Acetic acid Sigma-
Aldrich 
320099 - - 
Acetone Fisher 
Scientific 
10131560 - - 
Acridine orange (AO) Life Tech. A1301 5 mg/ml dH2O 
Agarose Bio-Rad 161-3100 - - 
Ammonium chloride Sigma-
Aldrich 
A9434 - - 
Bafilomycin Sigma-
Aldrich 
B1793 20 µM DMSO 
Bicinchoninic acid (BCA) Sigma-
Aldrich 
B9643 - - 
Bovine serum albumin (BSA) Sigma-
Aldrich 
A7906 - - 
Bromophenol blue Sigma-
Aldrich 
B0126 - - 
CA-074Me Sigma-
Aldrich 
C5857 10 mM DMSO 
CellTiter Blue Promega G8080 -  
Chloroquine Sigma-
Aldrich 
C6628 100 mM dH2O 
Cholera toxin Sigma-
Aldrich 
S8052 - - 
Clarity ECL reagent Bio-Rad 170-5060 - - 
Copper chloride (CuCl2)  Sigma-
Aldrich 
203149 20 mM dH2O 
Copper sulphate Sigma-
Aldrich 
C2284 - - 
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Dako oil Dako S3023 - - 
Dextran-Alexa 647 (10 kDa)  Life Tech. D-22914 10 mg/ml PBS 
Diethyldithiocarbamate (DDC) Sigma-
Aldrich 
228680 10 mM DMSO 
Disulfiram Sigma-
Aldrich 
86720 10 mM DMSO 
Dithiothreitol (DTT) Sigma-
Aldrich 
DTT-RO - - 
DMEM/ F12 Life Tech. 11330 - - 
Dimethyl sulfoxide (DMSO) Fisher 
Scientific 
10080110 - - 
Epidermal growth factor 
(EGF) 
Sigma-
Aldrich 
E9644 - - 
Ethanol Fisher 
Scientific 
12468750 - - 
Ethidium bromide Sigma-
Aldrich 
E1510 - - 
Ethylenediametetra acetic acid 
(EDTA) 
Sigma-
Aldrich 
E6758 - - 
Fluozin-3 Life Tech. F24195 5 mM DMSO 
Foetal bovine serum (FBS) Life Tech. 16000-044 - - 
Glycerol Sigma-
Aldrich 
G5516 - - 
Glycine Sigma-
Aldrich 
G8898 - - 
Hoescht 33342 Life Tech. H3570 - - 
Horse serum Life Tech. 16050 - - 
Hydrocortisone Sigma-
Aldrich 
H0888 - - 
Insulin Sigma-
Aldrich 
I 9278 - - 
Isopropanol Sigma-
Aldrich 
I9516   
JumpStart™ Taq DNA 
Polymerase 
(For use with LookOut® 
Mycoplasma PCR Detection 
Kit) 
Sigma-
Aldrich 
D9307 - - 
LookOut® Mycoplasma PCR 
Detection Kit 
Sigma-
Aldrich 
MP0035-1KT - - 
LysoSensor Green Life Tech. L-7535 - - 
Methanol Sigma-
Aldrich 
10365710 - - 
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Milk Marvel  - - 
MitoTracker Red Life Tech. M-7512 - - 
N,N,N′,N′-Tetrakis(2-
pyridylmethyl)ethylenediamine 
(TPEN) 
Sigma-
Aldrich 
P4413 10 mM DMSO 
Paraformaldehyde Sigma-
Aldrich 
P6148 - - 
Phenol-red free RPMI 1640 Life Tech. 11835-030 - - 
Polyvinylidene fluoride 
(PVDF) membrane 
Fisher 
Scientific 
10344661 - - 
Pre-cast gel: Mini-PROTEAN 
TGX (12%) 
Bio-Rad 4561041 - - 
Propidium iodide (PI) Life Tech. P3566 - - 
Protease inhibitor cocktail Roche 
Diagnostics 
11836153001 - - 
RPMI 1640 Life Tech. 21875 - - 
Sodium chloride  Sigma-
Aldrich 
S7653 - - 
Sodium dodecyl sulphate 
(SDS) 
Bio-Rad 161-0301 - - 
Sodium pyrithione (NaP) Sigma-
Aldrich 
H3261 10 mM DMSO 
Staurosporine Sigma-
Aldrich 
S4400 10 mM DMSO 
Sucrose Sigma-
Aldrich 
S7903 - - 
Tris-base Sigma-
Aldrich 
00000001070
8976001 
- - 
Tris-HCl Sigma-
Aldrich 
RES3098T - - 
Triton X-100 Sigma-
Aldrich 
X100 - - 
Trypan blue Fisher 
Scientific 
11538886 - - 
Trypsin/ EDTA Life Tech. 25300062 - - 
Zinc chloride (ZnCl2) Sigma-
Aldrich 
229997 20 mM dH2O 
Disulfiram analogues were designed, synthesised and assessed for purity by Dr. 
Andrew Westwell. They were dissolved in dimethyl sulfoxide (DMSO) to 
produce a stock concentration of 10 mM.  
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2.1.2. Antibodies 
Table 2.2. Primary antibody sources and dilutions. List of primary antibodies used for 
immunofluorescence (IF) or Western blotting (WB) in this thesis. *Dr. Emyr Lloyd-Jones 
(Cardiff University, School of Biosciences). †HRP conjugated primary antibody. 
Abbreviations: microtubule associated protein 1 light chain 3 B, LC3B; horse radish 
peroxidase, HRP.   
Antibody Species Source Cat. No. IF dilution WB 
dilution 
LC3B Rabbit Cell 
Signaling 
2775S 1:400 - 
Cathepsin D  
(H75) 
Rabbit Santa Cruz sc-10725 1:50-500 1:1000 
Cathepsin D  
(G19) 
Goat Santa Cruz 
(gifted by 
ELJ*) 
sc-6494 
 
1:200 - 
Cathepsin D  Rabbit Calbiochem 
(gifted by 
ELJ*) 
219361 1:200 - 
Cathepsin B  Goat Santa Cruz sc-6493 
 
1:250 1:1000 
Clathrin 
heavy chain 
Mouse BD 
Biosciences 
610449 - 1:1000 
Transferrin 
receptor 
Mouse Life Tech 13-6800 - 1:1000 
β-tubulin 
(HRP)† 
Rabbit Abcam ab21058 - 1:50,000 
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Table 2.3. Secondary antibody sources and dilutions. Antibodies were used for either IF or 
WB experiments with primary antibodies indicated in the “Use with” column. Abbreviation: 
microtubule associated protein 1 Light Chain 3 B, LC3B; Cathepsin D, CathD; Cathepsin B, 
CathB. 
 
2.2. Cells and cell culture 
2.2.1 Cells, media and cell culture conditions 
MCF-7, MDA-MB-231, T47D, and BT474 cells were originally obtained from 
AstraZeneca or directly from ATCC. MCF-10A cells were purchased during 
the course of this thesis from ATCC. Cells were cultured at 37
o
C and 5% CO2 
in a humidified incubator and their growth monitored every 2/ 3 days via 
brightfield microscopy. MCF-7, MDA-MB-231, T47D, and BT474 cells were 
maintained in RPMI 1640 media containing 300 mg/ ml L-glutamine and 
phenol red, as obtained from supplier, and additionally supplemented with 10% 
Antibody Species Tag Source Cat. 
No.  
Dilution Use with 
For IF:       
Anti-
rabbit 
Goat Alexa 
647 
Life 
Tech. 
A11010 1:400 LC3B, CathD 
(H75) 
Anti-goat Rabbit Alexa 
647 
Life 
Tech. 
A21085 1:400 CathD (G19), 
CathB 
Anti-
rabbit 
Goat Alexa 
488 
Life 
Tech. 
A31556 1:400 CathD 
(Calbiochem) 
For WB:       
Anti-
rabbit 
Goat HRP Thermo 
Scientific 
32460 1:1000 CathD  
Anti-goat Rabbit HRP Life 
Tech. 
R21459 1:1000 CathB 
Anti-
mouse 
Goat  HRP Thermo 
Scientific 
32430 1:1000 Clathrin heavy 
chain, 
transferrin 
receptor 
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heat inactivated FBS (HI-FBS; heat inactivated by 30 min incubation in a 56
o
C 
water bath) which was sterile filtered using a 0.22 µm filter. MCF-10A cells 
were maintained in phenol red and L-glutamine containing DMEM/ F12 
additionally supplemented with filter sterilised 5% HI-horse serum, 100 ng/ ml 
cholera toxin, 10 µg/ ml insulin, 20 ng/ ml EGF, and 500 ng/ ml hydrocortisone 
(Santner et al., 2001). Herein these are respectively termed cell culture media. 
All cell lines were grown in the absence of antibiotics. 
 
For microscopy studies, cells were placed in cell imaging media which 
consisted of phenol red free RPMI 1640 supplemented with 10% HI-FBS and 
50 mM HEPES pH 7.4 that was filter sterilised before use. 
 
2.2.2. Routine cell culture 
All cell culture solutions were pre-warmed to 37
o
C in a water bath and cell 
work was conducted in a sterile cell culture hood which was thoroughly 
disinfected with 70% ethanol prior to and following use. Once cells had 
achieved 70% confluency in a T75 cell culture flask they were passaged by 
washing once with sterile 1.5 ml phosphate buffered saline (PBS) and once 
briefly with 1 ml 0.05% trypsin/ EDTA. Cells were then incubated for 3 min 
(MCF-7, MDA-MB-231, T47D, and BT474) or 15 min (MCF-10A) with 1 ml 
trypsin/ EDTA or until 90% of cells were detached. Cell culture media (6 ml) 
was added to the resulting suspension which was centrifuged at 900x g for 3 
min and the supernatant containing the media and trypsin/ EDTA discarded, 
hereafter this process is referred to as trypsinisation. The cell containing pellet 
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was resuspended in 10 ml cell culture media and used in experiments or a 
proportion added to a new T75 cell culture flask. For MDA-MB-231, cells 
were split at a ratio of 1/ 5, whereas MCF-7 and MCF-10A cells were split 2/ 5 
and T47D and BT474 were split 1/ 2. Cell culture media was then added to the 
flask so that the final cell culture volume was 10 ml. 
  
Frozen cell stocks were made using cells at the lowest possible passage number 
(passage 12-16 for MCF-7, MDA-MB-231, T47D, and BT474 and passage 4 
for MCF-10A). Prior to freezing, cells were grown in T75 cell culture flasks 
until 65-70% confluent (log phase growth) before trypsinisation. Cells were 
then resuspended in 6 ml cell culture media containing 20% HI serum, 5% 
DMSO and 2 ml of the resulting suspension aliquoted into cryovials. These 
were then placed in an isopropanol containing Mr. Frosty™ freezing container 
and placed overnight first at -20
o
C and then -80
o
C, before long-term storage in 
liquid nitrogen. To defrost, cryovials were removed from liquid nitrogen and 
incubated at 37
o
C until completely defrosted. Immediately following this, the 
cells were added to 10 ml pre-warmed cell culture media and the resulting 
suspension centrifuged at 900x g for 3 min. The cell pellet was then 
resuspended in 6 ml cell culture media, which was added to a T25 flask. Upon 
achieving 70% confluency, cells were transferred to a T75 flask and passaged 
at least once more before use in experiments. Cancer cells (MDA-MB-231, 
MCF-7, T47D and BT474) were cultured until reaching a maximum passage 
28, whilst MCF-10A cells were cultured till passage 11 before new cell 
aliquots were defrosted. 
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2.2.3. Mycoplasma testing 
All cell lines grown in the lab were tested for Mycoplasma approximately 
every 6 months via the commercial polymerase chain reaction (PCR) based 
“LookOut® Mycoplasma PCR Detection Kit” used with “JumpStart™ Taq 
DNA Polymerase”. This assay amplifies a region of DNA highly conserved 
between Mycoplasma and Acholeplasma and can therefore detect all common 
cell culture infectants. For this, 500 µl samples of fresh (<24 hr) cell culture 
media from cells grown to 90-100% confluency were taken from T75 flasks. 
Samples were then heated at 95
o
C for 10 min, centrifuged at 13,000x g for 
10 sec and the supernatant retained and stored at 4
o
C before testing. PCR tubes 
were supplied pre-loaded with primers, nucleotides, internal control DNA and 
gel loading buffer, additionally positive control tubes contained DNA from 
non-infectious Mycoplasma orale. A mastermix of 0.5 µl polymerase (stock 
2.5 units/ µl) and 22.5 µl rehydration buffer (as provided by supplier) per 
sample was prepared and added to the pre-loaded PCR tubes. Samples or 
negative control (autoclaved dH2O) were added to tubes at a volume of 2 µl, so 
that final volume in the tube was 25 µl, for positive control 25 µl of mastermix 
only was added to each tube. Samples were then placed in a PCR thermal 
cycler with a 105
o
C heated lid and the programme set as follows: 
No activation step  
1 cycle 94
o
C for 2 min 
40 cycles 94
o
C for 30 sec 
                55
o
C for 30 sec 
                72
o
C for 40 sec 
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Held at 4
o
C and left over night. 
 
The following day a 1.5% agarose gel was cast by mixing 1.5 g agarose in 
100 ml TAE buffer (140 mM Tris-base, 20 mM acetic acid, 1 mM EDTA 
dissolved in dH2O). This was gradually heated in a microwave to prevent 
boiling, until complete dissolution of the agarose and allowed to partially cool. 
Ethidium bromide (50 µl of 5 µg/ ml stock) was added to the solution and the 
gel was cast using a 5 mm comb. After the gel had set, the tank was filled with 
TAE buffer, gel loaded with the 6 µl/ well PCR products and run for 2 hr at 
80 V. The gel was then analysed in a BioRad ChemiDoc imaging system. 
 
2.3. Viability studies 
2.3.1. Establishing density of cells in solution 
To calculate the number of cells per ml solution for use in counting studies 
(Section 2.3.2) and for plating, cells were trypsinised and resuspended in 10 ml 
cell culture media. A sample (50 µl) of the cell suspension was mixed in a 1:1 
ratio with trypan blue and gradually added to each of two chambers of a 
haemocytometer. The cells were then visualised using brightfield microscopy, 
and trypan blue-free cells counted in two of the four grids of each chamber in 
the haemocytometer, i.e. a total of four grids. The number of cells per ml was 
determined using the following equation: 
Cells per ml= Trypan blue-free cells counted x 2* x 10,000 
    4† 
*to account for 1:1 trypan blue dilution 
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†number of grids counted 
 
To calculate the volume of cell suspension required for cell plating the 
following equation was then used: 
Volume (ml)= Required no. cells per ml x total required volume (ml) 
                     Counted cells per ml  
This volume of cell suspension was then added to sufficient cell culture media 
for the total required volume.   
 
2.3.2. Cell counting to determine cytotoxic effects 
Cell counting is an established method to analyse the particular effect of any 
added reagent and was initially utilised to investigate disulfiram. MCF-7 and 
MDA-MB-231 cells were plated at a density of 70,000 and 56,000 cells per 
well respectively in 12 well plates in a final well volume of 2 ml. Cells were 
allowed to adhere for 24 hr before media was replaced with a 2 ml solution of 1 
or 10 µM disulfiram or equivalent volume DMSO in cell culture media. After 
24, 48 or 72 hr drug incubation, cells were trypsinised by briefly washing each 
well first with 500 µl sterile PBS then with 200 µl trypsin/ EDTA. They were 
then incubated with 150 µl tryspin/ EDTA for 3 min or until 90% detachment 
was observed and then resuspended in cell culture media to produce a final 
volume of 2 ml. The total number of cells in this suspension was determined 
using the methodology and equations described in Section 2.3.1. For each 
individual experiment duplicate assay points were obtained. 
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2.3.4. MTT and CellTiter Blue assays 
2.3.4.1. Cell plating 
To account for different growth rates, cells were seeded in 96 well plates at 
densities optimised to provide 70% confluency after a total incubation period 
of 96 hr. These are shown in Table 2.4. 
 
Table 2.4. Table of seeding densities for 96 well plates for each line used in this study. 
Cell Line Number of cells/ well 
MCF-7 2500 
MDA-MB-231 2000 
BT474 12,500 
T47D 11,000 
MCF-10A 3000 
 
Cells were seeded by preparing a cell suspension of the required density which 
was then added to wells using a multi-channel pipette. For MTT and cell 
morphology assays cells were plated in transparent 96 well plates in a volume 
of 100 µl/ well, whereas for the CellTitre Blue fluorescence assay plating was 
conducted in black 96 well plates containing 50 µl/ well. For all assays the 
outermost wells of the plate were kept empty in order to minimise the influence 
of edge effects. “Blank” wells were also included which were treated 
identically to treatment wells but in the absence of cells and drugs. 
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2.3.4.2. Serial dilutions and cell treatments 
Stock solutions of drugs were made at the highest possible concentration in 
order to minimise the effects of diluent on cytotoxicity (stock concentrations 
summarised in Table 2.1), for many drugs including disulfiram, DDC and 
disulfiram analogues this was 10 mM. Serial dilutions were typically prepared 
in a 10 fold dilution series to produce final concentrations ranging between 
0.0001 and 100 µM in cell culture media. At 100 µM drug concentration from 
a 10 mM stock, the volume of drug stock added to the cell culture media was 
1% of the total treatment solution, therefore this volume of diluent was added 
to negative control wells. Serial dilutions were prepared immediately before 
their addition to treatment wells and added in a volume equivalent to the media 
already present in the well. Additionally wells were treated with cell culture 
media in the absence of drug in order to determine the impact of DMSO on 
viability. Cells were treated in triplicate 24 hr after plating and then incubated 
for between 4-72 hr as described in results.  
 
2.3.4.3. MTT assay 
Exactly 4 hr prior to completion of the incubation time 20 l MTT (from 
5.5 mg/ ml stock in PBS) was added to each well using a multi-channel pipette. 
The plate was incubated for 4 hr under cell culture conditions before the 
contents of the wells were removed by inverting the plate. The formazan 
crystals produced by viable cells were dissolved by adding 200 µl DMSO to 
each well and the plate incubated at 37
o
C for 30 min. The absorbance produced 
by each well was finally measured on a plate reader set at 550 nm.  
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2.3.4.4. CellTiter Blue assay 
In a similar manner to the MTT assay, 20 µl CellTiter Blue reagent, as 
provided by supplier, was added to each well 4 hr prior to completion of the 
incubation time. The plate was then maintained under cell culture conditions 
for the remainder of the experiment and the fluorescence produced by live cells 
determined using a Fluostar Optima fluorescent plate reader (Excitation 
filter= 544nm, emission filter= 590nm). 
 
2.3.5. Live cell imaging of cell morphology following disulfiram treatment 
The morphology of MCF-7 and MDA-MB-231 cells was evaluated in order to 
qualitatively assess the toxic effects of disulfiram treatment following 72 hr 
incubation. For this, MCF-7 and MDA-MB-231 cells were seeded in 
transparent 96 well plates at a densities described in Table 2.4 at 100 µl/ well. 
Exactly 24 hr after plating, cells were treated with disulfiram in a 10 fold serial 
dilution between 1-100 µM, DMSO equivalent to the highest drug 
concentration (i.e. 1%) or cell culture media, in triplicate. Cells treated with 
cell culture media in the absence of drug or DMSO served as a comparison to 
determine the toxic effects of DMSO and ensure that untreated cells retained 
their characteristic growth rates and morphology as observed under normal cell 
culture conditions. Wells were incubated with the drug for 72 hr under cell 
culture conditions before a representative image of their morphology was taken 
using a Leica wide field DMIRB fluorescence inverted microscope equipped 
with a 40x objective on its brightfield setting. Media and DMSO treated wells 
were imaged last to ensure that that any toxic phenotype observed with 
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disulfiram treatment was not a result of cells being removed from cell culture 
conditions.  
 
2.3.6. Propidium iodide (PI) uptake in disulfiram treated cells 
As a means to measure cytotoxicity, the ability of disulfiram to influence 
uptake of PI, a dye only permeable to cells with a compromised plasma 
membrane, was analysed via microscopy. MDA-MB-231 and MCF-7 cells 
were plated onto 35 mm MatTek imaging dishes at a density of 75,000 and 
100,000 cells per dish. After 24 hr incubation, cell culture media was removed 
and replaced with a 2 ml solution of 1 µM disulfiram or equivalent DMSO in 
cell culture media. The dish was then incubated under cell culture conditions 
for an additional 72 hr, after which the treatment solution was replaced with 
cell culture media containing 500 ng/ ml PI. The dish was then incubated for a 
further 30 min before it was washed thrice with 1 sterile PBS, and imaging of a 
representative field conducted in the presence of cell imaging media using a 
Leica wide field DMIRB fluorescence inverted microscope equipped with a 
40x objective. Dishes were prepared immediately prior to imaging which lasted 
no more than 15 min in order to minimise the time which cells were outside of 
cell culture conditions. 
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2.4. Plating and fixation techniques for fluorescence microscopy  
2.4.1. Plating cells on coverslips  
In order to conduct the mitochondrial fragmentation and immunofluorescence 
studies described in Sections 2.5.1 and 2.6, cells were first plated onto 
coverslips. Coverslips were maintained in 70% ethanol, 30% dH2O to ensure 
sterility and added to a 12 well plate 30 min before the addition of cells. 
Coverslips were washed thrice with 1 ml sterile PBS before plating to ensure 
the complete removal of ethanol immediately prior to cell plating. MCF-7 and 
MDA-MB-231 cells were then added to the wells at a density of 125,000 and 
100,000 cells/ well respectively in 2 ml cell culture media and left overnight to 
adhere before being processed as described in Sections 2.5.1 and 2.6.  
 
2.4.2. Paraformaldehyde (PFA) fixation 
For cathepsin D and B immunofluorescence studies (Section 2.6.2), cells were 
fixed with PFA. For this fixation technique, wells were washed thrice with 1 
ml PBS before the addition of 1 ml 3% PFA dissolved in PBS. Following 15 
min incubation at room temperature, they were then subjected to an additional 
3x 5 min PBS washes. A 1 ml solution of 50 mM ammonium chloride 
dissolved in PBS was added to each well and incubated for 10 min at room 
temperature in order to quench autofluorescence. Wells were finally washed 
three times with PBS before being further processed for immunofluorescence 
analysis.  
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2.4.3. Methanol and acetone fixation 
Methanol was used for fixing cells in LC3B immunofluorescence studies 
(Section 2.6.1), acetone was used in mitochondrial fragmentation studies 
(Section 2.5.1) and optimisation of cathepsin D immunofluorescence involved 
both fixatives (Section 2.6.2). For these studies fixation involved removing 
cells from 37
o
C incubation and then maintaining them on ice throughout the 
fixation procedure. Coverslips were first washed three times with 1 ml chilled 
PBS, and then incubated with 1 ml chilled 100% methanol or 80% acetone, 
20% dH2O at -20
o
C for 10 min. Coverslips were washed again with PBS 3x 5 
min before being further processed for analysis. 
 
2.5. Fluorescent probes  
2.5.1. Effects of disulfiram on mitochondrial fragmentation  
The ability of disulfiram to alter the appearance of the mitochondrial network 
was determined as a means of more effectively evaluating the drug’s cytotoxic 
effects. MCF-7 or MDA-MB-231 cells were plated onto coverslips (Section 
2.4.1) and allowed to adhere overnight. The following day the media was 
replaced with a 2 ml solution of 1 µM disulfiram or equivalent volume DMSO 
diluted in cell culture media and incubated under cell culture conditions for 
between 1-72 hr in duplicate. The media was then removed and replaced with 
100 nM of MitoTracker Red reagent diluted in serum free RPMI 1640 and 
incubated under cell culture conditions for an additional 30 min. Cells were 
then fixed via acetone (Section 2.4.3) and mounted onto slides using Dako oil. 
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Slides were allowed to dry for 30 min before being sealed with clear nail 
varnish and a representative field imaged a Leica SP5 confocal inverted 
microscope equipped with a 40x objective and 633 nm laser. 
 
2.5.2. Live cell imaging of intracellular zinc 
The zinc dye, Fluozin-3, was used to visualise changes in intracellular zinc 
levels in live cells upon disulfiram treatment. MCF-7 or MCF-10A cells were 
plated onto 35 mm MatTek imaging dishes at densities of 250,000 and 300,000 
cells/ dish and left to adhere overnight. The following day, media was replaced 
with 1 ml cell culture media containing 5 µM Fluozin-3 and incubated under 
cell culture conditions for 30 min. The dish was then washed three times with 
PBS, 1 ml cell imaging media added and placed on a confocal microscopy 
stage pre-heated to 37
o
C. Representative regions of cells were captured using a 
488 nm laser before and subsequent to the drop wise addition of 1 ml cell 
imaging media containing 10 M disulfiram, sodium pyrithione (NaP; positive 
control) or diluent control. The same field was then imaged as indicated in the 
results over a period of 30 min.  
 
2.5.3. Flow cytometry to quantify disulfiram effects on Fluozin-3 
fluorescence 
A flow cytometry assay was developed to quantify changes in Fluozin-3 
fluorescence upon disulfiram treatment under various experimental conditions. 
For this MCF-7, MDA-MB-231 and MCF-10A cells were plated into 12 well 
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plates at densities of 125,000, 100,000 and 150,000 cells/ well respectively and 
returned to cell culture conditions overnight. Under normal experimental 
conditions, the following day media was replaced by 1 ml cell culture media 
containing 5 µM Fluozin-3 and incubated for 30 min. However, where 
indicated in results cells were instead incubated with serum free media +/- 
20 µM ZnCl2 or CuCl2 containing 5 µM Fluozin-3. In these studies this 
variation in media constituents was maintained throughout the experimental 
procedure. Wells were then washed three times with 1 ml PBS and treated for 
10 min with media containing 1-100 µM disulfiram, 100 µM DDC, 100 µM 
FS03EB, 10 µM NaP or DMSO equivalent to the highest drug concentration. 
Cells were detached as described in Section 2.3.2, resuspended in 500 µl PBS 
per well, added to a pre-cooled eppendorf and maintained on ice for all 
subsequent steps. Detached cells were pelleted by centrifugation at 200x g, 4
o
C 
for 5 min, the supernatant discarded, and washed with 500 µl pre-cooled PBS. 
They were centrifuged again before being resuspended in cell imaging media 
or serum free imaging media +/- 20 µM ZnCl2 or CuCl2. Flow cytometry was 
conducted using a BD Biosciences FACSVerse system using a 488 nm laser. 
For each assay point, 10,000 events were analysed and the geometric mean of 
samples recorded. 
 
2.5.4. Comparative localisation of intracellular zinc with endocytic probes 
in disulfiram treated cells 
As the endocytic fluorescent probe dextran-Alexa 647, specifically pre-labels 
the fluid phase endocytic pathway and lysosomes of cells, it therefore could be 
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used to investigate whether disulfiram localised zinc to endocytic organelles 
(Al-Taei et al., 2006; Sayers et al., 2014). MCF-7 cells were plated onto 35 
mm MatTek dishes as described in Section 2.5.2 and returned to cell culture 
conditions overnight. To label the entire fluid phase endocytic network, the 
following day media was replaced with 500 µl cell imaging media containing 
250 µg/ ml dextran-Alexa 647 for 4 hr. To specifically label lysosomes, cells 
were incubated with dextran-Alexa 647 for 2 hr followed by three 1 ml PBS 
washes and 4 hr chase incubation with 500 µl cell imaging media. During the 
final stages of this incubation, the media was supplemented with 5 µM 
Fluozin-3 for 30 min, washed with PBS, and treated with 10 µM disulfiram for 
10 min. Cells were then washed three times with 1 ml PBS, which was 
replaced with cell imaging media and representative images taken on a 37
o
C 
pre-heated stage via live cell confocal microscopy using 633 and 488 nm 
lasers.  
 
Pearson’s coefficient is a commonly used statistic that describes the extent of 
co-localisation between two differently coloured images where 1.0 is perfect 
co-localisation, 0 reflects random distribution and -1.0 is a perfect inverse co-
localisation. Pearson’s coefficient is calculated by analysis of each pixel’s 
intensity within two corresponding differently coloured channels, in this case 
red and green channels, to determine if there is a relationship between them. 
For this, ImageJ was used in combination with the JaCOP plug-in to quantify 
the extent of co-localisation between dextran-Alexa 647 and Fluozin-3. JaCOP 
was downloaded via the following link: 
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http://imagejdocu.tudor.lu/doku.php?id=plugin:analysis:jacop_2.0:just_another
_colocalization_plugin:start and saved in the “Plugins” folder of the ImageJ 
software. For analysis, confocal images from both fluorescent channels were 
opened in ImageJ individually. The JaCOP plug-in was opened in a new 
window by following the path: Plugins>JaCOP. Pearson’s co-efficient was 
selected under “Analysis to perform” and the “Analyze” button produced the 
Pearson’s coefficient value.  
 
2.5.5. Effect of bafilomycin on disulfiram induced zinc uptake 
Bafilomycin was used as an inhibitor of the endosomal H
+
-ATPase pump to 
determine whether the sequestration of endo-lysosomal zinc in response to 
disulfiram required the pH gradient that exists between these compartments 
and the cytosol. For this MCF-7 cells were plated onto 35 mm MatTek dishes 
as described in Section 2.3.6 and the following day the media replaced with 
2 ml cell culture media containing 80 nM bafilomycin or DMSO and returned 
to cell culture conditions for 2 hr. During the final stages of the incubation, 
cells were additionally treated with 5 µM Fluozin-3 for 30 min, washed three 
times with 1 ml PBS and treated for 10 min with 10 µM disulfiram or DMSO 
in cell culture media. Cells were then washed thrice with PBS and imaged in 
the presence of 2 ml cell imaging media via confocal microscopy using a 40x 
objective and a 488 nm laser on a stage pre-heated to 37
o
C. In order to ensure 
that this incubation period and concentration of bafilomycin could effectively 
decrease lysosomal pH, a bafilomycin control dish was prepared whereby cells 
were treated with 80 nM of the drug or DMSO for 2 hr as above and loaded 
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with 1 µM LysoSensor Green for the final 30 min of the incubation. 
LysoSensor Green is a fluorescent probe which localises to lysosomes and its 
fluorescent output is inversely proportional to lysosomal pH. Cells were then 
washed three times with PBS and imaged in cell imaging media via confocal 
microscopy.  
 
2.5.6. Optimisation of acridine orange (AO) as an indicator of lysosomal 
membrane permeabilisation (LMP) 
AO, a dye which becomes sequestered only in lysosomal compartments with 
intact membranes, was investigated for its potential to visualise LMP. For these 
studies, MCF-7 cells were plated onto 35 mm MatTek dishes as described in 
Section 2.3.6. After 24 hr under cell culture conditions, media was removed 
and replaced with 1 ml of 1.25, 2.5 or 5 µg/ ml AO in cell culture media. Cells 
were then incubated for 15 min under cell culture conditions before being 
washed three times with 1 ml PBS and addition of 1 ml cell imaging media. 
The dish was placed on a pre-heated 37
o
C microscope stage of a confocal 
microscope and a representative field imaged using a 488 nm laser and 40x 
objective (Pre-treatment). A “mock” treatment was added to the dish which 
consisted of 1 ml cell imaging media in the absence of drug and images of the 
same field taken between 2-10 min after treatment. 
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2.6. Immunofluorescence microscopy 
2.6.1. Effect of disulfiram on localisation of LC3B as an indicator of 
autophagy 
Immunofluorescence analysis was used to visualise changes in the localisation 
of LC3B, a protein which accumulates on autophagic membranes, upon 
disulfiram treatment. For this MCF-7 cells were plated onto coverslips as 
described in Section 2.4.1, and incubated overnight to allow adherence. The 
following day, cells were treated with disulfiram at a concentration of 10 µM 
for 6 hr, 1 µM for 24 hr, or an equivalent volume of DMSO in duplicate and 
maintained in cell culture conditions. Chloroquine (100 μM, 6 hr), an agent 
that causes LC3B accumulation via stabilisation of autophagosomal 
membranes, served as a positive control (Geng et al., 2010). Coverslips were 
fixed with methanol, as described in Section 2.4.3 and then removed from 12 
well plates and placed cell side down on 150 µl of blocking solution (5% FBS 
in PBS) for 1 hr at room temperature. They were then incubated overnight at 
4
o
C in a new 12 well plate which was placed in a humidified chamber and 
contained a 1:400 dilution of LC3B primary antibody (Table 2.2) in 300 µl 
antibody dilution buffer (1% BSA in PBS) per well. The following day cells 
were washed with PBS 3x 5 min and coverslips placed cell side down on 150 
µl of antibody dilution buffer containing Alexa 647 conjugated goat anti-rabbit 
secondary antibody diluted 1:400 (Table 2.3) and 1 µg/ ml Hoescht 33342 to 
label the nucleus. As secondary only controls, antibody dilution buffer only in 
the absence of primary antibodies was used. Coverslips were incubated with 
the antibody and dye for 2 hr at room temperature before being placed back in 
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the 12 well plate and washed with PBS 3x 5 min. Finally, coverslips were 
dipped in PBS then dH2O and mounted onto slides. Imaging of representative 
fields was conducted via epi-fluorescence microscopy on a Leica wide field 
DMIRB fluorescence inverted microscope or confocal microscopy on a Leica 
SP5 confocal inverted microscope equipped with a 40x objective as indicated 
in results.  
 
2.6.2. Optimisation of immunofluorescence methods for the detection of 
cathepsin B and D 
The fact that disulfiram was shown to cause accumulation of zinc in endo-
lysosomal compartments led to the investigation of whether these structures 
were damaged in response to the drug. For this, the ability of disulfiram to alter 
the localisation of lysosomal peptidases cathepsin B and D was determined via 
immunofluorescence. MCF-7 cells were plated onto coverslips (Section 2.4.1) 
and incubated overnight. Where indicated in results, cells were treated for 1 hr 
with 100 µM disulfiram or equivalent DMSO diluted in cell culture media and 
then fixed using PFA (Section 2.4.2), acetone or methanol (Section 2.4.3). 
Following washing in PBS the coverslips were placed on 150 µl of blocking 
solution (in the case of PFA fixation blocking solution was additionally 
supplemented with 0.3% Triton X-100 as a permeabilising agent) for 1 hr at 
room temperature. Coverslips were then returned to the 12 well plate and 
300 µl of a 1:50-1:250 final dilution (as indicated in results) of primary 
antibody diluted in antibody dilution buffer (with 0.3% Triton X-100 for PFA 
fixed cells) added per well. Plates were then placed in a humidified chamber 
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and incubated overnight at 4
o
C. The following day coverslips were washed 3x 
5 min with 1 ml PBS and placed on 150 µl of Alexa fluorophore conjugated 
secondary antibodies, as indicated in Table 2.3 and results in Chapter 6, diluted 
1:400 in antibody dilution buffer and incubated at room temperature for 2 hr. 
Coverslips were finally washed in PBS 3x 5 min, dipped once in PBS, once in 
dH2O and mounted onto slides. Imaging of a representative field was then 
conducted via confocal microscopy with a 40x objective using 633 nm or 
488 nm lasers. 
 
2.7. Lysate collection for Western blotting 
The ability of antibodies to detect cathepsin D and B lysosomal proteases via 
Western blotting was investigated using untreated MCF-7 lysates. To collect 
the lysates MCF-7 cells were plated into 6 well plates at a density of 250,000 
cells per well and left to adhere overnight. Plates were maintained on ice 
throughout the lysate collection procedure. They were first washed twice with 
ice-cold PBS (1 ml) and then 100 µl lysis buffer (150 mM sodium chloride, 
50 mM Tris-base, 1% NP-40, pH 8 and protease inhibitor cocktail) added per 
well. Cells were incubated with the lysis buffer for 5 min whilst subjected to 
continual shaking and then removed from the wells by cell scraping. The 
resulting lysate suspension was transferred to a pre-cooled eppendorf, 
centrifuged at 13,000x g, 4
o
C for 10 min and the supernatant collected into a 
sterile pre-chilled eppendorf. Western blotting (Section 2.9) was then used for 
the detection of cathepsins D and B. 
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2.8. Subcellular fractionation to generate membrane and cytosolic 
fractions of cells 
Subcellular fractionation was used to separate intracellular compartments and 
investigate localisation of cathepsin D and B within membrane and cytosolic 
fractions upon disulfiram treatment. For these studies MCF-7 cells were grown 
in 2x 10 cm cell culture dishes in a volume of 10 ml until 70-80% confluent, 
(Figure 2.1). Dishes were treated with 100 µM disulfiram or equivalent DMSO 
in 5 ml cell culture media for 1 hr, then the dishes were transferred onto ice, 
washed three times with 2 ml ice-cold HES buffer (20 mM HEPES, 1 mM 
EDTA, 250 mM sucrose, protease inhibitor cocktail, pH 7.4) and finally 
overlaid with 1 ml HES buffer. The cells were detached from plates via 
scraping, the resulting cell suspension added to a pre-chilled eppendorf and 
centrifuged at 200x g, 4
o
C for 5 min to isolate a cell pellet. The supernatant 
was discarded and cell pellets from dishes under the same experimental 
conditions (for example, pellets from two dishes treated with 100 µM 
disulfiram) combined in 500 µl HES buffer and added to a single eppendorf. 
Cells were then passed through a 21 gauge needle approximately 40 times until 
plasma membranes, but not nuclear envelopes, were lysed. This process was 
monitored via microscopy using trypan blue staining that will not label intact 
cells but clearly labels released nuclei. This suspension was centrifuged at 
4000x g, 4
o
C for 2 min, and the resulting post nuclear fraction (PNF) collected
 87 
 
 
Figure 2.1. Schematic of the subcellular fractionation procedure. 
 
as a supernatant. A 50 µl sample of PNF was retained and the remaining 
volume transferred to a clean pre-chilled tube and subjected to ultra-
centrifugation at 120,000x g, 4
o
C for 2 hr. The cytosolic fraction was collected 
from the supernatant and the pellet (membrane fraction) was resuspended in 
60 µl HES buffer. Cathepsin B and D was then detected via Western blotting, 
as described in Section 2.9. 
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2.9. Protein quantification and Western blotting 
2.9.1. Protein quantification: Bicinchoninic Acid (BCA) assay 
Once samples had been prepared (Sections 2.7 and 2.8), their protein 
concentration was determined via the BCA assay. BSA was used for 
preparation of protein calibration curves at concentrations of 0-1 mg/ ml. BSA 
was prepared in lysis or HES buffer for samples collected from cell lysates or 
subcellular fractionation respectively. Sample concentrations were expected to 
exceed the linear BSA range and were further diluted 1:2 with lysate or HES 
buffer. A solution of 49 parts BCA to 1 part copper sulphate was prepared and 
200 µl added to each well of a 96 well plate which was maintained on ice. BSA 
protein standards (in triplicate) and diluted samples (in duplicate) were added 
to the wells in a volume of 10 µl per well. The plate was then incubated at 
37
o
C for 30 min and absorbance measured using an automated plate reader at 
562 nm. The concentration of samples was determined by extrapolating from a 
calibration curve generated in Microsoft Excel using BSA standards. Samples 
were then diluted in buffer so that they were all at the same concentration for 
electrophoresis. 
 
2.9.2. SDS-PAGE electrophoresis, and Western blotting 
Samples were mixed in a 3:1 ratio with loading buffer (2% SDS, 10% glycerol, 
0.02% bromophenol blue, 62.5 mM Tris-HCl, 400 mM dithiothreitol (DTT)), 
and heated to 95
o
C for 5 min. They were then centrifuged at 13,000x g for 1 
min to pellet debris and either stored at -20
o
C or used immediately. A 12% pre-
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cast gel (Mini-PROTEAN TGX, Bio-Rad) was added to the electrophoresis 
tank which was filled with running buffer (385 mM glycine, 250 mM Tris-
base, 0.5% SDS dissolved in dH2O). Wells were washed in running buffer, 25 
µl of the samples added to six lanes and 5-10 µl of molecular weight marker 
added to two lanes of the gel. The proteins were separated for 1 hr 25 min at 
100 V and then the gels were then removed from the electrophoresis tanks and 
washed for 5 min with transfer buffer (250 mM glycine, 20 mM Tris-base pH 
8, 20% methanol and 80% dH2O) in preparation for protein transfer. 
 
2.9.3. Protein transfer and immunodetection 
PVDF membranes were pre-soaked for 1 min in methanol and 10 min in 
transfer buffer. Additionally the blotting paper and sponges was soaked for 10 
min in transfer buffer. The transfer sandwich was prepared with sponges, 
blotting paper, gel and PVDF membrane and added to the transfer tank which 
contained pre-chilled transfer buffer and an ice block. Transfer was conducted 
at 100 V for 1 hr during which the buffer was continually stirred with a 
magnetic stirrer. The membrane was removed from the transfer sandwich, 
washed once with dH2O, incubated at room temperature for 5 min with 
Ponceau S solution and washed again with dH2O. The Ponceau S stained 
membrane was used to check protein loading and transfer efficiency. The 
membrane was washed again with dH2O and blocked for 1 hr in 5% milk 
diluted in PBST (0.025% Tween in PBS). It was then cut into strips at 
appropriate molecular weight for the proteins of interest and incubated 
overnight at 4
o
C with 2% milk diluted in PBST containing primary antibodies 
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(cathepsin D, cathepsin B, transferrin receptor, and clathrin heavy chain) at 
concentrations indicated in Table 2.2. For subcellular fractionation samples ß-
tubulin and transferrin receptor was detected as loading controls for cytosolic 
and membrane proteins respectively and in order to normalise band intensities 
between disulfiram and DMSO treatment for each fraction. The membrane was 
then washed in PBST 3x 5 min and incubated with HRP conjugated secondary 
antibodies diluted in 2% milk for 1 hr as indicated in Table 2.3. The exception 
to this procedure was when using the HRP conjugated ß-tubulin primary 
antibody which was diluted in 5% milk and incubated with the membrane for 
1 hr at room temperature directly after blocking. The membrane was subjected 
to 3x 5 min PBST washes and developed by 5 min incubation at room 
temperature with Clarity ECL substrate. The membrane was then imaged using 
a Bio-Rad ChemiDoc. 
 
2.9.4. Densitometry  
Images were assessed for saturation using Bio-Rad’s Image Lab software 
which labels saturated pixels red. Non-saturated TIFF images were chosen for 
densitometry analysis, and were opened in ImageJ and converted to greyscale 
by Image>Type>8-bit. The “Rectangular Selections” tool was used to highlight 
the first band and the path Analyze>Gels>Select First Lane used to label the 
band as lane “1”. The rectangular selection was then dragged to the second lane 
and Analyze>Gels>Select Next Lane used to label lane “2”. This process was 
repeated until all lanes had been labelled and then Analyze>Gels>Plot Lanes 
used to show the profile plot of each selection with the height of the peak 
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indicating band intensity. The “Straight Line Tool” was used to mark the base 
of each peak in order to distinguish between band intensity and background 
noise. Using the “Wand Tool”, each peak was selected and the peak area 
displayed in a pop up window. Peak areas were copied into Microsoft Excel. 
Results are expressed as a percentage of the DMSO band intensity for each 
fraction.  
 
2.10. Statistical testing 
Unless otherwise stated in figure legends, the data presented represent analysis 
from three independent experiments. Significance of differences between two 
datasets were determined, as appropriate, using students two tailed T-test in 
Microsoft Excel and displayed as *p<0.05 or **0.001. For comparisons of 
three or more datasets, significance was determined by one-way analysis of 
variance (ANOVA) combined with Dunnett’s test using GraphPad Prism 
software. Data is presented as the mean, or for flow cytometry data geometric 
mean, and error bars represent standard error of the mean.  
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3. Cytotoxic effects of disulfiram in breast cancer cells  
3.1. Introduction 
Disulfiram induced cytotoxicity has been reported in a variety of cancer cell 
lines including myeloma, prostate, melanoma, glioblastoma, colorectal, 
osteosarcoma and breast, indicating that the drug may have potential in the 
treatment of a wide range of cancer types (Wang et al., 2003; Brar et al., 2004; 
Chen et al., 2006; Lovborg et al., 2006; Cho et al., 2007; Lin et al., 2011; 
Hothi et al., 2012). However, a biphasic response to the drug has been 
observed whereby despite sensitivity at lower concentrations viability is 
partially restored at ~10 µM which may have implications in its therapeutic use 
(Wickstrom et al., 2007; Guo et al., 2010; Yip et al., 2011). Despite its 
frequency within the literature and the possible clinical limitation, this effect 
remains largely uncharacterised and its molecular causes are unresolved. It has, 
however, been noted for the disulfiram analogue PDTC that extracellular signal 
regulated kinase (ERK) dephosphorylation and JNK phosphorylation in 
response to the drug also occurs biphasically (Chung et al., 2000). The ability 
of disulfiram to induce cell death has been largely attributed to occur via 
apoptosis as determined by cleavage of the caspase target protein poly ADP 
ribose polymerase (PARP) and increased Annexin V staining, a measurement 
of the apoptotic redistribution of phosphatidylserine onto the outer leaflet of 
the plasma membrane (Cen et al., 2004; Chen et al., 2006). However little has 
been done to determine the role of other cell death modalities in the anti-cancer 
response to the drug, although one study in fibrosarcoma and cervical cancer 
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cells has observed paraptosis, defined as the vacuolisation of the endoplasmic 
reticulum, in response to disulfiram (Tardito et al., 2011). 
 
One of the most widely studied potential anti-cancer applications of disulfiram 
is as a future breast cancer therapy; particularly as a supplement to other 
treatments. Here the drug’s cytotoxicity has most frequently been investigated 
in MDA-MB-231, MCF-7 and T47D cell lines (Yip et al., 2011). However 
there is conflicting evidence regarding the sensitivity of MDA-MB-231 cells to 
the drug, as it has been shown that IC50 values range from <0.5 µM to >10 µM 
(Brahemi et al., 2010; Yip et al., 2011; Liu et al., 2013). One study has 
suggested that these cells lack disulfiram sensitivity due to low expression of 
BCA2, an E3 ubiquitin ligase thought to be associated with ER
+
 breast cancer 
development and a proposed target of the drug (Brahemi et al., 2010). 
However other potential anti-breast cancer mechanisms exist and it has been 
observed that disulfiram is also able to inhibit the proteasome, NFB signalling 
and act as a copper ionophore which may also contribute towards its toxic 
effects (Chen et al., 2006; Yip et al., 2011; Allensworth et al., 2015). 
Interestingly breast cancer cells also differ in their biphasic response which has 
only been observed in MDA-MB-231 and MCF-7 but not T47D cells (Yip et 
al., 2011). Additionally, there is some evidence to suggest that disulfiram is 
selectively toxic to breast cancer cells, as MCF-10A breast epithelial cells 
retain normal morphology in conditions which produce apoptosis in the 
metastatic form of this cell line (Chen et al., 2006). 
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Many assays exist to measure viability effects, commonly they rely on end-
points such as morphological features, metabolic enzyme activity, membrane 
permeability, cell cycle arrest and detection of proteins involved in specific cell 
death pathways, for example caspases. An ideal viability assay would be highly 
reproducible, easy to implement and interpret and high through-put. 
 
Aims and Objectives 
The primary objective of this chapter is to compare commonly used viability 
assays and assess which is the most suitable for the study of disulfiram 
cytotoxic effects. A secondary objective is to provide further characterisation 
of disulfiram cytotoxicity in a range of breast cancer cell lines. The aims of this 
chapter are therefore: 
 To compare and optimise different cytotoxicity assays to measure the 
response of breast cancer cells to disulfiram. 
 To investigate the cytotoxicity profile of the drug in these cells. 
 To provide insight into the method of cell death in response to 
disulfiram.   
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3.2. Results 
3.2.1. Effect of disulfiram on cell number and morphology 
Studies were initially conducted to investigate the suitability of various 
viability assays in determining the sensitivity of MCF-7 (ER
+
) and 
MDA-MB-231 (ER
-
) cells to disulfiram. These cell lines were chosen due to 
reported differences in BCA2 expression and the inhibitory effects of 
disulfiram on this protein; more importantly they also differ in their expression 
of ER which could be used to identify potential future treatment populations 
(Brahemi et al., 2010). Initial experiments focussed on the effects of the drug 
on physical properties of cells, namely cell number and morphology. For 
counting experiments, cells were treated with 1 or 10 µM disulfiram or diluent 
control for 24-72 hr before detachment and cell counting on a haemocytometer. 
In MCF-7 cells 1 µM disulfiram significantly decreased cell number at 24 hr, 
however no statistical significance was achieved at longer time points, possibly 
due to high variability between repeat experiments (Figure 3.1A). When 
MCF-7 cells were treated with 10 µM disulfiram no significant data were 
obtained at any time point, although a 40% decrease in cell count was noted at 
72 hr (Figure 3.1B). In comparison, the drug was unable to decrease the 
number of MDA-MB-231 cells at any concentration or time point, suggesting 
that this cell line is unresponsive to disulfiram viability effects 
(Figure 3.1C-D).
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Figure 3.1. The effects of disulfiram on cell number. MCF-7 (A, B) and MDA-MB-231 
(C, D) were treated with 1 (A, C) or 10 µM (B, D) disulfiram (DSF) or diluent control (DMSO) 
for the indicated time points. Cells were then detached and counted using a haemocytometer. 
T-tests were conducted between equivalent time points to compare disulfiram and control 
data. *p<0.05. Error bars show standard error.
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To investigate the effects of disulfiram on cell morphology, cells were treated 
with 1-100 µM disulfiram and imaged via brightfield microscopy after 72 hr. 
In MCF-7 cells a biphasic response to the drug was observed whereby at 
10 µM morphology was comparable with diluent control, however at 1 and 
100 µM there was clear morphological damage indicating loss of viability 
(Figure 3.2A). In MDA-MB-231 cells, 1 µM disulfiram did not produce a toxic 
phenotype, however some cells exhibited signs of damage at 10 µM and at 
100 µM very few viable cells remained (Figure 3.2B).  
 
 
Figure 3.2. Representative images of the effects of disulfiram on cell morphology. MCF-7 
(A) and MDA-MB-231 (B) cells were treated with the indicated concentration of disulfiram or 
diluent control (DMSO) for 72 hr before imaging via brightfield microscopy. Scale bars show 
10 µm.
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3.2.2. Disulfiram increases uptake of Propidium Iodide (PI) in MCF-7 but 
not MDA-MB-231 cells 
To determine whether membrane permeability was an appropriate 
measurement for the cytotoxic effects of disulfiram, PI a dye which is only 
permeable to cells with a compromised plasma membrane, was investigated. 
This dye is often used to measure necrosis in short incubations and as a 
complementary necrosis probe in apoptosis assays that also measure the 
flipping of phosphatidylserine. For these studies cells were treated with 1 µM 
disulfiram for 72 hr before being stained with PI and live cells imaged 30 min 
later via epi-fluorescence microscopy. Accurate quantification of this technique 
using microscopy was not possible as the confluency of cells varied between 
fields of view and it was difficult to distinguish between individual cells in 
brightfield images. Despite this, the number of PI positive MCF-7 cells 
appeared to increase upon disulfiram treatment compared to diluent control 
(Figure 3.3A). In comparison and consistent with data from cell counting 
studies, MDA-MB-231 cells did not respond to the drug and the proportion of 
PI positive cells appeared similar between disulfiram and DMSO treatment 
(Figure 3.3B). 
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Figure 3.3. Disulfiram increases propidium iodide uptake in MCF-7 but not MDA-MB-231 cells. 
MCF-7 (A) or MDA-MB-231 (B) cells were treated with 1 µM disulfiram or diluent control (DMSO) 
for 72 hr prior to staining with propidium iodide (PI). Live cells were then imaged via epi-fluorescence 
microscopy. Scale bars show 10 µm. 
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3.2.3. Disulfiram produces a biphasic toxicity profile in MCF-7 cells  
Viability of disulfiram treated cells was then determined using assays which 
measure the activity of reductase enzymes. These enzymes alter the spectral 
properties of the redox sensitive dyes MTT and CellTiter Blue, therefore the 
detection of colorimetric or fluorescent products is higher in live cells. Initial 
experiments were conducted with serial dilutions of disulfiram for 72 hr prior 
to the addition of MTT or CellTiter Blue reagent. Reduction of MTT was then 
measured by dissolution of the resulting crystals in DMSO and analysis using a 
colorimetric plate reader. The CellTiter Blue assay provided a much simpler 
protocol whereby fluorescence was measured via an automated plate reader 
directly following incubation with the reagent, without the need for crystal 
dissolution. In both assays MCF-7 cells were highly sensitive to the drug with 
IC50 values of ~0.3 µM (Figure 3.4A-B). In support of earlier findings these 
cells also exhibited a biphasic peak where at 10 µM viability was partially 
restored, however this effect was more exaggerated in the CellTiter Blue assay. 
Despite data from the MTT assay indicating the sensitivity of MDA-MB-231  
Figure 3.4. Disulfiram produces biphasic toxicity in MCF-7. MCF-7 or MDA-MB-231 cells 
were treated with a serial dilution of disulfiram and viability analysed after 72 hr via MTT (A) 
or CellTiter Blue (B) assay. Error bars show standard error. 
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cells at 1 and 10 µM, limited cytotoxic effects were observed at these 
concentrations when the CellTiter Blue assay was employed. Due to the 
consistency between these and earlier findings and the ease of implementation, 
the CellTiter Blue assay was used in further studies.  
 
3.2.4. DMSO decreases cell viability at 1% and staurosporine produces a 
dose-response effect 
To provide negative and positive controls for the CellTiter Blue assay, cells 
were treated with serial dilutions of either DMSO or staurosporine, a drug 
commonly used as a potent apoptosis inducer (Hasegawa et al., 2012), for 
72 hr and viability measured. Both cell lines were sensitive to the effects of 
DMSO at 1%, equivalent to 100 µM disulfiram, where viability was reduced to 
67% and 80% for MCF-7 and MDA-MB-231 cells respectively (Figure 3.5A). 
However, no viability effects were noted below this concentration for either 
cell line. This data implies that some of the toxicity observed at 100 µM 
disulfiram in earlier studies may be attributable to the diluent. Despite the 
observed toxicity of DMSO at 1%, subsequent studies continued to extend the 
 
Figure 3.5. The cytotoxic profile of DMSO and staurosporine. Cells were treated with serial 
dilutions of DMSO (A) or staurosporine (B) for 72 hr and viability analysed via CellTiter Blue 
assay. 1% DMSO is equivalent to 100 µM disulfiram. Error bars show standard error. 
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concentration of the drug from 0.0001-100 µM for typical viability assays in 
order to demonstrate the limits of the biphasic peak observed at 10 µM (Figure 
3.4). Both cell lines exhibited similar sensitivity to staurosporine which 
potently decreased cell viability with IC50 for both cell lines <0.1 µM (Figure 
3.5B). Importantly, no biphasic peak was observed in MCF-7 cells 
demonstrating that this effect noted in previous studies is disulfiram dependent 
and not a result of this assay. 
 
3.2.5. The cytotoxic effect of disulfiram is dependent on cell line, time and 
concentration 
Viability studies using the CellTiter Blue assay were conducted in order to 
further characterise the cytotoxic effect of disulfiram on breast cancer cells. 
Viability was assessed in an extended panel of breast cancer cell lines chosen 
to model clinically relevant disease sub-types, these included ER
+
/ HER2
-
 
(T47D), ER
+
/ HER2
+
 (BT474) and the non-cancerous breast epithelial 
MCF-10A line. Similarly to MCF-7, toxicity was observed in the ER
+
 BT474 
cell line (IC50 0.3 µM) and produced a biphasic profile (Figure 3.6A). However 
not all ER
+
 cells responded equally to the drug (T47D IC50 >10 µM) indicating 
that the presence of ER is not a pre-requisite for sensitivity. Equally, disulfiram 
was unable to produce cytotoxicity in the MCF-10A cell line (<10 µM) 
demonstrating that the drug is selectively toxic to cancer cells.  
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Figure 3.6. The cytotoxic profile of disulfiram in breast cancer cells. (A) Cells were treated 
with a serial dilution of disulfiram and viability analysed after 72 hr using the CellTiter blue 
assay. (B) MCF-7 cells were treated for 8-72 hr with disulfiram prior to analysing viability. T-
tests were conducted between equivalent time points to compare 1 and 10 µM data. *p<0.05 
**p<0.001. (C) MCF-7 cells were treated for 72 hr with disulfiram at concentrations between 
1-100 µM prior to analysing viability. Error bars show standard error. 
 
It was then investigated whether this biphasic response was affected by 
incubation times. MCF-7 cells were treated with 1, 10 and 100 µM disulfiram 
over a range of time points and cell viability was then determined. Despite an 
initial cytotoxic phase at <8 hr, cell viability at 10 µM was restored at greater 
than 24 hr (Figure 3.6B). For other concentrations disulfiram produced a time 
dependent decrease in viability; at 1 µM viability steadily decreased between 4 
and 72 hr whereas at 100 µM there was a rapid loss of viability to <10% within 
4 hr. This data demonstrates that the 10 µM disulfiram response is due to 
recovery from initial effects and not inactivity of this drug at this 
concentration. When the biphasic peak in MCF-7 cells was investigated at 
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concentrations between 1 and 100 µM at a single 72 hr time point, viability 
was restored to >80% between 5-20 µM concentrations of the drug (Figure 
3.6C).  
 
3.2.6. Disulfiram causes fragmentation of the mitochondrial network 
The morphology of mitochondria treated with disulfiram was analysed in order 
to determine whether there were any cytotoxic changes in this organelle. As 
mitochondria and apoptosis are intrinsically linked the data may also provide 
information on the mechanism of action of this drug. MCF-7 and 
MDA-MB-231 cells were treated with 1 µM disulfiram for 1-72 hr before 
being stained with the mitochondrial probe MitoTracker Red and live cells 
imaged via confocal microscopy. High resolution images of DMSO treated 
MCF-7 cells show the mitochondria as a network of interconnected structures 
(Figure 3.7A). Upon incubation with disulfiram however mitochondria appear 
punctate at time points as early as 1 hr, indicating rapid mitochondrial 
fragmentation. In comparison fragmentation of MDA-MB-231 cell 
mitochondria is more subtle and only apparent after 24 hr (Figure 3.7B). The 
organisation of mitochondria within these two cell lines is very different and is 
a more obvious phenotypic change than the effects of disulfiram. In addition, 
data interpretation was made more difficult as within a single population of 
cells the morphology of the mitochondria within both cell lines was highly 
variable.  
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Figure 3.7. Disulfiram causes changes in mitochondrial structure. MCF-7 (A) and 
MDA-MB-231 (B) cells were treated with 1 µM disulfiram or equivalent DMSO for the 
indicated time points, stained using MitoTracker Red and fixed with acetone. Images were 
obtained via confocal microscopy and show a single z-projection through centre of the cells. 
Scale bars show 10 µm. 
 
3.2.7. Disulfiram does not induce autophagy 
In order to determine whether disulfiram promotes autophagy, MCF-7 cells 
were treated with 1 or 10 µM disulfiram for 6 or 24 hr respectively and 
analysed via immunofluorescence with antibodies recognising LC3B, a marker 
of autophagic membranes. For these experiments 6 hr treatment with 100 µM 
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chloroquine, an agent which causes accumulated LC3B via stabilisation of 
autophagosomal membranes, was used as a positive control (Geng et al., 
2010). Chloroquine treatment produced large LC3B containing structures 
representing autophagosomes, however this phenotype was absent in cells 
treated with disulfiram at both 10 µM for 6 hr (Figure 3.8A) and 1 µM 
for 24 hr (Figure 3.8B). 
 
Figure 3.8. Disulfiram does not alter the localisation of autophagic membranes. MCF-7 
cells were treated with 10 µM disulfiram for 6 hr (A), 1 µM for 24 hr (B), chloroquine 
(100 µM, 6 hr) or diluent control (DMSO). Immunofluorescence analyses were then conducted 
using antibodies recognising LC3B and in (A) nuclei were labelled with Hoescht 33342. 
Imaging was conducted via confocal microscopy in (A) where images show a single z-
projection or epi-fluorescence microscopy in (B). Scale bars show 10 µm.  
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3.3. Discussion 
Previous studies have investigated the ability of disulfiram to induce 
cytotoxicity using a variety of techniques including analysis of DNA content to 
indicate apoptosis, PARP fragmentation and MTT assays (Chen et al., 2006; 
Yip et al., 2011). The primary aim of this chapter was to determine which 
assay is the most suitable for studying the cytotoxicity of disulfiram in breast 
cancer cells. Initial studies focussed on the number of cells that remained 
attached to the plastic surface after disulfiram treatment and the morphology of 
those that were still adherent. Of these, cell counting studies (in MCF-7 and 
MDA-MB-231 cells) were unable to produce statistical significance between 
disulfiram and diluent control treated cells in all but one condition (1 µM, 
24 hr) despite an obvious trend indicating the toxic effect of the drug at this 
concentration at other time points. The lack of significant data is likely to be 
due to poor reproducibility between repeat experiments as indicated by the 
large standard error bars. Cell morphology studies very clearly demonstrated 
that MCF-7 cells exhibit a biphasic toxicity response, whereby at 10 µM 
viability is restored. Images demonstrating viability effects of disulfiram in 
MDA-MB-231 cells reveal that there is no effect at 1 µM although partial 
sensitivity occurs at 10 µM and there is extensive cell death at 100 µM. It 
should be noted that this effect in not solely attributed to the drug and that the 
diluent at 1% concentration had some inherent cytotoxicity. Previous reports 
conflict regarding the sensitivity of the MDA-MB-231 cell line to disulfiram. 
In one study, the morphology of cells treated with 15 µM for 24 hr do not 
display a toxic phenotype (Chen et al., 2006). Consistent with this, other 
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studies have also noted that disulfiram IC50 values in MDA-MB-231 cells, as 
determined by the MTT assay are >10 µM (Brahemi et al., 2010). Others have 
demonstrated IC50 values for disulfiram treated MDA-MB-231 cells of 
between 0.5-1.5 µM indicating much higher sensitivity than previously 
suggested (Yip et al., 2011; Liu et al., 2013). Additionally when these cells are 
used in xenograph models disulfiram inhibits tumour growth suggesting that 
the apparent lack of sensitivity is an in vitro artefact, possibly due to low 
copper concentrations in cell culture conditions and the requirement of this 
metal in disulfiram toxicity (Chen et al., 2006). 
 
Many viability assays are dependent on the metabolic activity of reductase 
enzymes in altering the spectral properties of a dye. What is therefore 
measured is the metabolic rate of a cell at a particular point in time rather than 
whether the cell is alive or dead. These assays have the advantage of being 
conducted in 96 well plates meaning that it is possible to investigate multiple 
conditions at the same time. This study compared two of these dyes that form 
part of the MTT and CellTiter Blue assays. Data from these studies produced 
conflicting results regarding the sensitivity of MDA-MB-231 cells, and it is 
possible that this is a result of differences in reduction of MTT and CellTiter 
Blue reagent within these cells. There was, however, correlation between the 
results of the CellTiter blue assay and morphology studies for this cell line and 
the data from MCF-7 cells reinforced the biphasic viability peak observed in 
the morphology studies. The CellTiter Blue assay was simple to perform and 
produced a fluorescent product which resulted in low standard error and a high 
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signal to noise ratio. In comparison the MTT assay involved multiple steps and 
a colorimetric product producing higher standard error. Due to this, and the 
good correlation of the results with earlier findings, the CellTiter Blue assay 
was chosen for all further studies. Further studies were not conducting using PI 
based methods as quantification using this technique was difficult. 
 
To further investigate the viability effects of disulfiram in breast cancer cells, 
cytotoxicity studies were carried out in an extended panel of breast cancer cell 
lines including BT474, T47D and non-cancerous breast epithelial MCF-10A. 
Of these only BT474 cells showed sensitivity to the drug at concentrations 
<100 µM, and produced a biphasic viability profile similar to that obtained 
with MCF-7 cells which occurred between 5-20 µM. Interestingly, both these 
disulfiram responsive cell lines are ER
+
 raising the possibility that the drug is 
only toxic to this breast cancer sub-type, although data with the T47D cell line 
indicates that not all ER
+
 tumours may respond to the drug. The selectivity of 
disulfiram for ER
+
 breast cancer cells, including T47D, has been previously 
been noted and attributed to the fact that these cells are also BCA2
+
 (Brahemi 
et al., 2010). Interestingly, this study also demonstrated that transfection of ER 
into MDA-MB-231 cells increased disulfiram sensitivity. As well as this, 
others have reported on the disulfiram sensitivity of T47D cells, however in 
this paper the cells were seeded at a lower density of 5000 cells per well 
compared to the 11,000 used in this thesis which may explain this apparent 
difference (Yip et al., 2011). Importantly, MCF-10A cells did not respond to 
the drug at concentrations <100 µM demonstrating selectivity towards breast 
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cancer versus non-cancerous breast epithelial cells which may indicate a 
favourable adverse effect profile in its clinical application.  
 
To further characterise the biphasic toxicity profile of the drug, experiments 
were conducted to investigate its time dependency at concentrations within this 
biphasic range. These studies demonstrated that this response is due to 
recovery of initially affected cells and is therefore highly time dependent. 
Importantly this may explain why it is frequently reported in the literature at 
time points greater than 24 hr (Wickstrom et al., 2007; Yip et al., 2011; Rae et 
al., 2013), however, to our knowledge, no studies have investigated the 
sensitivity of cells to disulfiram at shorter (<8 hr) time points. Although the 
clinical significance of this effect remains to be determined there is in vivo 
evidence that disulfiram doses of 25 µg/ mouse/ day are more effective at 
decreasing tumour weight in glioma xenographs than 120 µg/ mouse/ day 
(Marikovsky et al., 2002). No studies have provided a mechanism to describe 
the underlying cause of this biphasic effect, which has never been reported to 
increase viability beyond 100% indicating that this represents loss of cytotoxic 
effects rather than a growth promoting action at this concentration. A curious 
feature of this biphasic effect was that it was noted in all cell lines which 
demonstrated significant sensitivity to disulfiram in this study, indicating that 
this is a universal feature under the conditions used here. Several possibilities 
exist which could explain the biphasic nature of disulfiram, although none have 
been investigated thoroughly or provide a full explanation. It may be the case 
that the hydrophobic nature of disulfiram prevents its complete dissolution in 
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aqueous solutions, and the drug forms an inactive precipitate at 10 µM. 
However, this explanation does not explain the fact that at time points <24 hrs 
MCF-7 cells demonstrated significant sensitivity of the drug in this study or 
that cytotoxicity is restored at concentrations >10 µM. A complicating factor in 
disulfiram viability studies is the drug’s extensive metabolism and this feature 
may also provide an explanation for this biphasic phenomenon. It may be the 
case that an inactive disulfiram metabolite competes with the cytotoxic form of 
the drug, possibly by chelating copper or zinc ions within the cell which 
enhance the drugs cytotoxicity (Cen et al., 2004; Yip et al., 2011). Finally it 
has been proposed that this biphasic effect, also noted for the disulfiram 
analogue PDTC, may occur due to the activation of either ERK or JNK at 
certain concentrations and therefore may be a result of concentration dependent 
activation of signalling cascades (Chung et al., 2000).  
 
Apoptosis has been proposed to be the main route of disulfiram induced cell 
death as the drug has been demonstrated to promote cleavage of caspase 
substrates, indicating activation of these pro-apoptotic enzymes, and the 
generation of Annexin V positive cells (Cen et al., 2004; Yip et al., 2011). This 
protein (as a fluorescent conjugate) has binds phosphatidylserine that is flipped 
from the inner to the outer leaflet of the plasma membrane during apoptosis. 
The mitochondria are critical for apoptotic cell death whereby translocation of 
Bcl family members, including Bax and Bak, to the mitochondrial outer 
membrane, triggers release of cytochrome c from the inter membrane space of 
the organelle to the cell cytosol (Lalier et al., 2007). As well as this Bax/ Bak 
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mitochondrial translocation promote mitochondrial fission events and the 
resulting fragmentation of the mitochondrial network is a morphological 
feature of apoptosis (Sheridan et al., 2008; Young et al., 2010). For example 
treatment of cardiac cells with the anti-cancer agent doxorubicin caused visible 
mitochondrial fragmentation as revealed using mitochondrial dyes and 
confocal microscopy (Catanzaro et al., 2015). Extensive disulfiram induced 
mitochondrial fragmentation was noted in MCF-7 as early as 1 hr following 
treatment with 1 µM drug, indicating that this process occurs before reduction 
in metabolic activity as measured by the CellTiter Blue assay. This finding 
supports the hypothesis that cell death due to disulfiram occurs as a result of 
mitochondria induced apoptosis. Additionally when autophagy was 
investigated as an alternative cell death mechanism it was found that this 
process did not occur, providing further support for apoptosis being the cause 
of disulfiram induced cell death.
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4. Investigation into the zinc ionophore effect of 
disulfiram and its relation to viability in breast cancer 
cells 
4.1. Introduction 
Much of the current literature surrounding the anti-cancer properties of 
disulfiram focuses on its interaction with copper. It is well established that the 
drug forms a copper complex which is capable of inhibiting the proteasome, 
and is also an ionophore of this metal resulting in increased oxidative damage 
to cancer cells (Chen et al., 2006; Tardito et al., 2011; Han et al., 2013; 
Allensworth et al., 2015). Despite knowledge that the drug is also able to bind 
zinc, little has been done to characterise the effect of this metal in the anti-
cancer activities of the drug. However, the proteasomal inhibitory action of a 
complex involving the drug’s major metabolite, DDC, and zinc has been 
demonstrated in breast cancer cells (Cvek et al., 2008). The metabolite has also 
been shown to increase intracellular zinc levels in bovine endothelial cells, and 
through this mechanism inhibit NFκB activation (Kim et al., 2000). 
Additionally, the ability of the disulfiram analogue PDTC to induce pancreatic 
cancer cell death may be reversed by addition of zinc chelators raising the 
possibility that these anti-cancer properties are dependent on its demonstrated 
zinc ionophore action (Donadelli et al., 2009). As well as this, there is evidence 
to support the possibility that disulfiram may also have ionophore effects as it 
has been shown to elevate ROS levels in pancreatic cancer cells when co-
incubated with zinc (Pozza et al., 2011). However others have noted that the 
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drug decreases intracellular zinc levels in hepatic cells and attributed this to its 
zinc chelation activity (Hao and Maret 2006). 
 
To demonstrate the importance of zinc in biological systems, it has been 
estimated that 10% of the human proteome contains zinc binding proteins and 
40% of these are transcription factors (Andreini et al., 2006). Due to the 
important role of this metal in cellular processes, total intracellular zinc levels 
are between 0.1 and 0.5 mM, however the majority of this is in its protein 
bound form and <0.001% is available as free zinc (Eide 2006). The low 
availability of free zinc is likely due to the acute toxicity of this metal, whereby 
addition of as little as 1 µM free zinc ions to cell media can induce cell death 
(Bozym et al., 2010). Therefore intracellular zinc levels are maintained within 
a narrow range and zinc homeostasis mechanisms are critical to cell survival. 
Zinc binding proteins, including the metallothionein protein family, are thought 
to be predominantly responsible for this buffering effect under steady state 
conditions (Colvin et al., 2010). In support of this, expression of 
metallothioneins is regulated by zinc availability and their up-regulation 
protects cells from metal induced oxidative damage (Andrews 2000; Qu et al., 
2013). In zinc challenged cells these buffering processes are supported by the 
action of zinc transporter proteins which shuttle the metal into certain 
subcellular compartments to combat raises in free intracellular zinc levels, this 
is known as the “muffler model” (Colvin et al., 2010). Zinc transport to 
organelles requires the involvement of zinc transporter protein families 
including zinc transporters (ZnTs) which facilitate removal of the metal ion 
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from the cytosol and zinc influx transporters (ZIPs) responsible for zinc 
movement in the opposite direction. The subcellular location of transporters 
such as ZnT1, ZnT7 and ZnT2 have identified their role in delivering zinc to 
the endoplasmic reticulum, Golgi apparatus and secretory vesicles and endo-
lysosomes respectively (Kirschke and Huang 2003; Lazarczyk et al., 2008; 
Lopez and Kelleher 2009). In particular the endo-lysosomal accumulation of 
zinc has been noted in response to the zinc ionophore clioquinol and high 
oxidative stress, indicating that this may be a detoxification mechanism 
(Hwang et al., 2008; Yu et al., 2009). Additionally, the over-expression of 
ZnT2 has been shown to protect breast cancer cells from the cytotoxic effects 
of the metal ion by sequestering it in vesicles (Lopez et al., 2011).  
 
It has been widely reported that in breast cancer tissues, zinc levels are higher 
in cancer cells compared to the surrounding stoma (Rizk and Skypeck 1984; 
Riesop et al., 2015). In support of this, serum zinc levels are lower in breast 
cancer patients presumably as a result of zinc transport from the serum to the 
tumour (Gupta et al., 1991; Pavithra et al., 2015). Although to the best of our 
knowledge no comparative studies have quantified zinc levels in cancerous 
versus non-cancerous cells, semi-quantitive analysis in in vitro breast cancer 
cell models has revealed that zinc levels may be 2.5-5 fold greater than in non-
cancerous cell lines (Lopez et al., 2011; Chandler et al., 2016). This effect has 
also been observed in histology samples from breast cancer patients which 
report 72-320% higher zinc levels in breast cancer tissue compared to non-
cancerous breast from the same patient (Margalioth et al., 1983; Geraki et al., 
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2002). The ability of breast tumours to accumulate zinc is most likely due to 
increased expression of ZIP influx transporters, which in in vitro cell models 
also increase drug resistance and metastatic activity (Taylor et al., 2008; 
Hogstrand et al., 2013). Therefore not only is zinc accumulation a feature of 
breast tumours but also provides an indication of disease aggression, which has 
been demonstrated in patients where there is a correlation between tumour zinc 
levels and histological grade (Riesop et al., 2015). In this study histology 
samples were taken from nine tumours and zinc levels assessed in cancer and 
stroma cells. Not only did the results reveal that cancer cells contain higher 
zinc levels than stroma cells but also when the zinc levels were compared with 
histological grading, tumours with the highest grading (Grade 3) also contained 
cells with the most zinc. 
 
Despite these observations, the molecular mechanisms surrounding the role of 
zinc in the pathogenesis of breast cancer remains unclear, however there is 
mounting evidence to implicate the ion in signalling processes. For example its 
release from endoplasmic reticulum stores in response to calcium influx and 
MAPK activation results in inhibition of phosphatases in mast cells, which has 
led to the suggestion that here it acts as a secondary messenger (Yamasaki et 
al., 2007). In breast cancer cells, addition of zinc to cell culture media has been 
shown to activate EGFR signalling which may be related to the metal’s 
phosphatase inhibitory activity (Taylor et al., 2008). In this context release of 
zinc from intracellular stores maybe regulated via phosphorylation of ZIP7, 
demonstrating an additional regulatory mechanism which breast cancer cells 
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may utilise to raise intracellular zinc levels and facilitate signalling effects of 
the metal (Taylor et al., 2012).  
 
The literature surrounding zinc sequestration in breast cancer tissue implies 
that levels inside these cells may be closer to the toxic threshold than non-
cancer cells. This would therefore make them more sensitive to the toxic 
effects of zinc ionophores. 
 
Aims and Objectives 
This chapter investigates the potential zinc ionophore activity of disulfiram and 
how this may relate to the cytotoxic effects of the drug in breast cancer cells. 
The aims are therefore: 
 To develop methods to measure the effects of disulfiram on 
intracellular zinc levels of breast cancer cells. 
 To determine whether disulfiram produces different effects on the 
intracellular zinc levels of cancer and non-cancerous breast epithelial 
cells.  
 To investigate whether extracellular metal ion availability affects the 
cytotoxicity profile of disulfiram. 
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4.2. Results 
4.2.1. Disulfiram specifically increases intracellular zinc levels in breast 
cancer cells 
Initial experiments were conducted in order to visualise the effects of 
disulfiram on intracellular zinc levels in breast cancer cells. For this the 
intracellular zinc probe Fluozin-3 was employed which, according to the 
manufacturer, has a zinc affinity of 5 nM. Due to the fact that the affinity 
constant for many zinc binding proteins may be in the femtomolar range, this 
dye is thought to detect the labile zinc pool (Kochanczyk et al., 2015). Cells 
were pre-loaded with dye for 30 min and live cell confocal analysis conducted 
before and after the addition of the drug. In MCF-7 cells before the addition of 
disulfiram, weak zinc labelling was observed in punctate compartments and the 
addition of the drug rapidly (<10 min) increased intracellular zinc to levels 
comparable to those observed using the well established zinc ionophore sodium 
pyrithione (NaP; Figure 4.1). A proportion of NaP treated cells were also noted 
for displaying diffuse cytosolic Fluozin-3 labelling whereas zinc in disulfiram 
treated cells was only observed in punctate structures. Surprisingly, zinc levels 
remained unaffected by either disulfiram or NaP treatment in the non-
cancerous MCF-10A cell line.  
 
In order to further investigate the disulfiram effects seen by microscopy, a flow 
cytometry assay was developed for the specific purpose of quantitative 
comparison of intracellular zinc levels in disulfiram and NaP treated cells. The 
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 Figure 4.1. Disulfiram selectively increases intracellular zinc levels in punctate structures 
of breast cancer cells. Cells were pre-loaded with Fluozin-3 for 30 min and imaged before 
(Pre-treat) and subsequent to the addition of 10 µM disulfiram or sodium pyrithione (NaP) in 
cell imaging media. Images are multiple z-projections from a series of 10 equally spaced, 
single projections and are representative from three independent experiments. Scale bars show 
10 µm. 
 
data supported the microscopy findings as 100 µM disulfiram was shown to 
significantly increase intracellular zinc levels in both MCF-7 and 
MDA-MB-231 cell lines (Figure 4.2A), while zinc levels in MCF-10A cells 
remained unaffected by the same treatment. To rule out the possibility that the 
increase in fluorescence observed in disulfiram treated MCF-7 and 
MDA-MB-231 cells was due to higher autofluorescence of dead cells, 
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Figure 4.2. Disulfiram increases fluorescence of intracellular Fluozin-3. Cells were pre-
loaded with Fluozin-3 (A) or diluent control (B) and treated with disulfiram (DSF), DMSO or 
Sodium Pyrithione (NaP) for 10 min in complete media. Fluozin-3 fluorescence was then 
determined via flow cytometry. Error bars show standard error. Statistical testing was 
conducted using ANOVA and Dunnett’s test to compare DMSO and treatment groups. 
*p<0.05, **p<0.001. 
 
experiments were conducted using the same method as described above but in 
the absence of Fluozin-3 (Figure 4.2B). Statistical tests (ANOVA) revealed 
that there was not a significant difference between DMSO and either NaP or 
disulfiram for both cell lines, demonstrating that the results in Figure 4.2A are 
a result of increased Fluozin-3 fluorescence and not autofluorescence. 
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To further investigate the source of increased Fluozin-3 fluorescence, and 
minimise the effects of extracellular zinc in serum, the flow cytometry 
experiments were conducted in serum free media to lower zinc and copper 
concentration in the system. Under these conditions, neither NaP nor disulfiram 
evoked a statistically significant increase in intracellular zinc in MCF-7 cells 
(Figure 4.3A). Supplementation of serum free media with 20 µM zinc was 
sufficient to completely restore, and in fact exaggerate, the zinc ionophore 
ability of both disulfiram and NaP, demonstrating that this ionophore activity is 
dependent on extracellular zinc levels. This effect, with respect to the 
selectivity of the dye for zinc versus copper, which could possibly also provide 
Fluozin-3 fluorescence, was tested by conducting the experiments in serum 
free media supplemented with copper. Here copper was unable to significantly 
restore the fluorescence of Fluozin-3 in disulfiram or NaP treated cells (Figure  
 
Figure 4.3. Disulfiram delivers extracellular zinc into cells rather than releasing 
intracellular stores. MCF-7 cells were pre-loaded with Fluozin-3 and treated with disulfiram, 
DMSO or Sodium Pyrithione (NaP) for 10 min in Serum Free Media (SFM) +/- 20 µM zinc 
(Zn; A) or copper (Cu; B). Fluozin-3 fluorescence was then determined via flow cytometry. 
Error bars show standard error. T-tests were conducted between SFM and SFM + Zn/Cu for 
each treatment. *p<0.05, **p<0.001. 
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4.3B), demonstrating that the increased fluorescence of Fluozin-3 observed in 
Figures 4.1-4.3 were specifically due to the effects of zinc.  
 
4.2.2. Disulfiram sequesters intracellular zinc in endo-lysosomal 
compartments 
The observation that disulfiram sequestered zinc in punctate structures led to 
investigation of the subcellular nature of these compartments. In order to 
determine whether they were components of the endocytic network, fluorescent 
dextran was utilised as a fluid-phase endocytic probe for confocal microscopy 
co-localisation studies. By conducting a 2 hr endocytic pulse with dextran-
Alexa 647 followed by cell washing and a further 4 hr chase, the probe can be 
trafficked and confined to lysosomes (Al-Taei et al., 2006). Dextran pulse-
chase experiments were performed and cells were co-stained with Fluozin-3 
and finally treated with disulfiram; the degree of co-localisation between 
dextran-Alexa 647 and Fluozin-3 was then analysed using live cell confocal 
microscopy and the ImageJ software plug-in JaCOP to determine the Pearson’s 
coefficient (full description in Materials and Methods Section 2.5.4). Figure 
4.4A demonstrates that a significant portion of dextran labelled lysosomes 
were also labelled with Fluozin-3 and very few dextran only structures were 
observed (Pearson’s coefficient= 0.49 ± 0.06 for three independent 
experiments). When the entire fluid phase network was labelled with dextran as 
a single 4 hr endocytic pulse (Figure 4.4B), a higher degree of co-localisation 
was observed between the two probes (Pearson’s coefficient= 0.67 ± 0.04) 
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suggesting that disulfiram was also driving zinc into earlier compartments of 
the endocytic network.  
 
Figure 4.4. Disulfiram increases intracellular zinc in endo-lysosomal compartments of 
breast cancer cells. Dextran-Alexa 647 was used to highlight late endo-lysosomal 
compartments (A) or the entire fluid phase endocytic network (B) in MCF-7 cells, as described 
in Materials and Methods Section 2.5.4. Cells were then incubated with Fluozin-3, treated with 
10 µM disulfiram for 10 min and co-localisation between Fluozin-3 and dextran-Alexa 647 
analysed via confocal microscopy. Images show single z-projections through the cells and 
lower panel in (A) and (B) show a zoomed image of an identified cell in upper panel. Images 
shown are representative from three independent experiments. Co-localisation is marked by 
arrow heads. Scale bars show 10 µm.  
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4.2.3. The zinc ionophore effect of disulfiram occurs does not require 
acidic lysosomal pH 
To investigate whether the lysosomal zinc accumulation induced by disulfiram 
required the pH gradient between lysosomal and cytosolic compartments, 
experiments were conducted using the H
+
-ATPase inhibitor bafilomycin which 
inhibits acidification of lysosomes (Yoshimori et al., 1991). In initial 
experiments MCF-7 cells were treated with bafilomycin or diluent control for 
2 hr and then stained with LysoSensor to ensure that this protocol would 
increase lysosomal pH. LysoSensor is a pH sensitive dye which accumulates in 
lysosomes, and its fluorescence negatively correlates with the acidity of this 
organelle i.e. the lower the pH the greater the fluorescence. Data in Figure 
4.5A shows that LysoSensor in control cells labelled predominantly punctate 
compartments indicating distinctive endo-lysosomal staining. However, 
bafilomycin treatment resulted in almost complete loss of punctate structures 
and instead produced faint cytosolic and plasma membrane staining indicating 
raised lysosomal pH. Cells were then treated with bafilomycin as described 
above and in the final stages of the incubation stained with Fluozin-3 and 
treated with disulfiram or diluent control. In this experiment bafilomycin did 
not decrease Fluozin-3 fluorescence in endo-lysosomal compartments, and in 
fact seemed to increase Fluozin-3 fluorescence (Figure 4.5B). These images are 
comparable with both those in Figure 4.1 and 4.5C where cells were treated 
following the same protocol as for Figure 4.5B with the exception that DMSO 
was used as a control instead of bafilomycin. This demonstrates that the ability 
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of disulfiram to increase endo-lysosomal zinc levels occurs independently of 
lysosomal pH.  
 
Figure 4.5. The zinc ionophore activity of disulfiram is independent of lysosomal pH. (A) 
MCF-7 cells were treated with 80 nM bafilomycin or DMSO for 2 hr before staining with 
LysoSensor. (B, C) Cells were pre-treated with bafilomycin (B) or DMSO (C) for a total of 2 
hr and in the final stages of the incubation stained with Fluozin-3 and treated with disulfiram or 
DMSO. Images are multiple z-projections from a series of 10 equally spaced, single 
projections and are representative from three independent experiments. Scale bars show 10 µm.
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4.2.4. Supplementation with zinc or copper increases disulfiram potency 
The interaction between disulfiram and zinc observed in the previous results 
raised the possibility that enrichment of complete media with zinc or copper 
could affect the cytotoxicity of the drug in cancerous and non-cancerous breast 
cells. As control experiments, it was initially determined whether 
supplementing cell media with increasing concentrations of zinc or copper in 
the absence of disulfiram had any effect on cell viability. These studies 
demonstrated that ≤20 µM zinc or copper was without effect but toxicity was 
observed at higher concentrations of both metals (Figure 4.6A-B). Interestingly 
in MCF-7 and MCF-10A cells 200 µM copper produced a greater effect on cell 
viability than the same concentration of zinc, indicating a favourable effect on 
the tolerability of non-cancerous cells to this metal compared to copper. When 
a non-toxic dose of zinc or copper (20 µM) was given in combination with 
disulfiram, cytotoxicity was significantly enhanced in all cell lines 
(Figure 4.7A-C). In the case of MCF-7 cells, the disulfiram biphasic response 
was completely abolished by both zinc and copper supplementation, however
Figure 4.6. Zinc and copper do not effect MCF-7, MDA-MB-231 and MCF-10A cell 
viability <20 µM. Cells were treated with a serial dilution of zinc (A) or copper (B) for 72 hr 
in the presence of complete growth media before cell viability analysis was performed. Error 
bars show standard error. 
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Figure 4.7. Zinc and copper enhance the cytotoxicity of disulfiram enhance the 
cytotoxicity of disulfiram. MCF-7 (A), MDA-MB-231 (B) and MCF-10A (C) cells were 
treated with disulfiram +/- 20 µM zinc or copper in complete media for 72 hr prior to 
performing viability analysis. Error bars show standard error. 
 
cytotoxicity of disulfiram at lower concentrations was reduced by addition of 
either metal supplement. The minimum concentration of copper and zinc 
supplement required to influence cell recovery (biphasic peak) in MCF-7 cells 
was then determined and data in Figure 4.8A and B shows that 2.0 µM zinc and 
0.125 µM copper significantly reduced the ability of the cells to recover from 
disulfiram effects. At higher concentrations both metals completely reversed 
the biphasic response.  
 
Further experiments were conducted to determine whether decreasing zinc 
availability in media affected disulfiram cytotoxicity in MCF-7 cells. For this, 
the cell permeable zinc chelator TPEN was employed alone or in combination 
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Figure 4.8. A minimum of 2 µM zinc and 0.125 µM copper is required to significantly 
affect the 10 µM biphasic peak of disulfiram. Viability of MCF-7 cells treated with 
disulfiram +/- zinc (A) or copper (B) in complete media was analysed after 72 hr. Error bars 
show standard error. Statistical testing was conducted using ANOVA and Dunnett’s test to 
compare DMSO and treatment groups. *p<0.05, **p<0.001. 
 
with disulfiram (Figure 4.9). No viability effects were observed at 
concentrations below 1 µM for cells treated with TPEN alone, however at 
higher concentrations cell viability was decreased to <5%. The addition of 
1 µM TPEN to disulfiram serial dilution had no effect of the cytotoxicity of 
disulfiram at 1-100 µM. However, at lower disulfiram concentration (0.1 µM) 
TPEN was able to reverse the cytotoxicity of the drug. 
 
Figure 4.9. The addition of the cell permeable zinc chelator TPEN does not affect 
disulfiram viability. MCF-7 cells were treated with disulfiram, TPEN alone or disulfiram + 
1 µM TPEN for 72 hr before cell viability analysis. Error bars show standard error.  
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4.2.5. Sodium pyrithione does not produce a biphasic viability peak 
The observations that disulfiram was able to increase intracellular zinc levels 
and the biphasic viability peak was sensitive to the addition of zinc, led to 
investigation into whether the biphasic peak was a feature of other zinc 
ionophores. Viability studies were therefore performed using NaP in normal 
cell culture conditions in MCF-7 and MDA-MB-231 cells. Results in Figure 
4.10 demonstrate that NaP potently decreased cell viability in both cell lines 
with IC50 <1 µM. Importantly however a biphasic response to NaP was not 
observed in either cell line, demonstrating that the recovery peak observed in 
earlier studies with disulfiram is not a universal feature of zinc ionophores.  
 
Figure 4.10. Sodium pyrithione does not produce a biphasic cell viability peak. MCF-7 
and MDA-MB-231 cells were treated with sodium pyrithione (NaP) for 72 hr before cell 
viability analysis. Error bars show standard error.  
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4.3. Discussion 
Much of the literature surrounding the anti-cancer properties of disulfiram 
focuses on its interaction with copper, particularly as a disulfiram-copper 
complex (Chen et al., 2006; Liu et al., 2012). In contrast, the effect of zinc on 
the drugs toxicity is under-reported, despite knowledge that this metal is 
dysregulated in breast cancer cells (Rizk and Skypeck 1984; Riesop et al., 
2015). The aim of this work was to determine the role of intra and extracellular 
zinc in the anti-breast cancer properties of disulfiram. The data shown in this 
chapter represents the first real time visual observations of intracellular zinc in 
disulfiram treated cells. Additionally the findings demonstrate that under 
normal conditions (complete media) disulfiram selectively increases 
intracellular zinc in breast cancer cells. This property may have numerous 
cellular effects with some leading to toxicity, for example studies have shown 
that supplementing media with zinc to increase intracellular levels, presumably 
through zinc channels, induces oxidative toxicity and inhibits NFκB signalling 
(Uzzo et al., 2006; Bozym et al., 2010). It has previously been proposed that 
acetaldehyde produced as a result of disulfiram induced ALDH inhibition 
releases zinc from proteins (Hao and Maret 2006), raising the possibility that 
the source of this metal which accumulates inside drug treated cells may be 
from intracellular sources. However, the studies in this chapter show that the 
ability of the drug to increase intracellular zinc is dependent on the availability 
of extracellular levels of this metal, supporting the hypothesis that the drug is 
acting as a zinc ionophore. This finding could have far reaching clinical 
consequences as a recent study has demonstrated that zinc concentration in 
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breast cancer tissue is higher than in non-cancerous tissue and zinc 
accumulation correlates with histological grade (Riesop et al., 2015). This 
therefore implies that breast cancer cells may be more sensitive to the toxic 
effects of zinc than the surrounding stroma and additionally that through its 
zinc ionophore capability disulfiram may have particular benefit in more 
aggressive disease types. This is further supported by the observation in this 
chapter that the non-cancerous MCF-10A cell line was resistant to the zinc 
ionophore effects of disulfiram, although it is possible that there was an effect 
which was beyond the sensitivity limit of the microscopy and flow cytometry 
assays. The reason for this selectivity is unclear, it may be the case that these 
cells contain a greater zinc buffering capacity then cancerous cells and upon 
experiencing the zinc ionophore effect of disulfiram this metal is removed from 
the cell. To support this hypothesis it has been demonstrated that protein levels 
of ZnT efflux transporters are increased in MCF-10A compared to T47D cells, 
indicating that this cell line is more capable of removing zinc from the cell than 
cancerous cell lines (Chandler et al., 2016).  
 
The observation that disulfiram was able to increase endo-lysosomal zinc 
levels is previously unreported, and may have important implications in its 
selective anti-breast cancer effect. When under conditions of zinc overload, the 
cell may utilise certain compartments as a cytoprotective mechanism (Colvin et 
al., 2008). The distribution of excess zinc to lysosomes has recently been 
reported, however high lysosomal zinc sequestration was also able to induce 
apoptosis when lysosomal release mechanisms were compromised (Kukic et 
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al., 2014). In addition, and particularly relevant to the studies of this chapter, 
this paper also noted that bafilomycin increased zinc levels in endo-lysosomal 
compartments. The authors hypothesised that this was due to bafilomycin 
inhibiting the ability of lysosomes to fuse with the plasma membrane and 
release their contents. This mechanism may also explain the increased zinc 
levels observed in the bafilomycin treated cells of this chapter. Increased 
lysosomal storage of zinc has been observed in cancer cells treated with 
clioquinol, another zinc ionophore (Yu et al., 2009). The link between 
lysosomal zinc accumulation and cell death has also been demonstrated in 
neuronal cells, where zinc accumulation in this organelle was implicated in 
permeabilisation of its membrane causing release of hydrolytic enzymes 
(Hwang et al., 2008). The potential for disulfiram in producing a similar effect 
is the subject of Chapter 6. The fact that in untreated breast cancer cells zinc 
was still observed in endo-lysosomal compartments may provide further 
evidence to support the hypothesis that breast cancer cells have an intrinsic 
zinc burden which may be exploited by the zinc ionophore action of disulfiram. 
 
It has previously been reported that the addition of copper (Brar et al., 2004; 
Wang et al., 2011; Yip et al., 2011; Liu et al., 2012), zinc (Brar et al., 2004) 
and other metal ions such as cadmium (Li et al., 2008) to the extracellular 
media increases the potency of disulfiram across a range of cancer cell types. 
The incubation of copper to remove the biphasic phase has previously been 
reported (Yip et al., 2011) but here it is demonstrated that zinc supplement has 
the same effect. Critically the ability of either metal ion to remove the biphasic 
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peak implies that the toxicity of disulfiram at 10 µM is limited by the 
availability of copper and zinc in the media. When considering the ability of 
disulfiram to increase intracellular zinc and copper levels, it is likely that an 
increase in extracellular copper and zinc allows disulfiram to transport more of 
these metal ions into the cell, which accounts for the increased toxicity at this 
concentration. The low concentrations of either copper and zinc required to 
increase disulfiram potency, suggest that increasing the availability of either 
metal ion could be achievable in vivo with oral supplements to enhance the 
cytotoxic effects of the drug. However, data with the MCF-10A cell line imply 
that such supplementation may adversely alter the selectivity of the drug for 
breast cancer cells and could cause non-specific toxicity. The fact that 
MDA-MB-231 cells in this chapter were sensitive to the zinc ionophore effect 
but remained insensitive to the cytotoxic effect of disulfiram suggest that this 
resistance must occur via a different mechanism to MCF-10A cells which were 
resistant to both cytotoxicity and ionophore effects. It may be the case that 
these cells may tolerate higher levels of zinc than MCF-10A, perhaps by 
increased expression of detoxification enzymes such as SOD (Papa et al., 
2014).  
 
Surprisingly the addition of a non-toxic concentration of the zinc chelator 
TPEN did not affect the disulfiram response in MCF-7 cells, as would be 
expected if toxicity of the drug was dependent on zinc ion availability. 
However, the use of TPEN in this study was limited by its toxicity at higher 
concentrations in these cells and may have been insufficient to produce a 
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meaningful decrease in the availability of zinc ions. To demonstrate this, 
several studies have used a 10 fold higher concentration of TPEN to reduce 
zinc levels and affect the ability of the metal to inhibit cancer cell migration 
and induce cytotoxicity in response to PDTC (Kagara et al., 2007; Donadelli et 
al., 2009). Further optimisation studies to clarify whether the concentration of 
TPEN used in this study was able to affect intracellular zinc levels would 
determine whether this was the cause of the chelators inability to inhibit 
disulfiram induced cell death. This would additionally demonstrate the 
contribution of disulfiram’s zinc ionophore effects to cytotoxicity in 
comparison to other cytotoxic mechanisms which have previously been 
described.  
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5. Investigation into the structure-activity relationship 
of disulfiram analogues in breast cancer cells  
5.1. Introduction 
The fact that disulfiram is rapidly and extensively metabolised may imply its 
metabolic breakdown products are responsible for the drug’s biological effects. 
Initial metabolism proceeds via cleavage of the weak disulfide bond to form 
two molecules of DDC (Figure 5.1). Although this process is thought to occur
Figure 5.1. Reduction of disulfiram across the vulnerable disulfide bond to produce two 
molecules of DDC. 
 
non-enzymatically, binding of the parent drug to serum albumin has been 
shown to enhance DDC formation (Agarwal et al., 1983). Additionally in a cell 
free system, reduction of disulfiram is dependent on glutathione reductase 
enzyme activity (Nagendra et al., 1991). These processes mean that within 4 
min of disulfiram administration to blood it is completely reduced to DDC, and 
the parent drug is undetectable in clinical trials which instead must rely on 
detection of metabolites to address its pharmacokinetic properties (Cobby et 
al., 1977; Johansson 1992; Schweizer et al., 2013). Following reduction to 
DDC, further metabolism proceeds via enzymatic routes leading to methylated 
or glucuronidated DDC derivatives or non-enzymatic routes producing 
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diethylamine and carbon disulfide (Eneanya et al., 1981). The issues 
surrounding the instability of disulfiram imply that DDC, and other 
metabolites, could be responsible for the drug’s biological activity. In support 
of this, a disulfiram clinical trial has revealed that the ability of the drug to 
demethylate promoter DNA in prostate cancer cells, leading to re-expression of 
tumour suppressor genes, correlates with the ability of individuals to form the 
methylated DDC derivative, S-methyl N,N-diethyldithiocarbamate (Schweizer 
et al., 2013). However, this extensive metabolic pathway may limit the efficacy 
of the drug and improving its stability by encapsulation within liposomes has 
been shown to decrease tumour size in breast cancer mouse models when 
administered with copper more effectively than non-encapsulated disulfiram-
copper treatment (Liu et al., 2014).  
 
How the chemical features of disulfiram relate to its biological activity is 
incompletely understood, however some compounds with similar chemical 
structures also share its ability to alter biological processes, for example 
proteasome function and apoptosis. Of particular interest is PDTC which 
retains one thioester moiety of disulfiram but replaces the terminal ethyl groups 
with a nitrogen containing five membered ring known as pyrollidine (full 
structure compared to that of disulfiram and DDC in Figure 5.2). This 
compound is cytotoxic to pancreatic adenocarcinoma cells, an effect which can 
be enhanced by zinc co-incubation, and can also increase levels of 
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Figure 5.2. Comparison of the chemical structures of disulfiram, DDC and PDTC. (1) 
Indicates the N(C=S)S thioester moiety. (2) Disulfide bond. (3) Pyrollidine group.  
 
ROS. Interestingly these properties are also observed, but to a greater extent, 
when these cells are treated with disulfiram (Pozza et al., 2011). Structure-
activity relationship studies have revealed that the chemical groups attached to 
the nitrogen are critical for the ability of PDTC analogues to induce breast 
cancer cell death and inhibit the proteasome (Yu et al., 2007; Wang et al., 
2011). Specifically, analogues with the capacity to induce cytotoxicity in 
MDA-MB-231 cells at <10 µM contain a phenyl ring with a single or double 
carbon link and a single or double carbon chain attached to the nitrogen (Wang 
et al., 2011). One compound, chosen as docking studies revealed that it was 
unlikely to inhibit ALDH, was shown to inhibit the proteasome and induce 
apoptosis when combined with copper. This therefore indicates that the anti-
cancer activities of compounds structurally related to disulfiram may be 
separated from their ability to inhibit ALDH, an effect which potentially 
decreases in vivo efficacy. Other studies have focussed on combining 
dithiocarbamate analogues with thalidomide and shown that these are more 
potent at inducing cell death and inhibiting growth and migration of endothelial 
cells compared to thalidomide alone (El-Aarag et al., 2014). 
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In contrast to the knowledge of structural features which enhance the PDTC 
anti-cancer effect, little has been done to investigate the structure-activity 
relationship of disulfiram. The work in this chapter is an extension of a 
previous report produced by collaboration between Cardiff University and the 
Barbara Ann Karmanos Institute, Detroit, where four series of novel disulfiram 
analogues were investigated for their ability to produce cytotoxicity in ER
+
 
breast cancer cells (Brahemi et al., 2010). This work highlighted the 
importance of the central N(C=S)S-S bond in the ability of disulfiram 
analogues to induce viability effects in breast cancer cells and hypothesised 
that two classes of compounds were selectively toxic to ER
+
 and not ER
-
 breast 
cancer cell lines. These were: “disulfiram analogues” (referred to in this 
chapter as thiuram disulfide analogues) defined by a central structure of two 
thioester moieties joined by a disulfide bond with two R groups attached to 
each nitrogen, and “carbamo(dithioperoxo)thioates” which contained a core 
structure of a single thioester joined by a disulfide bond to an R1 group with 
two additional R groups attached to the nitrogen atom (core structures of both 
series compared in Figure 5.3). In this chapter the term “disulfiram analogues” 
is reserved for collectively describing all thiuram disulfide and 
carbamo(dithioperoxo)thioate analogues.  
 
Figure 5.3. Core structures of the thiuram disulfide and carbamo(dithioperoxo)thioate 
series of disulfiram analogues used in this study. 
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Aims and Objectives 
The primary objective of this chapter is to further investigate the structure-
activity relationship of disulfiram analogues with respect to their ability to 
induce cell death. In addition the zinc ionophore activity of DDC and its effect 
on cell viability will be compared with the parent drug. With these objectives 
in mind, the aims of this chapter are: 
 To compare the viability effects produced by thiuram disulfide and 
carbamo(dithioperoxo)thioate analogues in MCF-7, MDA-MB-231 and 
MCF-10A cells. 
 To further investigate how modifying the R group of disulfiram 
analogues alters their cytotoxicity profile. 
 To determine the relationship between DDC and disulfiram analogue 
cytotoxicity and possible zinc ionophore action. 
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5.2. Results 
5.2.1. MCF-7 and MDA-MB-231 viability effects in the thiuram disulfide 
series are dependent on R group size  
Disulfiram analogues were synthesised by Dr. Andrew Westwell (Cardiff 
University, School of Pharmacy and Pharmaceutical Sciences) and co-workers 
(Francesca Solfa and Matteo Morelli), and their ability to induce cytotoxicity 
was determined in breast cell lines chosen to model three disease states: ER
+
 
breast cancer (MCF-7), ER
-
 breast cancer (MDA-MB-231) and non-
tumourigenic breast epithelium (MCF-10A). Viability studies in these cells 
were conducted using the CellTiter Blue assay following 72 hr incubation with 
the analogue; structure and viability plots for each analogue are shown in 
Figure 5.4-5.9. Table 5.1 represents a summary of this data, with additional 
information regarding molecular weight. The extent of cytotoxicity in MCF-7 
and MDA-MB-231 cells varied between analogues with IC50 values for both 
cell lines between 0.1 and 60 µM. In contrast, no analogue produced IC50 
values <10 µM in the MCF-10A cell line demonstrating that these cells were 
highly resistant to the effects of compounds which share the thioester moiety 
and disulfide bond characteristic of disulfiram. 
 
Analogues were designed in order to determine which structural features were 
necessary for cytotoxic effects in MCF-7 and MDA-MB-231 cells. Two series 
of compounds were synthesised which differed in their core moiety; the 
thiuram disulfide series retained the two thioester groups joined by a disulfide 
bridge, characteristic of the parent drug, alternatively the 
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Table 5.1. Summary of the chemical properties and viability effects of disulfiram and 
analogues. Formula and molecular weight (Mw) information was obtained from reproducing 
the structure in “MarvinView 6.2.0” software and using Tools>Elemental Analysis. IC50 values 
are an estimation based on interpolation at 50% from viability curves shown in Figures 5.4-5.9. 
Disulfiram (DSF) is included as a comparison. *indicates a biphasic viability profile, defined 
as a statistical significance between viability effects at 1 and 10 µM where 1 µM produces a 
>45% cytotoxicity. Light grey indicates thiuram disulfide series; dark grey indicates 
carbamo(dithioperoxo)thioate series. Analogues are ranked by molecular weight. 
 
carbamo(dithioperoxo)thioate series contained a single thioester and disulfide 
bond (Figure 5.3). By comparing the cytotoxicity profiles of analogues which 
contained these core structures it was possible to assess the importance of the 
symmetry of the thioester moieties around the disulfide bond. Additionally, the 
R1 and R groups of each core structure allowed further chemical modification 
Analogue Formula Mw IC50  
MCF-7 
(µM) 
IC50  
MDA-MB-231 
(µM) 
IC50  
MCF-10A 
(µM) 
FS07PY C7H13NOS3 223.4 0.5 60 60 
FS06DE C7H15NOS3 225.4 0.6* 0.8* 60 
MM005 C11H21NS3 263.5 0.9 50 70 
KT06 C11H23NS3 265.5 0.7* 30 60 
MM002 C12H23NS3 277.5 0.6* 50 50 
MM003 C11H21NOS3 279.5 1 10 NA 
ANF-D12 C10H16N2S4 292.5 0.4 0.7 50 
MM004 C12H24N2S3 292.6 0.9 50 80 
DSF C10H20N2S4 296.5 0.3* 40 60 
ANF-D24 C12H20N2S4 320.6 0.1* 40 65 
FS01BM C18H20N2S4 392.6 1* 60 90 
FS02MP C20H24N2S4 420.7 40 60 NA 
FS03EB C20H24N2S4 420.7 50 60 NA 
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which provided insight into how the chemical structures at each terminus 
altered analogue cytotoxicity.  
 
The thiuram disulfide series contained five structural analogues: ANF-D12, 
ANF-D24, FS01BM, FS02MP, and FS03EB. Of these, ANF-D24 was the most 
structurally comparable with disulfiram as the R groups were substituted with 
piperidine moieties (six membered ring containing five carbons and one 
nitrogen atom) and therefore similar in size to the two ethyl groups found on 
the parent molecule (Figure 5.4A). This analogue produced a viability profile 
almost identical to that of the parent drug; cytotoxicity in MCF-7 cells was 
biphasic and produced an IC50 of 0.1 µM (compared to 0.3 µM for disulfiram), 
whereas MDA-MB-231 cells were resistant to viability effects with an IC50 of 
40 µM (Figure 5.4B). Interestingly when these piperidine groups were 
substituted for the smaller pyrollidine structures, as in the case of ANF-D12, a 
markedly different cytotoxic profile was observed (Figure 5.4C-D). Here, 
MCF-7 cells did not exhibit the characteristic biphasic cytotoxicity profile of 
disulfiram and instead there was almost complete loss of viable cells at 10 µM. 
In comparison, a slight biphasic peak was observed for MDA-MB-231 cells 
where viability was restored to 32% at 10 µM despite 1 µM reducing viability 
to 20%, however statistical testing revealed that the difference between 
viability at 1 and 10 µM was not significant. From comparison of these 
structurally similar analogues it is apparent that the size of groups attached to 
the terminal nitrogen are of critical importance for both the biphasic profile 
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Figure 5.4. Structure and viability data for ANF-D24, ANF-D12 and FS01BM. (A, C, E) 
Chemical structure of thiuram disulfide analogues. (B, D, F) MCF-7, MDA-MB-231 and 
MCF-10A cells were incubated with analogue in serial dilution for 72 hr prior to viability 
analysis via the CellTiter Blue assay. Error bars show standard error. 
 
seen in MCF-7 cells and the sensitivity of MDA-MB-231 cells. To further 
demonstrate this when the R groups were replaced with even larger moieties, 
as in the case of FS01BM which contained methyl and benzyl groups, the 
viability profile of MCF-7 cells was biphasic although sensitivity at 1 µM was 
reduced compared ANF-D12 and ANF-D24, and no viability effects were 
observed with MDA-MB-231 cells <10 µM (Figure 5.4E-F).  
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The final two analogues of this series differ from FS01BM by a single carbonyl 
at each of the two R groups; FS02MP contains methyl and phenethyl groups 
whereas FS03EB contains ethyl and benzyl groups (Figure 5.5A, C). In both 
cases IC50 values were >10 µM for both MCF-7 and MDA-MB-231 cells, 
demonstrating that the addition of a single carbonyl is sufficient to completely 
remove the sensitivity of MCF-7 cells to the effects of these analogues and 
indicating that size is a critical feature for cytotoxicity within this analogue 
series. The importance of analogue size in the thiuram disulfide series is further 
demonstrated when analogues are ranked by the percentage of viable 
cells remaining after 1 µM treatment: 
ANF-D12<ANF-D24< FS01BM<FS02MP and FS03EB (Figure 5.4-5.5), this 
sequence exactly correlates with molecular weight (Table 5.1). 
 
 
Figure 5.5. Structure and viability data for FS02MP and FS03EB. (A, C) Chemical 
structure of thiuram disulfide analogues. (B, D) MCF-7, MDA-MB-231 and MCF-10A cells 
were incubated with analogue in serial dilution for 72 hr prior to viability analysis via the 
CellTiter Blue assay. Error bars show standard error. 
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5.2.2. The chemical properties of moieties bound to the nitrogen (R), 
rather than those bound to the disulfide bond (R1), govern the response to 
MCF-7 and MDA-MB-231 cells to carbamo(dithioperoxo)thioate 
analogues 
Seven analogues (FS06DE, FS07PY, KT06, MM002, MM003, MM004 and 
MM005) belonged to the carbamo(dithioperoxo)thioate structural series, 
defined by a single thioester moiety attached to the disulfide bond (Figure 5.3). 
Viability profiles from five of these analogues formed part of a publication 
which also described their synthesis (Cilibrase et al., 2015). Similarly to the 
thiuram disulfide series, viability results within this dataset provided mixed 
results in terms of the response of MDA-MB-231 cells and although MCF-7 
viability effects were noted for all analogues within this series their ability to 
induce biphasic effects differed. This indicates that removal of the second 
thioester group does not produce an overall effect on the cytotoxicity profile of 
disulfiram analogues in terms of the MCF-7 biphasic peak and MDA-MB-231 
cell sensitivity. In further support of this, one analogue within this series, 
MM002, provided a biphasic MCF-7 viability profile and did not produce 
viability effects in MDA-MB-231 cells, in a similar manner to disulfiram 
despite lacking this second thioester group (Table 5.1). 
 
The fact that the core structure of the carbamo(dithioperoxo)thioate series was 
asymmetrical meant that it was possible to investigate the effect of altering the 
chemical groups on either terminus of the N(C=S)S-S bond. Initially analogues 
were compared which were identical with respect to the chemical moieties 
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attached to the disulfide bond (R1) but where groups bonded to the nitrogen 
(R) were altered. For example, FS06DE and FS07PY both contained a 
2-hydroxyethyl group at R1, whereas R was consisted of two ethyl groups for 
FS06DE and pyrollidine for FS07PY (Figure 5.6A, C). Both analogues 
produced markedly different viability profiles; biphasic cytotoxicity was 
observed for both MCF-7 and MDA-MB-231 cells treated with FS06DE and 
for FS07PY only MCF-7 cells responded to the analogue at concentrations 
<10 µM and no biphasic effect was observed. The fact that these profiles differ 
so dramatically despite having identical R1 groups suggests viability effects are 
a result of the chemical group attached to the nitrogen. The influence of the 
chemical moieties at R were further assessed by an extended panel of five
 
Figure 5.6. Structure and viability data for FS06DE and FS07PY. (A, C) Chemical 
structure of carbamo(dithioperoxo)thioate analogues. (B, D) MCF-7, MDA-MB-231 and 
MCF-10A cells were incubated with analogue in serial dilution for 72 hr prior to viability 
analysis via the CellTiter Blue assay. Error bars show standard error. 
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analogues (MM002, MM003, MM004 and MM005, KT06) which all contained 
identical hexane moieties R1 but varied with respect to the chemical group at 
R. Three of these analogues contained a six membered ring (MM002, MM003 
and MM004) and exhibited distinct differences in both their selectivity for 
MCF-7 cells versus MDA-MB-231 cells and ability to produce a biphasic 
profile: MM002 contained a piperidine moiety and produced biphasic viability 
effects in MCF-7 with no effect in MDA-MB-231 cells <100 µM (Figure 5.7A,  
 
 
 
Figure 5.7. Structure and viability data for MM002, MM003 and MM004. (A, C, E) 
Chemical structure of carbamo(dithioperoxo)thioate analogues. (B, D) MCF-7, MDA-MB-231 
and MCF-10A cells were incubated with analogue in serial dilution for 72 hr prior to viability 
analysis via the CellTiter Blue assay. Error bars show standard error. 
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B); MM003 contained a morpholine ring and produced viability effects in both 
cell lines at <10 µM and no biphasic effect was observed (Figure 5.7C, D); 
MM004 contained a N-methylpiperazine moiety and was selectively toxic to 
MCF-7 cells however did not produce a biphasic response (Figure 5.7E, F). 
These results demonstrate that the substitution of a carbon atom in the chemical 
moiety at R to an electronegative atom, such as oxygen or nitrogen, is able to 
remove the biphasic effect observed in MCF-7 cells. The fact that MM003 and 
MM004 differ in their ability to produce viability effects in MDA-MB-231 
cells at 10 µM indicates that the addition of oxygen, but not nitrogen, to the R 
group is able to produce cytotoxicity in this cell line. To further address the 
hypothesis that the chemical groups bound to the nitrogen (R) were critical for 
the cytotoxic properties of carbamo(dithioperoxo)thioate analogues, viability 
profiles were compared between analogues which were identical R but differed 
with respect to the chemical moiety bound at R1. The ability of MM005 and 
FS07PY, which both contained pyrollidine moieties at R but hexanyl or 
2-hydroxyethyl respectively at R1, to induce viability effects was analysed 
(Figure 5.8). Neither analogue was able to produce cytotoxicity in 
MDA-MB-231 cells at concentrations under <100 µM, and both were cytotoxic 
to MCF-7 cells (IC50 <1 µM) without producing a biphasic effect. Interestingly, 
the viability profile of MCF-7 cells in response to MM005 and FS07PY is also 
similar to ANF-D12 and all contain pyrollidine moieties, providing further 
evidence to support the hypothesis of Section 5.2.1 that the MCF-7 biphasic 
effect can be ablated by the addition of smaller chemical groups bound to the 
nitrogen (compare Figure 5.8B, D and 5.4D).  
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Figure 5.8. Structure and viability data for MM005 and FS07PY. (A, C) Chemical 
structure of carbamo(dithioperoxo)thioate analogues. (B, D) MCF-7, MDA-MB-231 and 
MCF-10A cells were incubated with analogue in serial dilution for 72 hr prior to viability 
analysis via the CellTiter Blue assay. Error bars show standard error. 
 
 
The critical importance of chemical groups at R was additionally investigated 
by comparison of carbamo(dithioperoxo)thioate analogues KT06 and FS06DE 
which both were identical at R (two ethyl groups) but KT06 contained a 
hexane chain and FS06DE contained 2-hydroxyethyl at R1 (Figure 5.9A, C). 
Both analogues demonstrate a trend towards biphasic cytotoxicity in MCF-7 
and MDA-MB-231 cells, although statistical significance was not achieved to 
indicate a difference in MDA-MB-231 cells treated with 1 or 10 µM KT06.  
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Figure 5.9. Structure and viability data for KT06 and FS06DE. (A, C) Chemical structure 
of carbamo(dithioperoxo)thioate analogues. (B, D) MCF-7, MDA-MB-231 and MCF-10A 
cells were incubated with analogue in serial dilution for 72 hr prior to viability analysis via the 
CellTiter Blue assay. Error bars show standard error. 
 
5.2.3. Cytotoxicity of DDC and FS03EB correlates with zinc ionophore 
activity 
Using compounds structurally related to disulfiram, it was next investigated 
how the cytotoxic response of MCF-7 cells related to zinc ionophore activity. 
In biological solutions disulfiram thought to be rapidly converted to DDC 
raising the possibility that metabolites are responsible for much of the drug’s 
biological functions (Agarwal et al., 1983). The cytotoxic and zinc ionophore 
properties of DDC were initially compared to those of disulfiram in MCF-7 
cells. DDC displayed a sharp increase in toxicity at concentrations higher than 
0.1 µM with evidence of recovery being observed at 100 µM, rather than at 
10 µM as in the case of the parent drug (Figure 5.10A). Supplementation with 
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Figure 5.10. Toxicity of DDC and FS03EB correlates with zinc ionophore activity. (A, C) 
MCF-7 cells were treated with DDC (A) or FS03EB (C) +/- 20 µM copper or zinc in complete 
media for 72 hr prior to performing viability analysis. (B, D) MCF-7 cells were pre-loaded 
with Fluozin-3, treated with DDC (B) or FS03EB +/- 20 µM zinc (D) for 10 min prior to 
measuring Fluozin-3 fluorescence via flow cytometry. Error bars show standard error. *p<0.05 
 
copper and zinc completely ablated the DDC biphasic effects and significantly 
enhanced its toxicity. The metabolite was also able to increase intracellular 
zinc levels (Figure 10B) but was a less potent zinc ionophore compared with 
disulfiram (Figure 4.2A). 
 
To address the issue of whether cytotoxicity may relate to the capacity of 
disulfiram and DDC to deliver zinc, studies were conducted to investigate the 
relationship between metal ions and the FS03EB analogue, chosen as it was 
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non-toxic under normal cell culture conditions at concentrations <100 µM. 
Viability studies revealed that co-incubation of this compound (>1 µM) with 
20 µM zinc or copper was able to significantly enhance toxicity leading to 
complete loss of viability at 1 µM and 10 µM for copper and zinc respectively. 
The ability of FS03EB to increase fluorescence of Fluozin-3 was then assessed 
using flow cytometry under normal cell culture (complete media) and high zinc 
(complete media + 20 µM zinc) conditions. In complete media, and contrary to 
the effects observed with disulfiram and DDC, data in Figure 5.10D show that 
the analogue was unable to significantly increase intracellular zinc levels in 
complete media. However, when the zinc ionophore activity of 100 µM 
FS03EB was investigated in conditions which induced toxicity at <10 µM 
(complete media + 20 µM zinc), it resulted in a >3 fold increase in Fluozin-3 
fluorescence. The fact that FS03EB cytotoxicity at concentrations <10 µM in 
MCF-7 cells is entirely dependent on the availability of metal ions within the 
media and only occurs under conditions which also produce a detectable 
increase in intracellular zinc levels, indicates that the zinc ionophore activity of 
the analogue is a requirement for these cytotoxic effects.  
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5.3. Discussion 
This chapter aimed to provide insight into how the chemical features of 
disulfiram analogues relate to its biological activity, particularly its ability to 
induce viability effects in breast cancer cells. Little prior research has been 
done to determine the structure-activity relationship of the drug, aside from a 
previous collaboration between Cardiff University and Barbara Ann Karmanos 
Institute, Detroit (Brahemi et al., 2010). This paper describes the effect of four 
classes of disulfiram analogues on the viability of breast cancer and epithelial 
cell lines. Two of these, benzisothiazolones and dithiocarbamates, lacked the 
disulfide bond and all analogues within these series’ (a total of 36) were 
inactive at <10 µM in breast cancer cell lines. In addition a further analogue, 
4,4-dithiomorpholine, lacking the thioester bond, was also unable to induce 
breast cancer cell cytotoxicity. Taken together these results demonstrated the 
requirement of both the disulfide bond and thioester in the biological activity of 
disulfiram. Due to this, further analysis was conducted using a panel of three 
thiuram disulfide and ten carbamo(dithioperoxo)thioate analogues which 
contained these structural features and demonstrated that these analogue series’ 
could produce IC50 values of <1 µM in ER
+
 breast cancer cells. This chapter is 
an extension of the previous collaboration focussing on a larger panel of 
thiuram disulfide and carbamo(dithioperoxo)thioate analogues and their 
activities in MCF-7, MDA-MB-231 and MCF-10A cells. 
 
This work represents the first time size has been described as a factor which 
determines the sensitivity of breast cancer cells to disulfiram analogues. This is 
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demonstrated by the observation that analogues containing a piperidine moiety 
in the R group were capable of inducing biphasic viability effects which could 
be removed by substitution with the slightly smaller pyrollidine. This result is 
particularly interesting in view of the literature surrounding a compound 
structurally related to disulfiram, PDTC, which also contains a pyrollidine 
group. Unlike the pyrollidine containing analogues of this chapter, biphasic 
viability has been observed with PDTC in neuronal cells and attributed to the 
ability of the compound to activate ERK or JNK at different concentrations 
(Chung et al., 2000). The fact that the biphasic effect was not observed for the 
pyrollidine containing analogues in this study may indicate that PDTC operates 
via a different mechanism of action compared to disulfiram analogues or that 
neuronal and MCF-7 cells respond differently to these compounds. Other 
studies investigating the structure-activity relationship of PDTC-copper 
complexes have found that substitution of the piperidine moiety for pyrollidine 
had no effect on breast cancer cell viability, although the effect of PDTC 
analogues in the absence of copper was not investigated (Yu et al., 2007). 
Interestingly and in accordance with the findings of this chapter, when the 
pyrollidine moiety of PDTC was replaced with larger R groups cytotoxic 
effects were dramatically reduced. The relationship between the structure of 
disulfiram analogues and how this relates to their ability to bind and transport 
zinc across the plasma membrane of cells is not known and could be the 
subject of further experimentation. The observation that cytotoxicity of PDTC 
has previously been demonstrated to be enhanced by zinc supplementation 
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indicates that the pyrollidine containing analogues of this chapter may also 
retain the drug’s zinc ionophore effect (Pozza et al., 2011).  
 
The fact that the core structure of the carbamo(dithioperoxo)thioate series was 
asymmetrical meant that it was possible to assess the impact of altering groups 
on either side of the disulfide bond on the viability profile of analogues. From 
these studies it is apparent that the chemical groups bound directly to the 
nitrogen atom (R) have a greater impact on the biphasic effect in MCF-7 cells 
and MDA-MB-231 cell sensitivity compared to the chemical groups bound to 
the disulfide bond (R1). Studies investigating the structure-activity relationship 
of PDTC analogues have previously focussed on altering the chemical groups 
bound to the nitrogen atom and found that chemical modification at this 
position could alter the ability of analogues to inhibit the proteasome and 
induce viability effects (Yu et al., 2007; Wang et al., 2011). These studies did 
not compare the effect of modifying the chemical groups at other positions, 
however imply that the biological activity of both PDTC and disulfiram are 
dependent of the chemical groups bound to the nitrogen atom. This finding 
could have implications not only in identifying other compounds with 
disulfiram-like activity in breast cancer cells but also may be used to aid 
characterisation of the drug’s biological effects. 
  
In vivo disulfiram is rapidly and extensively metabolised in a systemic manner; 
the first degradation product is DDC and this metabolite is thought to be a 
major contributor in the clinical effects of the drug (Nagendra et al., 1991). 
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DDC has been shown to have toxicity against breast cancer cells in vitro and 
increases intracellular copper in other model systems (Tonkin et al., 2004; 
Cvek et al., 2008). Additionally, a clinical trial has shown that adjuvant DDC 
is able to increase survival in patients at high risk of metastatic breast cancer 
(Dufour et al., 1993). In this chapter DDC, albeit to a lesser extent than 
disulfiram, was also able to increase intracellular zinc levels and this may be a 
mechanism behind its increased cytotoxicity in the presence of high 
extracellular levels of these metal ions.  
 
The fact that not all disulfiram analogues produced viability effects allowed 
further investigation into how cytotoxicity relates to zinc ionophore effects. 
These studies utilised FS03EB as it did not produce viability effects in MCF-7 
cells <100 µM under physiological conditions and compared its ability to 
induce cell death and alter intracellular zinc levels in either physiological or 
zinc enriched conditions. Contrary to effects observed with disulfiram and 
DDC, FS03EB under physiological conditions was unable to significantly 
increase intracellular zinc levels. Therefore, the lack of toxicity in cells treated 
with this analogue alone could be due to reduced zinc ionophore activity. 
However in zinc enriched conditions both cytotoxicity at 10 µM and zinc 
ionophore activity at 100 µM of the analogue were dramatically increased. 
This data provides a potential link between zinc ionophore activity and 
cytotoxicity, such that the observed toxicity profiles for disulfiram, DDC and 
FS03EB relate to their capacity to deliver intracellular zinc. An important 
limitation of this experiment is the fact that 100 µM FS03EB produced 
 167 
 
cytotoxicity in both physiological and zinc enriched conditions, however this 
concentration only produced an ionophore effect in the rich enriched scenario. 
This therefore indicates that at 100 µM other mechanisms must contribute to 
FS03EB cytotoxicity independent of its zinc ionophore properties. The use of a 
lower concentration of FS03EB would provide a stronger link between 
cytotoxicity and zinc ionophore action, to demonstrate this 10 µM FS03EB 
was only cytotoxic in the zinc enriched scenario and not under physiological 
conditions. A further study could be to determine the ionophore properties of 
this concentration of FS03EB in conditions of high (zinc enriched) and low 
(full serum media) MCF-7 cell sensitivity, this would provide strong evidence 
that the analogue is only cytotoxic in conditions which also provide zinc 
ionophore action.       
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6. Investigation into the ability of disulfiram to induce 
lysosomal membrane permeabilisation 
6.1. Introduction 
The observation that disulfiram was able to increase zinc levels specifically in 
endo-lysosomal compartments (Chapter 4) raised the possibility that the drug 
may induce damage to these structures. The phenomenon of lysosomal 
membrane permeabilisation (LMP) has previously been noted to occur in 
response to clioquinol, another zinc ionophore, upon sequestration of the metal 
in lysosomes, and as both drugs produce similar zinc loading effects in this 
organelle it may be the case that LMP also occurs in disulfiram treated cells 
(Yu et al., 2009). LMP involves the release of lysosomal proteases to the cell 
cytosol, of which the cathepsin family are considered the major contributors to 
cell death (Mrschtik and Ryan 2015). Cathepsins are categorised into three 
sub-families based on the amino acid found within their active site, namely 
serine (cathepsin A and G), cysteine (B, C, F, H, K, L, O, S, V, W and X), and 
aspartate (D and E) cathepsins. In particular cathepsins B, D and L are thought 
to be critical inducers of LMP and their chemical or genetic inhibition is able to 
partially protect cells from LMP inducers such as etoposide and acetate (Oberle 
et al., 2010; Marques et al., 2013). The subcellular location of mature 
cathepsins in the lysosome is a result of complex sorting and trafficking events 
which shuttle the immature protein from the endoplasmic reticulum and Golgi 
network via vesicles to the lysosome (Braulke and Bonifacino 2009). Once in 
the lysosome the immature protease undergoes cleavage of N-terminal residues 
to produce the mature cathepsin (Laurent-Matha et al., 2006).  
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One of the mechanisms by which LMP induces cell death is as an upstream 
mediator of apoptosis, in this context it has been demonstrated that pro-
apoptotic Bcl-2 family members are cathepsin substrates leading to their 
activation and LMP precedes cytochrome c release (Johansson et al., 2003; 
Droga-Mazovec et al., 2008). However it has also been proposed that LMP 
acts as a mediator of the apoptotic response, and has been shown to occur 
downstream of caspase activation in response to apoptosis inducers (Huai et 
al., 2013). Interestingly, over-expression of mutant cathepsin D is equally as 
effective as wild-type at inducing apoptosis, as measured by cytochrome c 
release and caspase activation, indicating that LMP may not be dependent on 
the protease activity of this protein (Beaujouin et al., 2006). 
 
Over-expression of cathepsins is frequently noted in breast cancer where 
cathepsin D and B levels correlate with increased lymph node involvement and 
decreased disease free survival (Westley and May 1987; Thomssen et al., 
1995; Lah et al., 2000; Nouh et al., 2011). Their mechanism within this context 
may be explained by the fact that inhibition of cathepsin B decreases 
degradation of ECM and attenuates bone metastases by breast cancer cells 
(Victor et al., 2011; Withana et al., 2012). In this model cathepsin B 
translocates to the invasive edge of the tumour where it is secreted into the 
tumour micro-environment resulting in ECM degradation, allowing more 
favourable conditions for tumour cell metastasis (Aggarwal and Sloane 2014). 
Similar data exists implicating cathepsin D in metastatic processes; here it has 
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been shown to activate ECM degradation enzymes in conditions which 
simulate the breast tumour micro-environment (Maynadier et al., 2013).  
 
The over-expression of these highly proteolytic enzymes in tumours may be a 
characteristic which could be clinically exploited. The fact that lysosome 
associated membrane proteins 1 and 2 (LAMP 1 and 2) required for lysosomal 
stability are down-regulated by cathepsins, imply that cancer cells may be more 
sensitive to LMP than non-cancer cells due to a less stable lysosomal 
membrane (Fehrenbacher et al., 2008). This may be particularly relevant for 
tumours which harbour apoptosis-limiting p53 mutation, due to the fact that 
LMP induced cell death has been shown to occur in p53-null cell lines (Erdal et 
al., 2005). Agents which increase ROS levels within cells have been shown to 
induce cell death via this mechanism, indicating that the lysosome may be 
particularly sensitive to oxidative damage (Kagedal et al., 2001a). Equally 
LMP has been demonstrated to be a consequence of lysosome sequestered zinc 
in conditions of zinc overload (Hwang et al., 2008; Kukic et al., 2014). Taken 
together these observations suggest that drugs which increase ROS levels, such 
as zinc ionophores, are potential LMP inducers and cancer cells may be more 
sensitive to this effect than non-cancer cells. Perhaps surprisingly, the 
accumulation of lysosomal zinc and subsequent cell death via LMP is a feature 
of non-cancerous breast epithelial cells during mammary gland involution, the 
process responsible for the reduction of mammary gland size after weaning 
(Hennigar et al., 2015). This therefore implicates the sequestering of lysosomal 
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zinc and subsequent LMP as an endogenous means of regulating cell number 
within breast tissue during normal (non-cancerous) development.  
 
Particularly relevant to the study of disulfiram, proteasome inhibitors have 
previously been demonstrated to cause lysosomal release of cathepsin D by an 
unknown mechanism (Berndtsson et al., 2009). Here, disulfiram-copper co-
incubation was shown to increase cytosolic staining of cathepsin D and its 
knockdown was able to partially protect cells from disulfiram-copper induced 
cell death. However, the involvement of disulfiram alone has not been 
investigated. The hypothesis that the drug can alter the functioning of 
lysosomes is supported by immunofluorescence studies conducted by PhD 
student Jen Wymant in the laboratory which demonstrated that the drug 
influences the spatial organisation of LAMP 2 but not the early endosomal 
marker, early endosome antigen 1 (EEA1; Wymant 2015). Here, disulfiram 
was observed to have no effect on the localisation of early endocytic structures 
(Figure 6.1A), however caused late endosomes and lysosomes to be 
redistributed from typical perinuclear clusters observed in control cells to more 
diffuse scattering throughout the cytoplasm (Figure 6.1B). This provides 
evidence that the drug is capable of altering the biological processes of these 
organelles as the intracellular localisation of endo-lysosomal components is 
integral to their cellular function. For example, starvation and altered 
intracellular pH have been shown to redistribute lysosomes between 
perinuclear and peripheral regions of the cell (Korolchuk et al., 2011; Malek et 
al., 2012). 
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Figure 6.1. Disulfiram causes mislocalisation of lysosomes, however does not alter 
localisation of early endosomes. Experiment conducted by Jen Wymant and figure taken from 
Wiggins et al., 2015. MCF-7 cells were treated with 1 µM disulfiram for 3 hr and then 
analysed via immunofluorescence microscopy using antibodies recognising EEA 1 (A), or 
LAMP 2 (B). Blue nuclei are labelled with Hoechst 33342. Images show a single projection 
through the centre of cells and are representative from three independent experiments. Scale 
bars show 10 µm. 
 
Subcellular fractionation 
Subcellular fractionation describes the process of separating intracellular 
organelles from the nucleus and cytosol and may be used to monitor the 
intracellular location of cathepsins (Oberle et al., 2010; Amritraj et al., 2013). 
In order to gain access to these subcellular structures it is first necessary to 
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disrupt the plasma membrane whilst leaving the organelles intact, typically by 
gentle homogenisation or repeated freeze thaw cycles in isotonic buffers. For 
basic subcellular fractionation, this homogenate is centrifuged first to remove 
the nuclei and cellular debris, retaining the post nuclear fraction from the 
supernatant and then further separated by high speed (>100,000x g) ultra-
centrifugation to produce the membrane fraction (containing organelles) and 
cytosol. More complex methods may be used to isolate specific organelles by 
virtue of their buoyancy within a density gradient of viscose material. This 
method, however, involves high technical precision and is labour intensive. 
 
The basic subcellular fractionation method is commonly used to monitor the 
release of cathepsin proteases from membrane bound fractions into the cytosol 
of cells in response to apoptotic stimuli (Oberle et al., 2010; Amritraj et al., 
2013). However, no study has previously investigated the effects of disulfiram 
in this regard.  
 
Aims and Objectives 
It is the hypothesis of this chapter that disulfiram is able to induce LMP as a 
consequence of its ability to increase lysosomal zinc levels. The aims of this 
chapter are: 
 To compare and optimise different methods to measure LMP, including 
subcellular fractionation.  
 To investigate the ability of disulfiram to cause release of cathepsins 
from the lysosome to the cytosol. 
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 To determine whether LMP precedes apoptosis in disulfiram treated 
cells. 
 To characterise the role of LMP in the disulfiram cytotoxic response. 
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6.2. Results 
6.2.1. Analysis of the use of acridine orange (AO) as a marker of LMP in 
live cells 
One commonly employed method to measure LMP is by monitoring the 
fluorescence of AO, a membrane permeable dye that accumulates in acidic 
endo-lysosomal compartments (Erdal et al., 2005). When localised in these 
structures AO produces orange/ red fluorescence when excited with 488 nm 
photons (Kagedal et al., 2001b; Boya and Kroemer 2008; Oberle et al., 2010). 
However, the dye is also capable of binding nucleic acids upon which it omits 
green fluorescence. Initially it was determined how AO localised in MCF-7 
cells. For this cells were pre-loaded with AO at 1.25, 2.5 and 5 µg/ ml and live 
cells imaged before (Pre-treat) or after a “mock” treatment whereby an eqi-
volume of imaging media, in the absence of drug, was added to the dish. 
Subsequent images were then taken between 2-10 min after treatment (Figure 
6.2). Pre-treatment images show ubiquitous red staining in punctate 
compartments within cells at all AO concentrations, although this phenotype is 
more obvious at the highest concentration. However, after the addition of 
“mock” treatment these endo-lysosomal structures rapidly photobleached and 
there was substantial loss of fluorescence within these compartments at time 
points as early as 2 min, particularly at concentrations <5 µg/ ml. By 5 min 
there was almost complete loss of vesicular AO staining at all concentrations of 
the dye. In comparison, green nucleic acid staining was more photostable and 
little bleaching occurred at any dye concentration up to 10 min post-treatment.  
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Figure 6.2. Extensive photobleaching of acridine orange occurs rapidly after the addition 
of “mock” treatment. MCF-7 cells were pre-loaded with AO at a concentration of 1.25, 2.5 or 
5 µg/ ml for 15 min and imaged before (Pre-treat) and subsequent to the addition of cell 
imaging media representing a “mock” treatment. Images are multiple z-projections from a 
series of 10 equally spaced, single projections. Red represents AO localised in endo-lysosomal 
structures and green represents AO bound to nucleic acids. Scale bars show 10 µm. 
 
6.2.2. Optimisation of cathepsin D and B antibodies for 
immunofluorescence and Western blot 
The rapid photobleaching of AO prevented its use as an indicator of LMP, and 
instead immunofluorescence techniques were enlisted in an attempt to image 
localisation of cathepsin D and B using fluorescence microscopy. As, in their 
mature form, these proteins are usually localised to the lysosome and 
translocate to the cytosol upon LMP, their subcellular location may be used to 
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indicate lysosomal membrane damage and leakage (Erdal et al., 2005; 
Berndtsson et al., 2009). Initial studies were carried out to optimise an 
immunofluorescence protocol in MCF-7 cells based on the use of commercial 
antibodies. For this cells were plated, 24 hr later fixed with PFA and probed 
with antibodies purchased from Santa Cruz (hereafter referred to as H75 
antibody in reference to its product code, full details of all antibodies used in 
this chapter are given in Material and Methods, Table 2.2) at either 1:50 or 
1:250 dilution. Images in Figure 6.3A demonstrate that very little punctate 
staining was observed and instead the antibody produced predominantly 
cytosolic staining, with evidence of nucleolus accumulation. Due to the 
limitations of imaging vesicular cathepsin D using the H75 antibody alternate 
cathepsin D antibodies were obtained as a gift from Dr. Emyr Lloyd-Jones 
(School of Biosciences, Cardiff University), these are referred to as G19 and 
Calbiochem antibodies. Similarly to the images produced by H75, cells probed 
with the G19 antibody demonstrated a cytosolic staining pattern but notably 
there was no nucleolus labelling (Figure 6.2B). When the Calbiochem antibody 
was used occasional punctate staining was observed however the majority of 
cells displayed faint a non-specific cytosolic staining pattern.  
  
Experiments were then conducted comparing acetone and methanol as 
alternative fixation methods to PFA, using the H75 antibody. Both acetone and 
methanol provided much lower cytosolic staining compared to PFA but again 
there was no evidence of the location of this protein in vesicles; in the case of 
methanol fixation, fluorescence was almost completely absent (Figure 6.3C).  
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Figure 6.3. Immunofluorescence analysis using cathepsin D antibodies. MCF-7 cells were 
fixed via PFA (A, B, D), acetone or methanol (C) and subjected to immunofluorescence 
analysis conducted with the indicated dilutions of H75, G19 or CalBiochem (CalBio) primary 
antibodies recognising cathepsin D or secondary antibody only controls (2
o
 only). In (D) cells 
were treated with either 100 µM disulfiram or equivalent DMSO for 1 hr prior to being fixed 
via PFA and immunofluorescence analysis conducted with the H75 cathepsin D antibody at a 
dilution of 1:50. Nuclei were labelled with Hoescht 33342 and all studies represent an n=1. 
Images show a single z-projection through the centre of cells and scale bars represent 10 µm. 
 
Similarly to images in Figure 6.3A, a high level of nucleolus staining was also 
observed with both fixatives. Immunofluorescence studies have previously 
demonstrated the release of cathepsin D into the cytosol by increased 
immunoreactivity of antibodies; here it was noted that cells undergoing LMP 
and subjected to immunofluorescence analysis using anti-cathepsin D primary 
antibodies produced a higher level of fluorescence compared to control 
(Hwang et al., 2010). Therefore it was next determined whether disulfiram 
altered the immunoreactivity of antibodies. For this, MCF-7 cells were treated 
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for 1 hr with 100 µM disulfiram or diluent, fixed with PFA and labelled with 
the H75 cathepsin D primary antibody. Images in Figure 6.3D show that, 
although there was no difference in staining patterns, disulfiram produced a 
marked increase in both cytosolic and nucleolus labelling compared to diluent. 
This therefore indicates that upon addition of the drug there is greater 
availability of the cathepsin D.  
 
Due to the failure of cathepsin D antibodies to visualise vesicular protein, it 
was instead investigated whether a cathepsin B antibody produced better 
results. For these experiments only one cathepsin B primary antibody was used 
and three secondary antibodies were compared in order to optimise the 
immunofluorescence protocol. Here, PFA fixed MCF-7 cells were probed with 
a cathepsin B antibody and secondary antibodies conjugated with Alexa 488 or 
647 raised in rabbit or donkey (Figure 6.4). All secondary antibodies produced 
limited evidence of punctate fluorescence, and staining patterns were 
comparable in secondary only control cells indicating that the fluorescence 
produced with the primary antibody was non-specific.
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Figure 6.4. Immunofluorescence analysis using a cathepsin B primary antibody. MCF-7 
cells were PFA fixed and labelled with a primary antibody recognising cathepsin B at 1:250 
dilution or secondary antibody only control. Secondary antibodies were generated in rabbit 
conjugated with Alexa 647 or donkey conjugated with Alexa 647 or 488 as indicated. Studies 
represent n=2 and nuclei are labelled with Hoescht 33342. Images show a single z-projection 
through the centre of cells and scale bars represent 10 µm. 
 
These unsuccessful attempts to visualise cathepsin localisation within the 
lysosome using immunofluorescence meant that alternative techniques were 
necessary to measure LMP and subcellular fractionation was selected as this 
has previously been used to demonstrate release of these enzymes into the 
cytosol (Oberle et al., 2010). Methods were initially optimised to detect 
cathepsin D and B via Western blotting of MCF-7 cell lysates. For this, lysates 
were collected from untreated cells and the amount of protein quantified via the 
BCA assay. The same amount of protein was then added to each well of an 
SDS-PAGE gel and Western blotting conducted using cathepsin D and B 
primary antibodies; clathrin heavy chain and transferrin receptor were used as 
loading controls as they were of an appropriate molecular weight and the 
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antibodies were well characterised by the laboratory (for full methods see 
Materials and Methods Section 2.7 and 2.9). A single strong band was detected 
for both proteins at approximately 48 and 35 kDa for cathepsin D and B 
respectively (Figure 6.5). The observed molecular weight of cathepsin D (~52 
KDa) corresponds to the immature form of the protein, which undergoes 
cleavage of N-terminal residues to form the mature protease (Laurent-Matha et 
al., 2006). Whereas the molecular weight observed for cathepsin B relates to 
the mature form of the protein. 
 
Figure 6.5. Detection of Cathepsin D and B in untreated MCF-7 whole cell lysates. Lysates 
were collected from untreated MCF-7 cells and protein levels of cathepsin D (A) and B (B) 
analysed via Western blotting in duplicate. For cathepsin D the H75 antibody was used. 
Clathrin heavy chain and transferrin receptor are shown as molecular weight appropriate 
loading controls using antibodies well characterised in the laboratory. 
 
6.2.3. Disulfiram causes translocation of cathepsin D and B from 
membrane to cytosolic compartments 
The fact that cathepsin antibodies were capable of detecting these proteins via 
Western blotting meant that this technique could be used in combination with 
subcellular fractionation in order to separate intracellular compartments. For 
these studies MCF-7 cells were treated with 100 µM disulfiram or diluent for 
1 hr before detachment and ultra-centrifugation to produce post-nuclear (PNF), 
cytosolic (CYT) and membrane (MEM) fractions (detailed in Materials and 
Methods Section 2.8). The level of cathepsin D and B in each fraction was then 
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compared via Western blotting. Blots were also probed for transferrin receptor 
and ß tubulin as markers of the membrane and cytosolic fractions respectively. 
Data in Figure 6.6A shows that there is almost no overlap of transferrin 
receptor and ß tubulin between membrane and cytosolic compartments 
indicating that subcellular fractionation had effectively segregated these 
fractions. In cells treated with DMSO cathepsin D and B were almost entirely 
found in the PNF and membrane fraction indicative of their sequestration 
within membrane bound structures.  
Figure 6.6. Disulfiram increases levels of cathepsin D and B in cytosolic compartments. 
(A) MCF-7 cells were treated with either 100 µM disulfiram or diluent for 1 hr prior to the 
collection of PNF, CYT or MEM subcellular fractions as described in Materials and Methods 
Section 2.8. Fractions were then blotted for transferrin receptor, ß tubulin, cathepsin D or B. 
(B, C) Western blots were quantified via densitometry and changes in levels of cathepsin D (B) 
or B (C) expressed as a percentage compared to DMSO control for each fraction. Error bars 
represent standard error, n=2 *p<0.05. 
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However disulfiram treatment resulted in simultaneous reduction in the amount of 
cathepsin D and B found in membrane fractions and increased levels of these 
proteins in the cytosolic compartments. When these results were quantified via 
densitometry, disulfiram produced a statistically significant increase in cytosolic 
levels of cathepsin D and cathepsin B producing a 1.71 and 2.45 fold increase 
compared to diluent (Figure 6.6B, C). Despite this, statistical significance to 
indicate decreased levels in membrane compartments upon drug treatment was not 
achieved for either cathepsin. These results therefore demonstrate that disulfiram 
is able to increase cytosolic levels of cathepsin D and B, and indicate that the drug 
is capable of inducing LMP.  
 
In order to determine whether the disulfiram induced increase in cytosolic 
levels of cathepsin D and B occur before the morphological features of cell 
death, cells were treated under the same conditions as described for subcellular 
fractionation (100 µM disulfiram or diluent, 1 hr) and imaged via brightfield 
microscopy. In these studies, MCF-7 cells retain normal morphology and 
images of cells treated with disulfiram are comparable to DMSO treatment 
(Figure 6.7). In comparison cells treated with staurosporine, a protein kinase 
inhibitor known to induce apoptosis, demonstrate morphological changes 
consistent with apoptosis and extensive cell blebbing is observed (Hasegawa et 
al., 2012). These results indicate that the release of cathepsins into the cytosol 
occurs prior to cell morphological effects. 
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Figure 6.7. Lysosomal membrane permeabilisation precedes disulfiram induced cytotoxic 
changes in morphology. Brightfield imaging was conducted in MCF-7 cells treated for 1 hr 
with 100 µM disulfiram, equivalent DMSO or positive control (1 µM staurosporine, 30 min). 
Scale bars show 10 µm. 
 
6.2.4. The cathepsin B inhibitor, CA-074Me does not protect cells from 
disulfiram induced death 
The release of cathepsin B from lysosomes to the cytosol has previously been 
shown to promote apoptosis (Guicciardi et al., 2000). In order to determine 
whether the activity of cathepsin B was required for disulfiram induced cell 
death in MCF-7 cells, the inhibitor CA-074Me was employed. CA-074Me is a 
cell permeable cathepsin B inhibitor, although it has also been proposed to 
inhibit other cysteine proteases (Montaser et al., 2002). Studies were initially 
conducted to determine the maximum concentration of the inhibitor which 
could be used without effecting MCF-7 cell viability (Figure 6.8). Almost no 
viable cells remained after 100 µM CA-074Me treatment however 10 µM was 
without effect, therefore further studies were conducted in cells treated with 
serial dilution of disulfiram in combination with 10 µM CA-074Me. The 
addition of the inhibitor to disulfiram produced little effect on the viability 
profile of the drug, although at 10 µM disulfiram the magnitude of the biphasic 
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peak was reduced. This data therefore suggests that CA-074Me is unable to 
protect cells from disulfiram induced cell death. Time constraints inhibited 
further analysis regarding the localisation of cathepsin B and D in these cells in 
the presence of disulfiram. 
 
Figure 6.8. The cathepsin B inhibitor, CA-074Me does not protect cells from disulfiram 
cytotoxicity. Viability of MCF-7 cells treated with CA-074Me alone or disulfiram +/-10 µM 
CA-074Me was analysed after 72 hr treatment. Error bars show standard error. 
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6.3. Discussion 
The fact that the zinc ionophore activity of disulfiram, described in Chapter 4, 
significantly raised levels of this metal in endo-lysosomal compartments led to 
investigation of whether this had any effect on their integrity. In order to 
examine the toxic consequences of disulfiram induced endo-lysosomal zinc 
sequestration, LMP was investigated as a potential cell death mechanism. 
Determination of LMP via imaging techniques i.e. the lysosomal dissipation of 
AO and changes in intracellular localisation of cathepsin D and B proteases 
proved problematic due to the rapid photobleaching of AO and poor labelling 
by cathepsin antibodies. Other studies have successfully employed AO as an 
indicator of LMP in live cells (Erdal et al., 2005), however these studies 
focussed on a single time point and it remains to be determined whether this 
would sufficiently improve the dye’s photostability for use in this work. 
Previous immunofluorescence studies using cathepsin D and B antibodies 
provide mixed results in terms of their localisation, however diffuse cytosolic 
staining with limited evidence of punctate structures is frequently observed in 
the literature, similar to the cathepsin D studies of this chapter (Hwang et al., 
2010; Lipton 2013). This makes data interpretation very difficult. Despite this, 
immunofluorescence has been used to determine LMP, measured by an 
observed increase in the immunoreactivity of cathepsin D and B antibodies 
upon drug treatment, indicating increased availability of these proteases within 
the cytosol (Hwang et al., 2010). In this study, similar results were obtained for 
disulfiram treated cells whereby the drug increased fluorescence in cells probed 
with cathepsin D antibodies, however the fact that the antibodies did not 
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recognise the proteases inside endo-lysosomal structures led to ambiguity as to 
whether this truly represented cathepsin D translocation. In addition to the 
imaging techniques used in this chapter, fluorogenic cathepsin B and L 
substrates exist which may be used to measure the activity of these enzymes 
within cells (Creasy et al., 2007). This method utilises the protease activity of 
cysteine cathepsins to cleave a non-fluorescent substrate into a fluorescent 
product which can then be measured via flow cytometry or fluorescence 
microscopy. Using this technique studies have previously demonstrated 
cathepsin B activity in lysosomes of untreated cells which then becomes 
cytosolic upon treatment with the LMP inducer Docetaxel (Mediavilla-Varela 
et al., 2009). Whether such a method may provide a more powerful means of 
visually determining the translocation of cathepsin proteases between the 
lysosome and cytosol in disulfiram treated breast cancer cells remains to be 
determined.    
 
As a more definite method of measuring LMP, subcellular fractionation studies 
were developed to compare levels of cathepsin D and B in membrane and 
cytosolic fractions of disulfiram or diluent treated cells. The data from this 
method represents the first time that the release of lysosomal cathepsin D and 
B into the cytosol has been observed following disulfiram treatment, although 
disulfiram-copper co-incubation has previously been shown to have this effect 
on cathepsin D (Berndtsson et al., 2009). This process was shown to occur 
prior to morphological changes associated with cell death, indicating that 
disulfiram induced LMP occurs upstream of apoptosis. The sequestration of 
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zinc into breast epithelial cell lysosomes and subsequent LMP has previously 
been demonstrated to occur as an endogenous means of regulating the number 
of cells within non-cancerous breast tissue following weaning (Hennigar et al., 
2015). This, when viewed in the context of the data in this chapter, implies that 
by increasing lysosomal zinc levels disulfiram may be promoting endogenous 
cell death processes which normally occur in non-cancerous tissue. As the 
release of lysosomal cathepsins has previously been shown to occur in 
response to oxidative damage and accumulation of metal ions within this 
organelle, this data suggests that the disulfiram induced sequestration of zinc in 
lysosomes promotes oxidative damage to these structures ultimately leading to 
their rupture (Kagedal et al., 2001a; Hwang et al., 2008; Kukic et al., 2014). 
Not only does this provide a novel mechanism which may contribute to 
disulfiram’s observed cytotoxicity, it may also implicate the drug as an agent to 
enhance endosomal escape of therapeutic agents and therefore aid drug 
delivery. In this context, the delivery of endocytic cargo to the lysosome 
prevents the access of therapeutic drugs to their intracellular targets (Shete et 
al., 2014). By promoting lysosomal rupture, disulfiram may be able to increase 
the intracellular delivery and therefore efficacy of anti-cancer drugs. 
Chloroquine has this effect and is often used as endosomolytic agent in drug 
delivery research (El-Sayed et al., 2009). This may provide an alternate 
mechanism to describe the ability of disulfiram to act in synergy with cancer 
drugs such as 5-Fluorouracil, gemcitabine and paclitaxel (Wang et al., 2003; 
Guo et al., 2010; Liu et al., 2013). 
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The fact that CA-074Me, an inhibitor of cathepsin B protease activity, was 
unable to rescue cells from disulfiram suggests that cathepsin B activity is not 
essential for the drug’s cytotoxicity. However, as multiple cathepsins including 
B, D, and L are released during LMP it is possible that there is redundancy 
within this cell death response or other cathepsins are required for this effect 
(Oberle et al., 2010). To fully examine this possibility, multiple chemical 
inhibitors targeting several cathepsins or silencing their expression of these 
proteins with siRNA may provide a more conclusive approach to study their 
role in the disulfiram cytotoxic response.   
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7. General discussion 
The fact that the clinically approved anti-alcoholism drug disulfiram is well 
tolerated in patients, ex-patent and cheap to administer, make it an ideal 
candidate for repurposing as an anti-cancer agent. Considering the drug has 
relatively few adverse effects, when given in the absence of alcohol, it is 
perhaps surprising that it has been reported to interfere with so many biological 
processes by virtue of its capacity to bind thiol groups and divalent cations 
(Sauna et al., 2005; Skinner et al., 2014). Much of the current literature 
surrounding the potential therapeutic benefits of disulfiram as an anti-cancer 
agent focuses on its interaction with copper, in particular as a copper complex, 
which can inhibit the proteasome and NFB activity (Chen et al., 2006; Guo et 
al., 2010; Liu et al., 2012; Duan et al., 2014). Despite evidence that zinc co-
incubation can increase the oxidative damage produced by disulfiram and 
knowledge that the drug is also a zinc chelator, little has been done establish 
the role of zinc in the anti-breast cancer properties of the drug (Pozza et al., 
2011). The interaction between zinc and disulfiram is particularly relevant to 
the study of anti-breast cancer therapeutics due to the fact that accumulation of 
the metal within breast cancer cells positively correlates with metastasis, 
resistance and histological grading (Taylor et al., 2008; Hogstrand et al., 2013; 
Riesop et al., 2015). With this in mind the goal of this study was to provide the 
first time that the relationship between disulfiram and zinc in breast cancer 
cells had been investigated in detail.  
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Previous studies have investigated the anti-breast cancer effect of disulfiram 
and attributed cell death due to inhibition of the proteasome, BCA2, NFB and 
ALDH activity (Chen et al., 2006; Brahemi et al., 2010; Guo et al., 2010; Liu 
et al., 2013). The data from Chapter 3 provides further evidence to support this 
anti-breast cancer potential, and expands upon knowledge of the cytotoxic 
profile of the drug in breast cancer cell lines. One of the key findings from this 
chapter was that of the breast cancer cell lines examined only ER
+
 MCF-7 and 
BT474
 
breast cancer cells responded to disulfiram at <100 µM, indicating that 
the drug may have therapeutic potential in this breast cancer sub-type. In 
further support of this it has been demonstrated that transfection of ER into ER
-
 
MDA-MB-231 cells increases their disulfiram sensitivity (Brahemi et al., 
2010). The fact that in this work T47D cells were resistant to disulfiram 
cytotoxicity suggests that not all ER
+
 tumours may respond to be drug, 
although previous studies have demonstrated sensitivity of these cells when 
plated at a lower density to that used in this thesis (Yip et al., 2011). It has 
previously been suggested that the E3 ubiquitin ligase BCA2 is a disulfiram 
target and as some studies have indicated its over-expression in ER
+ 
breast 
tumours this may explain, or at least contribute, to the selective toxicity 
towards these cell lines (Burger et al., 2005; Brahemi et al., 2010). How 
expression levels of this protein relate to its oncogenic properties are unknown, 
however studies from our laboratory have suggested that it has a role in EGFR 
trafficking (Wymant 2015). This thesis from PhD student Jen Wymant also 
revealed relatively high expression of BCA2 in MDA-MB-231 and T47D cells, 
neither of which responded to disulfiram in the studies of Chapter 3; this 
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indicates that the sensitivity of breast cancer cells is not exclusively determined 
by expression of BCA2, but instead other mechanisms must also play a role. 
Additionally, the fact that other studies have previous demonstrated that 
MDA-MB-231 cells are sensitive to disulfiram cytotoxic effects further 
questions this apparent BCA2/ disulfiram selectivity (Yip et al., 2011; Liu et 
al., 2013). 
 
The cell lines which responded to disulfiram produced an intriguing biphasic 
cytotoxicity profile, whereby viability was partially restored at ~10 µM despite 
being reduced to >50% at 1 µM. This effect has been previously reported in a 
variety of cell lines including MCF-7 and MDA-MB-231 (Wickstrom et al., 
2007; Guo et al., 2010; Yip et al., 2011). Surprisingly, this had not received 
further attention. This disulfiram recovery could limit its potential therapeutic 
application and it may be the case that this translates into the clinic, especially 
considering in vivo studies have demonstrated that doses of 25 µg/ mouse/ day 
produce a greater anti-cancer effect in glioma xenographs than 
120 µg/ mouse/ day (Marikovsky et al., 2002). The results in Chapter 3 provide 
greater insight regarding the concentration range (5-20 µM) and time 
dependency of this peak; in particular that it represents recovery of cells from 
initial cytotoxic events which occur within 8 hr rather than complete inactivity 
of the drug at this concentration. This thesis highlights strategies that could 
reverse this efficacy limiting phenomenon, either by co-incubation with copper 
or zinc (Chapter 4) or through the use of disulfiram analogues (Chapter 5) 
which do not display the biphasic effect. Other studies have previously shown 
 202 
 
that copper co-incubation can reduce the impact of biphasic peak but to our 
knowledge this is the first time that zinc has also been shown to have this effect 
(Yip et al., 2011; Rae et al., 2013). The fact that such low concentrations of 
these metal supplements produced dramatic differences in the biphasic 
response (peak height) may imply that this could be achievable in 
physiological conditions with dietary supplements. However it should be noted 
that copper/ zinc co-incubation increased the potency of disulfiram, not only in 
breast cancer cells, but also in the non-cancerous MCF-10A cell line. This 
finding raises the possibility that this combination may produce toxic effects in 
non-cancerous tissue, made particularly important given that a recent clinical 
trial involving disulfiram noted toxicity concerns (Schweizer et al., 2013). 
Despite this, the studies of Chapter 4 investigating the toxicity of both metals 
(in the absence of disulfiram) in MCF-10A cells found that 200 µM copper 
produced a threefold greater decrease in cell viability compared to this 
concentration of zinc. This may indicate that in a clinical setting zinc 
supplementation could produce fewer side effects than copper whist still 
increasing disulfiram efficacy.  
 
Experiments were then performed to determine whether disulfiram could alter 
intracellular zinc levels and how this may contribute to its cytotoxic effects. 
The theory that disulfiram could act as a zinc ionophore in breast cancer cells 
was supported by evidence that co-incubation with zinc enhances levels of 
ROS in pancreatic cancer cells and that the disulfiram analogue PDTC and 
metabolite DDC had this ionophore activity in pancreatic cancer and bovine 
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endothelial cells respectively (Kim et al., 2000; Donadelli et al., 2009; Pozza et 
al., 2011). The fact that zinc can be toxic to cells and its intracellular levels are 
tightly regulated implies that a zinc ionophore may increase levels of this metal 
beyond the toxic threshold (Bozym et al., 2010). The development of the flow 
cytometry assay to measure fluorescence of the zinc dye Fluozin-3 (Chapter 4) 
allowed us to quantitatively compare zinc levels under various conditions; it 
would have been quite difficult to perform this analysis using confocal 
microscopy. The flow cytometry work supported the fluorescence microscopy 
data, and unequivocally demonstrated that disulfiram could potently and 
rapidly increase zinc levels in MCF-7 and MDA-MB-231 cells but not non-
cancerous MCF-10A breast epithelial cells. When considering this ionophore 
action together with the previously reported observation that ER
+
 breast 
tumours contain 80% higher zinc levels than ER
-
, it may be the case that ER
+
 
tumours are closer to the toxic threshold for zinc and therefore more sensitive 
to zinc ionophores (Farquharson et al., 2009). Despite this, the results in 
Chapter 4 did not reveal a difference in basal zinc levels between these cell 
lines, although this may be beyond the sensitivity limit of the assay. The 
relationship between the zinc ionophore activity of disulfiram and its ability to 
induce cytotoxicity was further assessed by the use a non-toxic analogue 
(FS03EB) in Chapter 5. Here it was shown that under physiological conditions 
FS03EB was unable to increase intracellular zinc levels. However, in zinc 
enriched conditions both cytotoxicity and zinc ionophore activity of the 
analogue were dramatically increased indicating these two factors were 
intrinsically linked. Similarly the fact that zinc (and copper) supplementation 
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could enhance the disulfiram cytotoxic effect indicates that toxicity is limited 
by extracellular metal availability. The relationship between the zinc ionophore 
activity of disulfiram and cytotoxicity is further demonstrated by the fact that 
MCF-10A cells are resistant to both cytotoxic effects and zinc ionophore 
activity of the drug. However, it is also apparent that ionophore independent 
mechanisms contribute to disulfiram cytotoxicity, as 1 µM disulfiram did not 
show a measurable increase in intracellular zinc levels in MCF-7 cells (Chapter 
4), however produced >50% decrease in cell viability (Chapter 3). The fact that 
the drug is able to raise intracellular zinc levels within breast cancer cells may 
have important clinical applications. It has previously been shown that breast 
cancer cells harbour higher zinc levels than non-cancerous cells and that zinc 
levels correlate with histological grade (Riesop et al., 2015). This therefore 
indicates that increasing zinc levels further in these tissues will provide not 
only a selective mechanism of action to target cancer cells but also that the 
drug may have an enhanced effect in more aggressive disease types.  
 
Not only did the use of analogues in Chapter 5 provide structures which avoid 
the biphasic effects observed with disulfiram, they also allowed for 
investigation into which of the drug’s chemical features are responsible for its 
effect on breast cancer cell viability. The results in this chapter indicated that 
the chemical groups bound to the nitrogen had a greater effect on breast cancer 
cell viability than those bound to the disulfide bond and that R group size was 
also an important consideration in MDA-MB-231 cell sensitivity and MCF-7 
biphasic effects. This is the first time these observations have been described 
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and may allow for identification of other disulfiram-like compounds which 
may also possess anti-cancer properties and operate through similar 
mechanisms. Importantly none of the analogues studies in this chapter 
exhibited cytotoxicity in MCF-10A cells at concentrations <100 µM; 
demonstrating that non-cancerous cells are highly resistant to the effects of 
compounds which share the core structure of disulfiram. This chapter also 
investigated the cytotoxic and zinc ionophore effects of the drug’s major 
metabolite DDC. As in vivo disulfiram is rapidly metabolised and undetectable 
within 4 min of addition to blood, metabolites are thought to contribute to the 
drug’s biological properties (Cobby et al., 1977; Nagendra et al., 1991). The 
idea that metabolites are important for disulfiram effects is further supported 
by a clinical trial in which its efficacy correlated with the ability of individuals 
to form the methylated DDC derivative, S-methyl N,N-diethyldithiocarbamate 
(Schweizer et al., 2013). In Chapter 5 DDC produced a similar cytotoxic 
profile (metal dependant biphasic peak) and zinc ionophore effects as the 
parent drug, providing further evidence that this metabolite may be the active 
form of the drug in cell culture systems. 
 
Chapter 4 represents the first real time visual observation of intracellular zinc 
in cells treated with disulfiram, and a major finding from this study was that 
the drug raises zinc levels specifically in endo-lysosomal compartments. It has 
previously been noted that increased lysosomal zinc is required for inducing 
autophagy in tamoxifen treated MCF-7 cells (Hwang et al., 2010). Despite 
increasing lysosomal zinc levels, the results in Chapter 3 reveal that disulfiram 
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did not induce autophagy and also represent the first time autophagy has been 
investigated in response to this drug. The increase in endo-lysosomal zinc 
levels could, however, affect processes regulated by these organelles in 
different ways. In support of this was data from PhD student Jen Wymant 
indicating that disulfiram causes mislocalisation of these organelles, whether 
this mislocalisation is a consequence of the increased zinc burden remains to be 
determined (Wiggins et al., 2015; Wymant 2015).  
 
The sequestering of zinc into certain sub-cellular compartments has been 
proposed as a mechanism to limit the toxic effects of this metal and has been 
noted to occur upon treatment with another zinc ionophore, clioquinol (Colvin 
et al., 2008; Yu et al., 2009). However, studies have also demonstrated that 
lysosomal zinc sequestration damages lysosomal membrane integrity and 
increases porosity, leading to release of hydrolytic enzymes and eventual 
apoptosis; indicating that there is a limit to this cytoprotective effect (Hwang et 
al., 2008). The ability of disulfiram (in the absence of copper) to induce 
lysosomal membrane permeabilisation (LMP) has never before been 
investigated and was the subject of Chapter 6. In this chapter several assays 
were developed to determine whether LMP occurs in disulfiram treated cells, 
and of these, subcellular fractionation to specifically determine the subcellular 
location of cathepsins D and B produced the most fruitful results. The mature 
forms of these hydrolytic proteases are enriched in lysosomes, however upon 
LMP they are released to the cytosol (Oberle et al., 2010; Amritraj et al., 
2013). Using subcellular fractionation, the results in Chapter 6 reveal that 
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disulfiram was able to cause release of cathepsin B and D from membrane 
bound compartments into the cytosol. Although a disulfiram-copper co-
incubation has previously been shown to have this effect, this chapter 
represents the first time disulfiram alone has been shown to induce LMP 
(Berndtsson et al., 2009). As the release of cathepsins into the cytosol has been 
observed to initiate an apoptotic response, this could provide a new mechanism 
to describe disulfiram induced cell death (Johansson et al., 2003; Huai et al., 
2013). In this model the drug increases lysosomal zinc, causing 
permeabilisation of the lysosomal membrane and the release of cathepsins in 
the cytosol that then promotes apoptosis (Figure 7.1). This model is further 
supported by the fact that LMP occurs before the morphological features of cell 
death and provides evidence that LMP precedes apoptosis under these 
conditions. 
 
Figure 7.1. Model of disulfiram induced lysosomal membrane permeabilisation following 
endo-lysosomal zinc sequestration. Disulfiram binds extracellular zinc and transports it into 
cancer cell lysosomes, leading to permeabilisation of the organelle’s membrane and release of 
cathepsin D (CD) and B (CB) into the cytosol, promoting apoptosis.  
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7.1. Further studies emanating from this work 
One possible limitation of this work is that it has been conducted in two 
dimensional cell culture models which limit its physiological relevance. In 
addition, results from the cytotoxicity studies of this thesis may be dependent 
on the number of cells plated and their confluency, which may explain the 
apparent discrepancy between the results in this thesis regarding the 
insensitivity of MDA-MB-231 and T47D cells to disulfiram and the work of 
others (Yip et al., 2011). This previous study also used three dimensional 
“mammosphere” cell culture systems to demonstrate the sensitivity of 
MDA-MB-231 and T47D cells to disulfiram-copper co-incubation, although 
disulfiram alone had little effect. One possible extension of this thesis could be 
to examine multiple cell lines using this mammosphere approach in order to 
further address the issue of ER
+
 sensitivity and compare the effects of zinc and 
copper on mammosphere formation. 
 
Another consideration is the fact that in cancer cells Fluozin-3 was exclusively 
observed in endo-lysosomes. Although disulfiram raised zinc levels within 
these subcellular compartments, it may be the case that the dye accumulated 
within these organelles was unable to enter other structures. Fluozin-3 is the 
most widely used zinc dye; however there has been very recent developments 
in the detection of free zinc by using fluorescence resonance energy 
transfer (FRET) sensors which make use of targeting sequences to measure 
zinc levels in specific organelles. The FRET method was successfully 
employed to quantify zinc concentration in subcellular regions such as the 
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cytosol, mitochondria, endoplasmic reticulum and vesicles (Hessels et al., 
2015). One future study could be to measure zinc concentration using these 
FRET sensors in other organelles following disulfiram treatment. 
 
Although this thesis has highlighted the fact that disulfiram is able to induce 
LMP, it remains to be determined whether this occurs as a result of its zinc 
ionophore activity. Further work to address this could be conducted to 
determine whether disulfiram induced LMP is exaggerated with greater zinc 
availability (zinc co-incubation) and inhibited when zinc levels are reduced, 
either by conducting the experiments in serum free media or through the use of 
established zinc chelators.  
 
7.2. Conclusions 
This thesis aimed to investigate the role of both intra and extracellular zinc in 
the anti-breast cancer properties of disulfiram. The fact that the drug was 
observed to increase endo-lysosomal zinc levels and that supplementation with 
low concentrations of this metal could enhance the disulfiram anti-breast 
cancer effect, indicates that zinc should be an important consideration in its 
future therapeutic application. Although further work is required, data in this 
thesis supports a new model which may partially explain the drugs 
cytotoxicity; disulfiram induced sequestration of zinc in endo-lysosomes leads 
to rupture of these compartments and release of hydrolytic enzymes to the 
cytosol. This model may be particularly relevant in conditions where the cell is 
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already under increased zinc load and more susceptible to zinc induced 
damage, for example ER
+
 or high histological grade breast tumours.
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A B S T R A C T
Disulﬁram, a clinically used alcohol-deterrent has gained prominence as a potential anti-cancer agent
due to its impact on copper-dependent processes. Few studies have investigated zinc effects on
disulﬁram action, despite it having high afﬁnity for this metal. Here we studied the cytotoxic effects of
disulﬁram in breast cancer cells, and its relationship with both intra and extracellular zinc. MCF-7 and
BT474 cancer cell lines gave a striking time-dependent biphasic cytotoxic response between 0.01 and
10 mM disulﬁram. Co-incubation of disulﬁram with low-level zinc removed this effect, suggesting that
availability of extracellular zinc signiﬁcantly inﬂuences disulﬁram efﬁcacy. Live-cell confocal
microscopy using ﬂuorescent endocytic probes and the zinc dye Fluozin-3 revealed that disulﬁram
selectively and rapidly increased zinc levels in endo-lysosomes. Disulﬁram also caused spatial
disorganization of late endosomes and lysosomes, suggesting they are novel targets for this drug. This
relationship between disulﬁram toxicity and ionophore activity was consolidated via synthesis of a new
disulﬁram analog and overall we demonstrate a novel mechanism of disulﬁram-cytotoxicity with
signiﬁcant clinical implications for future use as a cancer therapeutic.
 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
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Many current cancer therapies are limited by the severity and
frequency of adverse side effects and there is high demand for non-
toxic alternatives. One source of new therapies may be through
repurposing of clinically approved drugs, where safety in patients
has already been demonstrated. Disulﬁram has a long medical
history as an alcohol deterrent, however more recently has
demonstrated anti-cancer effects in a range of solid and
hematological malignancies [1]. The biological activity of disulﬁ-
ram is attributed to its ability to bind divalent cations and
consequently disrupt metal dependent processes, particularly
those involving copper and zinc [2,3]. Observations that both these
metal ions are involved in oncogenic development have led to
increased interest in the anti-cancer potential of this drug [4]. As
part of a copper complex, disulﬁram has been reported to induce
apoptosis in both cultured breast cancer cells and xenografts
through proteasomal inhibition [5–7]. These complexes have also
been shown to stabilize the NFkB inhibitor protein, IkB, thus* Corresponding author.
E-mail address: jonesat@cardiff.ac.uk (A.T. Jones).
http://dx.doi.org/10.1016/j.bcp.2014.12.014
0006-2952/ 2015 The Authors. Published by Elsevier Inc. This is an open access articre-sensitizing gemcitabine resistant tumors with enhanced NFkB
signaling [8]. In a case study of a patient with stage IV ocular
melanoma with liver metastases, combination therapy involving
disulﬁram and zinc gluconate was able to induce remission with
almost no side effects [9]. These observations have led to its
introduction to clinical trials, including one involving patients with
hepatic malignancies treated with disulﬁram and copper gluconate
(NCT00742911, University of Utah). Additionally, disulﬁram
treatment has been reported to remove essential copper and zinc
ions from enzymes that regulate extracellular matrix degradation
and oxygen metabolism resulting in suppression of cancer invasion
and angiogenesis in vitro and in vivo [2,3].
Much of the current literature surrounding disulﬁram focuses
on its capacity to bind copper ions, via two metal binding regions
in its structure (Fig. 1A). Relatively little has been done to
determine the role of zinc in its anti-cancer properties despite the
fact that it also has high afﬁnity for this metal [3]. Studies have
highlighted the role of zinc in the etiology of breast cancer where
high expression of zinc transporter proteins such as ZIP7 and ZIP10,
in breast cancer cell models increases intracellular zinc levels and
is associated with endocrine therapy resistance and increased
invasiveness [10,11]. Additionally, zinc has been reported to
increase pro-survival signaling [12] and inhibit caspases [13] inle under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Fig. 1. Structure of disulﬁram and the disulﬁram analog FS03EB. (A) *Indicates metal
binding regions within the structure. (B) 1H NMR (500 MHz, CDCl3) d 1.30 (3H, bs,
CH3), 1.47 (3H, s, CH3), 4.05 (4H, bs, CH2CH3), 5.26 (2H, s, CH2Ph), 5.41 (2H, s,
CH2Ph), 7.39 (10H, m, ArH);
13C NMR (125 MHz, CDCl3) d 11.12 (CH3), 13.20 (CH3),
47.18 (CH2), 52.04 (CH2), 55.80 (CH2), 59.54 (CH2), 127.48 (ArCH), 127.72 (ArCH),
128.20 (ArCH), 128.49 (ArCH), 128.79 (ArCH), 128.99 (ArCH), 134.57 (ArC), 135.24
(ArC), 198.82 (C5S), 195.33 (C5S); MS (EI+) m/z 420.08 (M+); HR-MS (ESI+) m/z
[M+H]+ calculated 421.0895, found 421.0896.
H.L. Wiggins et al. / Biochemical Pharmacology 93 (2015) 332–342 333vitro. Taken together these reports suggest that high zinc levels
promote cancer cell survival. Paradoxically, high intracellular zinc
is also associated with oxidative toxicity, implying that the cell
maintains tight homeostatic control of this metal and that drugs
which dysregulate this ﬁne balance may induce toxicity [14]. As
the concentration of zinc is higher in cancerous compared to non-
cancerous breast tissue [15] it is possible that drugs which alter
intracellular zinc levels would be selectively toxic to cancer cells.
In this study we investigate the role of both intra and
extracellular zinc in the anti-cancer activity of disulﬁram. We
demonstrate the effect of zinc and copper on the cytotoxicity of the
drug across a panel of cancerous and non-cancerous breast cell
lines. We describe a novel mechanism of action for disulﬁram, via
its ability to rapidly increase intracellular zinc levels in endo-
lysosomal compartments and alter the subcellular localization
speciﬁcally of late lysosomal structures. Both these effects
potentially impact on lysosome function. Interestingly, zinc levels
in a non-cancerous breast cell line remain unaltered by disulﬁram
treatment and taken in the context of the literature surrounding
zinc dysregulation in breast cancer, our results demonstrate a
selective effect of disulﬁram that may have signiﬁcant clinical
implications for its future clinical use.
2. Materials and methods
2.1. Chemicals and reagents
Disulﬁram, diethyldithiocarbamate (DDC), sodium pyrithione,
DMSO, Na-HEPES, NH4Cl, Triton X-100, BSA, ZnCl2, CuCl2, cholera
toxin, insulin, epidermal growth factor, and hydrocortisone were
obtained from Sigma–Aldrich (Dorset, UK). Disulﬁram, DDC, and
sodium pyrithione were dissolved in DMSO to produce a stock
concentration of 10 mM and stored at 20 8C. CellTiter blue
viability reagent was purchased from Promega (Southampton, UK).
Anti-EEA1 (#6104490), anti-LAMP2 (#H4B4), and anti-LC3B
(#2775) antibodies were obtained from BD Bioscience (Oxford,
UK), Developmental Studies Hybridoma Bank (Iowa, USA) and Cell
Signaling Technology (MA, USA) respectively. RPMI, FBS, DMEM/
F12, horse serum, Fluozin-3, Hoechst 33342, dextran-Alexa
647 (10 kDa), Alexa-488 (A-11001) and Alexa-546 (A-11010)conjugated anti-mouse and anti-rabbit antibodies were from Life
Technologies (Paisley, UK).
2.2. Synthesis of disulﬁram analog
FS03EB (bis(N-benzylethylthiocarbamoyl)disulphide; Fig. 1B)
was synthesized according to the method of Liang et al. [16]. Brieﬂy,
N-benzylethylamine and carbon disulphide (2:1 molar ratio) were
mixed together in the presence of carbon tetrabromide (one
equivalent) in dimethylformamide as solvent at room tempera-
ture. Following puriﬁcation by column chromatography, the
identity and purity of the product was conﬁrmed using NMR
spectroscopy and mass spectrometry [17]. FS03EB was then
dissolved in DMSO to produce a stock concentration of 10 mM.
2.3. Cell culture
MDA-MB-231, MCF-7, T47D, and BT474 were maintained in
RPMI 1640 supplemented with 10% FBS. MCF-10A cells were
maintained in DMEM/F12 supplemented with 5% horse serum,
100 ng/ml cholera toxin, 10 mg/ml insulin, 20 ng/ml epidermal
growth factor, and 500 ng/ml hydrocortisone [18]. Herein these are
respectively termed complete media. All cell lines were obtained
from ATCC and routinely tested for mycoplasma infection.
2.4. Viability assays
To account for different growth rates, cells were seeded in black
96-well plates at densities that provided 70% conﬂuency after 72 h.
After a minimum of 24 h, cells were treated with disulﬁram,
disulﬁram metabolite DDC, FS03EB or DMSO  copper or zinc
supplements for the indicated time points. Viability studies were
conducted using the CellTiter Blue assay according to manufacturer’s
protocol. All viability studies were conducted in complete media.
2.5. Live cell imaging of intracellular zinc
Microscopy analysis was conducted on a Leica SP5 confocal
inverted microscope equipped with a 488 nm laser and 40
objective using Leica LAS AF software. For this, cells were
preloaded with 5 mM Fluozin-3 diluted in cell imaging media
(phenol red free RPMI media supplemented with 10% FBS and
50 mM Na-HEPES pH 7.4) for 30 min, before being washed thrice
with PBS which was then replaced with 1 ml cell imaging media. In
live cells representative region of interest was captured before and
subsequent to addition of a 1 ml solution of 10 mM disulﬁram,
sodium pyrithione (positive control) or diluent control. Images are
displayed as a multiple projection of 10 z-planes through the cells.
2.6. Flow cytometry
Cells were preloaded with Fluozin-3 for 30 min as above and
treated with disulﬁram, DDC, FS03EB, sodium pyrithione or diluent
control in cell imaging media or serum free imaging media (phenol
red free RPMI supplemented with 50 mM Na-HEPES pH 7.4)
20 mM zinc or copper for 10 min. Following trypsinization, cells
were resuspended in PBS, and centrifuged three times at
150  g. Cells were then resuspended in media, and 10,000 events
were analyzed via ﬂow cytometry using a BD Biosciences FACSVerse
system equipped with a 488 nm laser.
2.7. Comparative localization of intracellular zinc with endocytic
probes in disulﬁram treated cells
To label the entire ﬂuid-phase endocytic network, MCF-7 cells
were incubated for 4 h with 2.5 mg/ml dextran-Alexa 647 diluted
H.L. Wiggins et al. / Biochemical Pharmacology 93 (2015) 332–342334in cell imaging media. To speciﬁcally label lysosomes, cells were
incubated with dextran-Alexa 647 for 2 h followed by a 4 h chase
[19]. During the ﬁnal stages of this incubation, cells were incubated
with Fluozin-3 for 30 min, washed with PBS, and treated with
10 mM disulﬁram for 10 min. Cells were then washed three times
with PBS, and analyzed via live cell confocal microscopy.
2.8. Localization of endocytic organelles and induction of autophagy
in disulﬁram treated cells
MCF-7 cells were treated with 1 mM disulﬁram or equivalent
diluent control for 3 h (for endosomes and lysosomes) or 24 h
(for autophagosomes) before being washed in PBS, ﬁxed and
permeabilised by either 20 8C methanol for 10 min (for LAMP2)
and LC3B labeling) or with 3% PFA for 15 min, 50 mM NH4Cl for
10 min and 0.2% Triton X-100 for 5 min (for EEA1 labeling).
After ﬁxation the cells were washed three times in PBS,
incubated for 1 h in blocking buffer (2% FBS, 2% BSA in PBS)
then incubated for 1 h with primary antibody diluted 1:200
(LAMP2 and EEA1) or 1:400 (LC3B) in blocking buffer. The
cells were then washed three times in PBS before being
incubated for 1 h with secondary antibodies and Hoechst
33342 (1 mg/ml). Following a further three washes with PBS
they were mounted in oil. Imaging was conducted via confocal
microscopy for LAMP2 and EEA1. For LC3B imaging was
conducted on a Leica DMIRB inverted epi-ﬂuorescent micro-
scope, equipped with a 40 objective.Fig. 2. The cytotoxic proﬁle of disulﬁram in breast cancer cell models. (A) Cells were treat
72 h. (B) MCF-7 cells were imaged using brightﬁeld microscopy following 72 h disulﬁram
with disulﬁram prior to analyzing viability. T-tests were conducted between equivalent ti
treated for 72 h with disulﬁram at concentrations between 1 and 100 mM prior to ana2.9. Statistical testing
For all studies three independent experiments were conducted in
triplicate (for viability studies) or duplicate (for ﬂow cytometry
studies) and signiﬁcance of data determined, as appropriate, using
students two tailed T-test in Microsoft Excel and displayed as
*p < 0.05 or **0.001. Data is presented as the mean and standard error
of the mean. Co-localization via microscopy was determined using
JaCOP plugin of ImageJ and the Pearsons coefﬁcient was used as a
measure of the ratio of pixels which were labeled with dextran-Alexa
647 and Fluozin-3 where 1.0 is complete co-localization [20]. Pear-
son’s coefﬁcient is expressed as standard error of the mean.
3. Results
3.1. Disulﬁram produces a biphasic cytotoxic response in some breast
cancer cell lines
Initial cell viability experiments were conducted to investigate
the sensitivity of a panel of breast cancer cell lines to disulﬁram.
These were chosen to model clinically relevant disease sub types,
including estrogen receptor positive (ER+), human epidermal
growth factor receptor 2 (HER2) negative (MCF-7 and T47D), ER+/
HER2+ (BT474) and ER/HER2 (MDA-MB-231) and the non-
cancerous breast epithelial MCF-10A line. Disulﬁram over 72 h
was only toxic to ER+ cells (MCF-7 and BT474, IC50 0.3 mM vs. MDA-
MB-231 IC50 and MCF-10A IC50 > 10 mM; Fig. 2A), however not alled with a serial dilution of disulﬁram in complete media and viability analyzed after
 (DSF) treatment. Scale bar shows 100 mm. (C) MCF-7 cells were treated for 8–72 h
me points to compare 1 and 10 mM data, *p < 0.05, **p < 0.001. (D) MCF-7 cells were
lyzing viability. Error bars show standard error.
H.L. Wiggins et al. / Biochemical Pharmacology 93 (2015) 332–342 335ER+ cells responded equally to the drug (T47D IC50 > 10 mM)
demonstrating that the presence of ER is not a prerequisite for
sensitivity. In disulﬁram responsive cells (MCF-7 and BT474)
cytotoxicity was biphasic, producing a recovery peak at 10 mM
with almost complete restoration of viability. The biphasic effect in
MCF-7 cells was conﬁrmed by microscopy showing clear
morphological damage at 1 mM that is consistent with loss of
cell viability. These effects were absent at 10 mM where
morphology was comparable to diluent controls; increasing the
disulﬁram concentration to 100 mM then restored the toxic 1 mM
phenotype (Fig. 2B).
To further investigate this biphasic response we determined
whether it was affected by disulﬁram concentration at different
incubation times. MCF-7 cells were treated with 1, 10 and 100 mM
disulﬁram over a range of time points and cell viability was then
determined. Despite an initial cytotoxic phase at <8 h, cell viability
at 10 mM was restored at greater than 24 h (Fig. 2C). For other
concentrations disulﬁram produced a time dependent decrease in
viability; at 1 mM viability steadily decreased between 4 and 72 h
whereas at 100 mM there was a rapid loss of viability to <10%
within 4 h. This data demonstrates that the 10 mM disulﬁram
response is due to recovery from initial effects that are not
manifest as cell death but rather a reduction in metabolic rate as
determined by this assay. When the biphasic peak in MCF-7 cells
was investigated at concentrations between 1 and 100 mM at aFig. 3. Disulﬁram selectively increases intracellular zinc levels in punctate structures of b
(pre-treat) and subsequent to the addition of 10 mM disulﬁram or sodium pyrithione (
equally spaced, single projections and are representative from three independent expesingle 72 h time point, viability was restored to >80% between
5 and 20 mM concentrations of the drug (Fig. 2D).
3.2. Disulﬁram speciﬁcally increases intracellular zinc levels in breast
cancer cells
To investigate the relationship between disulﬁram and
intracellular zinc levels we employed live cell confocal microscopy
using the zinc probe Fluozin-3. In complete media, disulﬁram
rapidly (<10 min) increased intracellular zinc levels in MCF-7 cells,
speciﬁcally to label punctate compartments, to levels comparable
to those obtained using the well established zinc ionophore
sodium pyrithione (Fig. 3). A signiﬁcant proportion of sodium
pyrithione treated cells were also noted for displaying diffuse
cytosolic Fluozin-3 labeling whereas zinc in disulﬁram treated
cells was only observed in punctate structures. Surprisingly, zinc
levels remained unaffected by either disulﬁram or sodium
pyrithione treatment in the non-cancerous MCF-10A cell line.
In order to further investigate the disulﬁram effects seen by
microscopy, a ﬂow cytometry assay was developed to enable
quantitative comparison of intracellular zinc levels in disulﬁram
and sodium pyrithione treated cells. The data supported the
microscopy ﬁndings as 10–100 mM disulﬁram signiﬁcantly
increased intracellular zinc levels in both MCF-7 and MDA-MB-
231 cell lines (Fig. 4A), while zinc levels in MCF-10A cells remainedreast cancer cells. Cells were preloaded with Fluozin-3 for 30 min and imaged before
NaP) in cell imaging media. Images are multiple z-projections from a series of 10
riments. Scale bars show 10 mm.
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Fig. 4. Disulﬁram delivers extracellular zinc into cells rather than releasing intracellular stores. Cells were preloaded with Fluozin-3 and treated with disulﬁram (DSF), DMSO
or sodium pyrithione for 10 min in complete media (A) or serum free media (SFM) 20 mM zinc (B) or copper (C) in MCF-7 cells. Fluozin-3 ﬂuorescence was then determined via
ﬂow cytometry. Error bars show standard error. T-tests in (A) were conducted between DMSO and treatment groups and in (B, C) were conducted between SFM and SFM + Zn/Cu for
each treatment, *p < 0.05, **p < 0.001.
H.L. Wiggins et al. / Biochemical Pharmacology 93 (2015) 332–342336unaffected by the same treatment. To further investigate this, and
minimize the effects of extracellular zinc in serum, the ﬂow
cytometry experiments were conducted in serum free media- low
zinc and copper conditions. Under these conditions, neither
sodium pyrithione nor disulﬁram evoked a statistically signiﬁcant
increase in intracellular zinc in MCF-7 cells (Fig. 4B). Supplemen-
tation of serum free media with 20 mM zinc was sufﬁcient to
completely restore, and in fact exaggerate, the ionophore ability of
both disulﬁram and sodium pyrithione, demonstrating that this
ionophore activity is dependent on extracellular zinc levels. This
effect, with respect to the selectivity of the dye for zinc versus
copper which could possibly also provide Fluozin-3 ﬂuorescence,
was tested by conducting the experiments in serum free media
supplemented with copper. Here copper was unable to signiﬁ-
cantly restore the ﬂuorescence of Fluozin-3 in disulﬁram or sodium
pyrithione treated cells (Fig. 4C), demonstrating that the increased
ﬂuorescence of Fluozin-3 observed in Figs. 3 and 4 was speciﬁcally
due to the effects of zinc.
3.3. Disulﬁram sequesters intracellular zinc in endo-lysosomal
compartments
The observation that disulﬁram sequestered zinc in punctate
structures lead us to investigate the nature of these compartments.
In order to determine whether they were components of the
endocytic network, ﬂuorescent dextran was utilized as anendocytic probe for co-localization studies. By conducting a 2 h
pulse with dextran-Alexa 647 followed by cell washing and a
further 4 h chase, the probe can be trafﬁcked and conﬁned to
lysosomes [19]. Dextran pulse-chase experiments were performed
and cells were co-stained with Fluozin-3 and treated with
disulﬁram; the degree of co-localization between dextran-Alexa
647 and Fluozin-3 was then analyzed using live cell confocal
microscopy. Fig. 5A demonstrates that a signiﬁcant portion of
dextran labeled lysosomes were also labeled with Fluozin-3 and
very few dextran only structures were observed (Pearsons
coefﬁcient = 0.49  0.06 for three independent experiments). When
the entire ﬂuid phase network was labeled with dextran as a single
4 h pulse (Fig. 5B), a higher degree of co-localization was observed
between the two probes (Pearsons coefﬁcient = 0.67  0.04) suggest-
ing that disulﬁram was also driving zinc into earlier compartments of
the endocytic network.
To investigate whether disulﬁram inﬂuences the spatial
organization of these endocytic structures MCF-7 cells were
treated with the drug for 3 h prior to performing immunoﬂuores-
cence analysis using antibodies recognizing the early endosomal
marker, Early Endosome Antigen 1 (EEA1) or the late endosomal/
lysosomal marker, Lysosome Associated Membrane Protein 2
(LAMP2) [21]. Disulﬁram was observed to have no effect on the
localization of early endocytic structures (Fig. 6A), however caused
late endosomes and lysosomes to be redistributed from typical
perinuclear clusters observed in control cells to more diffuse
Fig. 5. Disulﬁram increases intracellular zinc in endo-lysosomal compartments of breast cancer cells. Dextran-Alexa 647 was used to highlight late endo-lysosomal
compartments (A) or the entire ﬂuid phase endocytic network (B) in MCF-7 cells, as described in Section 2. Cells were then incubated with Fluozin-3, treated with 10 mM
disulﬁram for 10 min and co-localization between Fluozin-3 and dextran-Alexa 647 was analyzed via confocal microscopy. Images show single z-projections through the
cells and lower panel in (A) and (B) show a zoomed image of an identiﬁed cell in upper panel. Images shown are representative from three independent experiments. Co-
localization is marked by arrow heads. Scale bars show 10 mm.
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Fig. 6. Disulﬁram causes mislocalization of lysosomes, however does not alter localization of early endosomes or autophagic membranes. MCF-7 cells were treated with 1 mM
disulﬁram or chloroquine (100 mM, 6 h) and then analyzed via immunoﬂuorescence microscopy using antibodies recognizing EEA1 (A), LAMP2 (B) or LC3B (C). Blue nuclei are
labeled with Hoechst 33342. Image shows single projection through the middle of the cell and is representative from three independent experiments. Scale bars show 10 mm.
H.L. Wiggins et al. / Biochemical Pharmacology 93 (2015) 332–342338scattering throughout the cytoplasm (Fig. 6B). The ability of
disulﬁram to induce autophagy was investigated using antibodies
recognizing a marker of autophagic membranes, microtubule-
associated Light Chain 3 B (LC3B). For this experiment cells were
either treated with disulﬁram for 24 h prior to LC3B immunoﬂuo-
rescence analysis, or for 6 h with chloroquine, an agent which
causes accumulated LC3B via stabilization of autophagosomal
membranes [22]. Chloroquine treated cells displayed large LC3B
containing structures representing autophagosomes, however this
phenotype was absent in cells treated with disulﬁram (Fig. 6C).3.4. Supplementation with zinc or copper increases disulﬁram
potency
The interaction between disulﬁram and zinc observed in our
previous results lead us to consider whether enrichment of
complete media with zinc or copper could affect the cytotoxicity of
the drug in cancerous and non-cancerous breast cells. As control
experiments, we initially investigated whether supplementing cell
media with increasing concentrations of zinc or copper in the
absence of disulﬁram had any effect on cell viability. These studies
H.L. Wiggins et al. / Biochemical Pharmacology 93 (2015) 332–342 339demonstrated that 20 mM zinc or copper was without effect but
toxicity was observed at higher concentrations of both metals with
MCF-7 and MCF-10A showing particular sensitivity to copper
(Fig. 7A). When a non-toxic dose of zinc or copper (20 mM) was
given in combination with disulﬁram, cytotoxicity was signiﬁ-
cantly enhanced in all cell lines (Fig. 7B, Table 1). In the case of
MCF-7 cells, the disulﬁram biphasic response was completely
abolished by both zinc and copper supplementation, however0
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Fig. 7. Zinc and copper enhance the cytotoxicity of disulﬁram. (A) Cells were treated with
before cell viability analysis was performed. (B) Cells were treated with disulﬁram 20 m
and D) Viability of MCF-7 cells treated with disulﬁram  zinc or copper in supplemented in
data in Fig. 7B are provided in Table 1.cytotoxicity of disulﬁram at lower concentrations was reduced by
addition of either metal supplement. The minimum concentration
of copper and zinc supplement required to inﬂuence cell recovery
(biphasic peak) in MCF-7 cells was then determined and data in
Fig. 7C and D shows that 2.0 mM zinc and 0.125 mM copper
signiﬁcantly reduced the ability of the cells to recover from
disulﬁram effects. At higher concentrations both metals complete-
ly reversed the biphasic response.0
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Table 1
Co-incubation of copper/zinc signiﬁcantly altered the cytotoxico proﬁle of disulﬁram.
MCF-7 MDA-MB-231 MCF-10A
[DSF] 0.1 mM 1 mM 10 mM 100 mM 0.1 mM 1 mM 10 mM 100 mM 0.1 mM 1 mM 10 mM 100 mM
DSF alone 54.5  10.5 30.2  7.5 82.2  8.7 0.1  0.2 91.6  2.8 77.0  10.8 74.0  12.3 0.02  0.1 95.5  1.6 99.8  1.6 100.3  2.9 2.4  1.2
DSF + Zn 95.8  4.2** 44.6  3.5* 0.1  0.2** 0.1  0.3 89.1  4.6 63.9  9.3 0.1  0.1** 0.02  0.1 93.3  3.9 94.3  2.9 0.3  0.1** 0.3  0.1
DSF + Cu 92.8  9.8* 0.6  0.2** 1.0  0.4** 0.7  0.2* 98.5  2.2 27.9  12.5* 0.7  0.1** 1.0  0.2* 95.7  9.5 110.7  7.1 0.16  0.1** 0.3  0.1
Breast cells were treated with the indicated concentrations of disulﬁram 20 mM zinc or copper for 72 h prior to performing viability analysis. Values displayed are percentage
viability and standard error of the mean. T-tests were conducted between disulﬁram treatment alone and disulﬁram + zinc/copper.
* p < 0.05
** p < 0.001.
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structural analog correlates with ionophore activity
Disulﬁram in vitro and in vivo is rapidly metabolized to give two
molecules of DDC [23]. The possibility that this major metabolite
was able to induce toxicity and also act as a zinc ionophore was
also investigated in MCF-7 cells. DDC displayed a sharp increase in
toxicity at concentrations higher than 0.1 mM with evidence of
recovery being observed at 100 mM, rather than at 10 mM as in the
case of disulﬁram (compare Fig. 8A and 2A). Supplementation with
copper and zinc completely ablated the DDC biphasic effects
(Fig. 8A) and signiﬁcantly enhanced its toxicity (Table 2). The
metabolite was also able to increase intracellular zinc levels (Fig. 8B)
but was a less potent zinc ionophore compared with the parent drug
(Fig. 4A).
To determine how cytotoxicity may relate to the capacity of
disulﬁram and DDC to deliver zinc, a close structural analog ofA.
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Fig. 8. Toxicity of DDC and FS03EB correlates with zinc ionophore activity. (A, C) MCF-7 ce
for 72 h prior to performing viability analysis. (B, D) MCF-7 cells were preloaded with Fluo
Fluozin-3 ﬂuorescence via ﬂow cytometry. Error bars show standard error. *p < 0.05, p-vadisulﬁram, FS03EB, was synthesized and viability assays were
performed with this compound. FS03EB lacked any signiﬁcant
toxicity at concentrations below 100 mM in complete media and a
biphasic response was not observed (Fig. 8C). Here, the core zinc
binding thiuram disulﬁde pharmacophore was retained, but two
of the terminal ethyl groups were replaced by the related benzyl
group (see Fig. 1B for chemical structure and physical characteri-
zation of FS03EB). In complete media, and contrary to the effects
observed with disulﬁram and DDC, data in Fig. 8D show that
FS03EB was unable to signiﬁcantly increase intracellular zinc
levels. However, co-incubation of this compound (>1 mM) with
20 mM zinc or copper was toxic leading to complete loss of
viability at 1 mM and 10 mM for copper and zinc respectively
(Table 2). When the zinc ionophore activity of FS03EB was
investigated in conditions which induced toxicity (complete
media + 20 mM zinc), it resulted in a >3-fold increase in Fluozin-3
ﬂuorescence.0
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lls were treated with DDC (A) or FS03EB (C) 20 mM copper or zinc in complete media
zin-3, treated with DDC (B) or FS03EB 20 mM zinc (D) for 10 min prior to measuring
lues for data in (A and C) are provided in Table 2.
Table 2
Co-incubation of copper/zinc signiﬁcantly altered the cytotoxic proﬁle of DDC and FS03EB.
[DDC] [FS03EB]
0.1 mM 1 mM 10 mM 100 mM 0.1 mM 1 mM 10 mM 100 mM
No supplement 81.7  15.1 15.3  2.1 29.3  11.1 56.4  11.0 98.9  3.1 92.4  5.4 76.4  1.1 0.7  0.4
Zn supplement 99.5  2.4** 38.8  7.1** 21.1  7.6 0.7  0.1** 104.4  4.6 88.2  9.3 1.1  0.2** 0.7  0.2
Cu supplement 89.5  4.4 17.3  4.3 7.2  2.8 9.7  4.1* 63.4  1.9* 1.5  0.2** 0.8  0.2** 0.8  0.1
MCF-7 cells were treated with DDC or FS03EB 20 mM zinc or copper for 72 h prior to performing viability analysis. Values displayed are percentage viability and standard error of
the mean. Student two-tailed T-tests were conducted between DDC or FS03EB treatment alone and FS03EB or DDC + zinc/copper.
* p < 0.05.
** p < 0.001.
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Much of the literature surrounding the anti-cancer properties of
disulﬁram focuses on its interaction with copper, particularly as a
disulﬁram-copper complex [6,24]. In contrast, the effects of zinc on
the drugs toxicity are under-reported, despite knowledge that this
metal is dysregulated in breast cancer cells [15]. The aim of this
study was to determine the role of intra- and extracellular zinc in
the anti-breast cancer properties of disulﬁram. We demonstrated
that under normal growth conditions the drug is able to selectively
kill MCF-7 and BT474 breast cancer cell lines, whilst having no
effect at physiologically relevant concentrations on T47D, MDA-
MB-231 and the non-cancerous breast epithelial MCF-10A cell line.
In disulﬁram sensitive cells a biphasic cell viability proﬁle was
produced, manifest at concentrations between 5 and 20 mM. The
biphasic response has, to varying extents, previously been implied
in other studies involving breast [25] and other cancerous cell lines
[1], however the underlying cause and its clinical signiﬁcance
remains to be determined. To investigate this further we examined
the time dependent toxicity of disulﬁram at concentrations within
this biphasic range, and demonstrated that the response is due to
recovery of initially affected cells. This effect is highly time
dependent and may explain why this is frequently reported in the
literature at time points greater than 24 h [1,25,26], however to
our knowledge, no studies have investigated the sensitivity of cells
to disulﬁram at shorter (<8 h) time points.
Studies have shown that supplementing media with zinc to
increase intracellular levels, presumably through zinc channels,
induces oxidative toxicity [14] and inhibits NFkB signaling
[27]. Our ﬁndings demonstrate that under normal conditions
(complete media) disulﬁram selectively increases intracellular
zinc in breast cancer cells and this may have numerous cellular
effects with some leading to toxicity. However, the fact that
disulﬁram resistant cells (MDA-MB-231) are sensitive to the zinc
loading activity of disulﬁram suggests a complex link between
viability and intracellular zinc. It is also apparent that ionophore-
independent mechanisms could contribute to disulﬁram cytotox-
icity, as 1 mM disulﬁram did not show a measurable increase in
intracellular zinc levels in MCF-7 cells, however produced >50%
decrease in cell viability. Previous studies have demonstrated that
disulﬁram releases zinc from proteins [28], raising the possibility
that the source of this metal which accumulates inside drug
treated cells may be from intracellular proteins. However, our
studies show that the ability of the drug to increase intracellular
zinc is dependent on the availability of extracellular levels of this
metal, supporting the hypothesis that the drug is acting as a zinc
ionophore. This ﬁnding could have far reaching clinical conse-
quences as comparative studies between cancerous and non-
cancerous breast tissue from the same patient have shown that the
latter has elevated zinc levels [15]. Tumors may therefore provide a
more favorable environment for disulﬁram to induce zinc-
associated toxicity by providing an increased source of zinc for
the drug to exert its ionophore action.The observation that disulﬁram is able to increase endo-
lysosomal zinc levels is previously unreported, and may have
important implications in its selective anti-breast cancer effect. The
possibility exists that the cell utilizes certain compartments as an
intracellular pool of zinc [29], and we hypothesize that breast cancer
cells treated with disulﬁram experience a sudden increase in zinc
which the cell compartmentalizes to endo-lysosomes in an attempt
to buffer the excess. The cytoprotective distribution of excess zinc to
lysosomes has recently been reported, however high lysosomal
zinc sequestration was also able to induce apoptosis when lysosomal
release mechanisms were compromised [30]. Additionally, in-
creased lysosomal storage of zinc has been observed in cancer cells
treated with clioquinol, another zinc ionophore [31]. High zinc levels
led to lysosomal dysfunction, causing the release of lysosomal
enzymes to the cytoplasm and consequently apoptosis. Whether
this represents a mechanism underlying disulﬁram action here is not
yet known but currently under investigation. It has been established
that intracellular localization of endo-lysosomal components is
integral to their cellular function, for example starvation and altered
intracellular pH have been shown to redistribute lysosomes
between perinuclear and peripheral regions of the cell [32,33]. Here,
we show that disulﬁram is able to alter the sub-cellular localization
of endo-lysosomal components and by this mechanism may alter
their function, providing more evidence that the lysosomal
sequestration of zinc may promote lysosomal disruption. Other
studies have noted that increased lysosomal zinc is required for
inducing autophagy in tamoxifen treated MCF-7 cells [34]. Despite
increasing lysosomal zinc levels, we found that disulﬁram did not
induce autophagy.
It has previously been reported that the addition of copper
[5,9,24,25], zinc [9] and other metal ions such as cadmium [35] to
the extracellular media increases the potency of disulﬁram across a
range of cancer cell types. The incubation of copper to remove the
biphasic phase has previously been reported [25] but here we
demonstrate that zinc supplement has the same effect. Critically
the ability of either metal ion to remove the biphasic peak implies
that the toxicity of disulﬁram at 10 mM is limited by the
availability of copper and zinc in the media. When considering
the ability of disulﬁram to increase intracellular zinc and copper
levels, the possibility exists that an increase in extracellular copper
and zinc allows disulﬁram to transport more of these metal ions
into the cell, which accounts for the increased toxicity at this
concentration. The low concentrations of either copper and zinc
required to increase disulﬁram potency, suggest that increasing
the availability of either metal ion could be achievable in vivo with
oral supplements to enhance the cytotoxic effects of the drug.
However, data with the MCF-10A cell line suggests that such
supplementation may adversely alter the selectivity of the drug for
breast cancer cells and could cause non-speciﬁc toxicity.
In vivo disulﬁram is rapidly and extensively metabolized in a
systemic manner; the ﬁrst degradation product is DDC and this
metabolite is thought to be a major contributor in the clinical
effects of the drug [36]. DDC has been shown to have toxicity
H.L. Wiggins et al. / Biochemical Pharmacology 93 (2015) 332–342342against breast cancer cells in vitro and increases intracellular
copper in other model systems [7,37]. Additionally, a clinical trial
has shown that adjuvant DDC is able to increase survival in
patients at high risk of metastatic breast cancer [38]. We show here
that DDC, albeit to a lesser extent than disulﬁram was also able to
increase intracellular zinc levels and this may be a mechanism
behind its increased cytotoxicity in the presence of high
extracellular levels of these metal ions.
Measurable cytotoxicity <100 mM, and zinc ionophore activity
of the new disulﬁram analog, FS03EB, was only observed with zinc
supplementation. This provides a direct link between zinc
ionophore activity and cytotoxicity, and supports our hypothesis
that the observed toxicity proﬁles for disulﬁram, DDC and FS03EB
relate to their capacity to increase intracellular zinc. Overall we
propose that extracellular zinc levels and ionophore activity
should be given higher prominence when discussing the effects of
disulﬁram on cancer cells.
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